var title_f33_59_34736="Ovarian torsion sonogram";
var content_f33_59_34736=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ovarian torsion sonogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound with color Doppler image of ovarian torsion in a pregnant woman. Yellow arrow shows ovary with no vascularity. Red arrow shows the fetus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles C Kilpatrick, MD and Francisco J Orejuela, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_59_34736=[""].join("\n");
var outline_f33_59_34736=null;
var title_f33_59_34737="Dracunculiasis papule";
var content_f33_59_34737=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Dracunculiasis papule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 190px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The female guinea worm induces a painful blister (A); after rupture of the blister, the worm emerges as a whitish filament (B) in the center of a painful ulcer which is often secondarily infected.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Dracunculiasis. Available at:",
"     <a href=\"file://dpd.cdc.gov/dpdx/html/Dracunculiasis.htm\" target=\"_blank\">",
"      file://dpd.cdc.gov/dpdx/html/Dracunculiasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_59_34737=[""].join("\n");
var outline_f33_59_34737=null;
var title_f33_59_34738="Wet Bulb Globe Temperature Chart";
var content_f33_59_34738=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 634px\">",
"   <div class=\"ttl\">",
"    Wet Bulb Globe Temperature Chart",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 614px; height: 351px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Thermal Comfort Observations. Australian Government Bureau of Meteorology. Available at:&nbsp;",
"     <a href=\"file://www.bom.gov.au/info/thermal_stress/\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      file://www.bom.gov.au/info/thermal_stress/",
"     </a>",
"     (Accessed 6 March 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_59_34738=[""].join("\n");
var outline_f33_59_34738=null;
var title_f33_59_34739="Atracurium: Patient drug information";
var content_f33_59_34739=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Atracurium: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/14/6374?source=see_link\">",
"     see \"Atracurium: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/15/42229?source=see_link\">",
"     see \"Atracurium: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2935595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Atracurium Besylate Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to calm muscles during surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691273",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to calm muscles while on a breathing machine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to atracurium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to benzyl alcohol, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698250",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11579 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-518C2F532B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_59_34739=[""].join("\n");
var outline_f33_59_34739=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2935595\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018459\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018461\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018460\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018464\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018465\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018467\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018463\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018468\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018469\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/14/6374?source=related_link\">",
"      Atracurium: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/15/42229?source=related_link\">",
"      Atracurium: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_59_34740="Echo MR post MI four chamber color Doppler echo";
var content_f33_59_34740=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/54431/4chcmrpm_conv.mp4?title=Echo+MR+post+MI+four+chamber+color+Doppler+echo\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echocardiogram four-chamber post MI mitral regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 257px; height: 436px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Four chamber view from a 2-D echocardiogram with color flow Doppler shows mitral regurgitation with a jet directed toward the posterior left atrial wall as a result of a previous anterior septal myocardial infarction and papillary muscle dysfunction involving primarily the anterior mitral valve leaflet.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_59_34740=[""].join("\n");
var outline_f33_59_34740=null;
var title_f33_59_34741="EEG generalized slow activity";
var content_f33_59_34741=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F59514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F59514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 610px\">",
"   <div class=\"ttl\">",
"    Generalized theta and delta activity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 590px; height: 405px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGVAk4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoornLzxx4as7rVba41m0W60wIbuANmSMv8AdUKOWY9Aq5OSBjJFAHR1Vl1Gyi1CGwlvLdL6ZGkitmlUSSKOrKuckDuRXJx+P0vVW10jQ9Ym1xjzp11bNamJf78sjAoqY6EFic4AJyBnax4Z1GOwHiG6t47/AMTx39tfOtmBuSCNgGt4S5BIEbS9SN7M3TIAAO513VbXRNHu9Sv2Zba2jMjbRlm9FUd2JwAO5IFZnhHxHJrZvrbUNPfStXsXVbiykmWUqrruRwy8FWGefVWHasfTtO8Q+JNTtb/xOtrZaJBL9rtNKjRvtG8E+Wbl9xU7Rh9igAMRknZk2viJ4RtfEWmyXlvaxf8ACRWUZk068yUeKVTuQblIJXcBwcj2oA6+iub8P+NtA1waXFaanaC/1C3+0xWRmXzgABvVlByGU5BHqrehxc8Wa2mgaLJd+UZ7lmWC1tlPzTzudqRj6k8nsAT2oA2KK4rwvqeq6VrN7oni/Uobu4+zDUbe98pYEaPpNHgcYjbbyedsi5yQTV3WvF1vHpOnzeHBBrV7qpKadFBMPLmxy0jOM7Y0HLNzjgAFiAQDqKK47w34+0rUNHmk1O6trHV7C2efVNPMmZLTy+JCV+8VBHBxyCPWtTwr4iGvR3SzadeaZe2zqstpebPMVWUMj/KxGGU+uQQwPINAG7UV3cw2drNdXcqQ28KNJJJI21UUDJYk9AAM5rE8T+L9H8My28WrTyrJMrSbYYHmMca43SvsB2RjIy5wBmsRZf8AhYV3EYhnwbbyCQyEcarIpyAB3gUjOf8AloQP4QdwB0fhfxJpniexku9ImkeOOQxSJLE8UiNgEBkcBhlSrDI5DA962K43UTDoXxH0+9djBa65btYzMcCNrqMhoM/7bIZlB77VHYCrh8ZWJ8Yp4figupWJMT3iKDBHcbDIIC2c7/LUvgDAGO5oA6aiuY8c+ILvSbW3sdAS0ufEuov5VhbXLER+ryybfmEaLkkj2UcsK5G/8f8AiE2x0O78OT6P4p1GFY9LVpRPHM5O2aQlMhFi+/ycldp4JxQB6rVfUr2303T7q+vpVhtbaJppZG6IijJJ+gFebadNF8LtSn0qVNWvNDvYkm0/y4Zbt/tY+WWEEbiDIdsgBIXJk6AVaOsxfEi7g0mytL+30i0kWbWRe2zQNvUgpaYYfMSwDOVJXaoGTvoA3vBPi9fEonhutLvNH1GFI5zZ3m3e0EgJjlBUkEHBBHVWBBHr1Ncb40huNL1/RvE9jZXN4LRZbO+htIvMma2kwQyoOW2SIhwOcFsehteD/Et5rN9q1jrGkvpF/Zukkdu8yys9tID5chK8AkpICoztK4yaAOoooqnpmqafqsc0ml31teJDK0EjQSrIEkX7yHB4I9KALlFFcbP8TfCNvPfQz6xFHLaEja6Mv2gg7SIMj98Q3yEJuO7jrQB2VFee3HjjWdSjOm+HvDOoWniN3H7vWLdktbeLG4SyTR7lYEcBEYtu4IGCREniTWvGqRab4aF54duoRnVr24tBIbKUf8u0YkXZK5bkuMqEGerrgA9Horg/Dejy+FvGcdp/aV9fRatYyXFzJeTNIZbuJ0BkA+7HuSTG1QFwi4HFdL4q1K50zSGfTooptRnkS2tY5mIQyuwUFsc7VyWOOcKcUAa9Fef3U3jrRriPVdTktNXsID5M2maPZlZZkI/16+Y5O8NgeWGxtJOScUuj2+o6R4m0q91S4uRd6+06Xdo9w0sMLhPMiSMZ2qURGUlcBjknPGADv6KKztf1mz0LSrnUNQkKwwpuKqMu5zgKq92JIAHckUAaNFcRP44vjArWfg/X5J4sveRTwiLyI1+9sbJWZ/7qxlt3qKmuddk8S3drYeEtTSKGS3F5c6lCiy+VGThEUMCu9iGPzDgIeMkUAdVHeWst5NaR3ML3cKq8sKuC8atnaWXqAcHGeuDU9ed614RPhm0m8R+F5QdftIZZLqa8QSvqiffaOZl2ndlRsIwE6BduVrqNe8TWmkaXaXi293qD3jKlra2SB5rglS3ygkDhQWJJAwD7CgDcoqrpWoWurabbX9hKJbW4QSRuO4PqOx7EHkHiub07xVdXPiqS1ns4YtFmnlsrG68w+ZNcRAmQFcY2nbIFOc5hbPUUAddRWBpnjHQNV1xtJ0vVLe8vFh8//R28yPbnBAcfKWGQSucgEHGDW/QBQ1LWdL0ue2h1LUbO0muW2QJPOsbStkDCgnk5IHHqKv1yGkadaeJjrup30Ky2upodOhB72sZZc/8AAnaRgR1Up6Vp+DLue40GGG/bdqFkxs7o8/NJH8u7nsww49mFAG5RWBqvi7RtMe1We68xLgt+8gQypEqttZ5GXIRAxClmwAfocWdM8RaTqmpXNhp97HcXNuNzhAduM4O1sbWweDtJweDg0Aa1FYmueK9C0G8gtdZ1W1sppl3KJ32gLnGWPRRngEkZPArO0fxiL7UIkutPls9NvpGj0u+d8pd7c9RgeWWALIDneozkHigDrKK5TVfH/h7SdWvrDUrt7aSziEjyPE3lyNgExRkD95KAyHy1y2HXAPaTRfHOg61dSxaddSSxRwtMbkwskPy43pvIHzoGXcvVc4PIIABsw6vp82sXGlRXkDalbxrNLbBxvRG6Ej/PUeozerhdP8LReIPDen3l5canpt/cySX7zWdwYZwJjuMJfqF27F4wR5a4IIrf8IXc1zpLwXcrzXVlPJZyyuuDIUYgMfdl2n8aANuiiigAooooAKKKKACiiigAooooAKKKKACiiigAoqjq+r2GjwLNqVykCudqKclpG/uooyzH2AJrnE8Sa1q2stp+iaL9mt40V57/AFF9oiz0UQr8xcj5trFMDBOMgEA7GismPRn8k+fqeoyXJ588S7Np9kA2Y9ip980/Qb2a5iube8K/bLOYwSlQAH4DK+MnG5WU47HI7UAadYXijxNZ6AkMTxzXup3WVtNOtQGnuCOu0dAo7uxCqOpFY2reKb/VdTm0XwNFBdXcL+Xe6pOC1pYnuvH+tlH/ADzUjH8TL0Ox4Z8M2uhmW5eaa/1e5AF1qN0Q00+Og4wEQZ4RQFHpnJIBV0LStZu7+HV/FN0iXMe422m2bt9ntdw2nc3BmfBI3EBRk7VHU9RRRQByWvaNr/8AwkD33hm+sLSO9t1trw3MTO0ZQkpLGo4ZgHYYYgfdJzjB0NJ8J6LpkGmpHYwzz6fvaC6uEEk6vJzJJvIzvc5LEYyTW7RQAUUUUAFFFFAHGePNKt7DTF1vTNOiF7YX8OpTNbRASyqp2zH5Rl28l5RjnPSk0O4Txl4gg123Yv4f09SNOfkLdTMCrzgHqqqSinHO5yOME9pQBgYHSgDL17w9pHiGKCPXNNtL+OCQSxrcRhwrdM4P8uhqHRfC+j6Lqd/f6bZrDdXrbpX3E4BOSqA8IpbLELgFiT1raooA5zxb4Q0/xTNYPqMt3GLUsClvLsFxG2N8MnGTGdqkgY+6OaztY1Kz8N+O5tQ1OeK2sr3SDvkfj5raQnHuStw2AOTtNdpVW+06y1A25v7O2ujbyieHzolfypBnDrkcMMnBHPNAGL4OsJdlzrepW7Q6rqrCWRJPv28I/wBVAfTavJA43s5710gGBgdKKKAKmrabZaxp81hqlrDd2cw2yQzIGVu44PocEHsRXLeIvDNtpfhWyj8N6Wf+JTew6hDaWxAeXa+ZACxG52RpPvHknk12lFAHL+D9Kn+13/iHV7YQavqZUeU2C1rbJ/q4cjvyXbHG52HIANdRRRQAUUUUAFcV8UdKi/4R7UfEVpcXVjrWkWFxPbXdrIUYhUL+XIOkkZZVJVgRxxg812tMmijmheKZFkikUq6OMhgeCCO4oA5jxvqVz/ZVppWmSGLV9ab7NA6HJgQjMsw/3EyQf7xQd6ytTsLXwHqOmaxpsIt9BWBNN1OONCQkS/6ic467GyrE/wAMhJ+7W94c8J2Gg3clxbTXlxJ5QtoPtUvmfZoAciGPjIXPrljgZJwMdDQBwIfxB41cz6dfjR/CcwMSkW7C9vI+8qOSPJVui/KW25YYJXHY2WlWFlaWdra2cEVvZqEtkVBiIAYG3044q7RQAUUUUAc94w0+8nXTtS0iBLjUtMuPPjhd9nnIylJI9x4BKsSM8blXOBzVbTrXVNc1q21TXLFtMtLAsbOwklSSRpSCpmkKEqMKzKqgn7zEnJAXqqKACuZ8fMbTS7LVl250y+huWLcARlvLlOe2I5HP4V01RXVvDd20tvdRJNbzIY5I5FDK6kYIIPUEdqAOZ8XXmqXOqafofhzUEsdRkVrya4aJZhFCnADIezuQvBBwr4IIyE0fwXarqo13xELbV/EmQVvHt9q2yjO2OBSWMajJ7kkkkn01vD3h3SfDsEsOjWaWySsGkIZmZyBgZZiSQBwBnAHStagAqtZafZ2BuDY2lvbG4kM0xhiVPMkPV2wOWOByeas0UAI6h0ZXAKsMEHuKwPDvhSx0P7N5U93dm0hNvaG7kEhtojj5EOBx8qjJyxCjJOK6CigDzm31pfDN/wCI9Ag+e/e5FzpFq7AGU3ALbVX+4solJPQD6V08HhTTH8KW2g6pawahaRookE0YIlk6tJjsxYluO5raNvCblbkwxm4VDGJSo3BSQSM9cZA49qloA5rW9BW3sbafw3Y2kF7Y3AuooIkSFZuNskZOMDchIz6hc8Cs2e48Y61JPbrpdvpOk3gWJZZbkfbLVefMdlXchLA4QK3ykZJOcDt6KAIbO2hs7SC1tY1it4EWOONeiqowAPoBXP6x4f1CbULq40XVhpy36LHeAwGRjtGBJE24bJNvy5IYcKcZHPTUUAZGieGtE0K3mg0fSrKyimVVlWGFV80AYG/+9wTyc9T61X1Xw1BLaWC6M8ekXOnEmzkt4F2RKRho9nAKMOq8cgHggVv0UAZOhaKmmLdSTTveXt4/mXNzKoDSEDAUAcBAOAvbnqSSbWrabZ6vp8tlqUCz2suNyNkcggggjkEEAgjBBAIq5RQBn2Gi6bp9lBaWtnCsEEnmxhhvIk5y+5skucnLE5OTzVbxJ4b0/wARW0EGoCYRxSb8QytHvBBDo2PvIwJDKeCD+NbNFAABgYHSud0pms/GGs2MhUR3aR6hAAuOwikGe+CkZ/4HXRVi+JdOurlLW90ryhqllJ5kIlYqkinh42IBwGXvg4IU4OKALd3qSQavYaesZknuhJIcHHlxoBlz/wACZFx/texq/WH4f027S8vdV1hYF1O7CR+XA5kSCFM7YwxA3cs7E4GS2OgFblABRRRQAUUUUAFFFFABRRRQAUUU2R1jRnkYKiglmY4AA7mgB1YmoancXOoSaVoxT7XGAbm4dSyWoIyBj+JyDkLkYHJ4wGqyXer69ETojx6bp0i/JfzR+ZLIP70cR4A9GfOeu0jBORYfDDRLW0EWo3muazErNKyX9/I6yOxLMzom1XJJP3gfT0oAt2154T0K8eeXU7e51QKUmu5ZfPuMdwSudg/2QFX2rL8CavF4hgtbOxIUW0zXt+6S7mcl2MW/gFWkI8zaeVVQp6iuktdXgsoEhttB1O3tlHyrFZgKox/dU5/DFYHi3xT4WjkthLFPeeIpv3Vlp1qrw6hITk4C/K6JwSXbCAAkmgDqfEfiHTfDsEU+r3UNrbuW3SyyBFRVUsWOfoBgc5YV4+r6j4o8Y6xq2b3QvBtzLb2uoAs0F5doIv3btnmCElhkqVkKv820dNS5+GGv+KLSG/8AFevsNQiLtZaayJcW9grADBcqGkmAHEx+6SdoPfv/AAulhBbT6PJZ/Zb0hprq3nlM7T7uGk8xuZVPAyenAIXgUAbWl6dZ6Tp8FhpltDaWUC7IoYUCog9ABVqsbRDJY3U2kTuzrEvm2jtkloc42knqUPH0KE8k1s0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVy+vX9pe3M9ndyiPSrR0F22CTPKcMtuoHLcbSwGcghe5xc8W6pfWFgINDtUvNbuspaQu+1FPGZZD2jTIJxyeAOWFc74Z0aaWJTDdtM6ArJqmOCzHMn2ZTkfMc7pTkk9MgDaAa2o65dzMkFmDaTOM+V5Xn3QUjg+WDtj+rnHqO1eYfEL41Wvw01aLTb6yv9T1O5AlmjmvELW0fO0lUXywx6hVPTkkcZ9usLG20+ExWkQjUncxySzt/eZjyx9ySa+SP2i/hF4y1j4n32s6Dpb6pY6p5TK0LLuhZI1jKvuIIHy5z0wR3FAHrVl8S9a8caTt8CaMl6pQNNqzCRIbJj1VY3VTNMq5OxW25K5bnFdB4b8C2VjZnUbW8g1+6uwHur/W4vOmlI4IEnBjUYICYIXHTOam+B3hC68BfDPT9J1eWP7anmXFxtYFImdi20H2GAT0znHFXtPRdVa2tzGv2S/aTVLlOqtGWAhQj0fhiO+xgepoAtQeJITE1vZfY8R7Yop47gT2wbsjsvzIT0G4Yz6nipblrTXs2Vz5mna1b5eDJAlibkebGf40PfsRww6iue8deIvAen6nFpOta7p2k60U2xtuAaJSOFk42hCMfK/BH4Gtlrq3vYZrHxJEkd5Zxi5jubcMFePp58JGWXGcMM5XPJKkEgGfLr0v9sWFrqkUNrrVhcRrMM/Jc28w8rzYc8lfMZMg8qVweME93XmHjnUNC/sVofFuq6RbeINFlW8sbi5mjiZ3UhopEGcgPjawAxkNgYxWjpvxMttdsba48LaBr+srcRh1eO0+zwqcZwZZyin0yu6gDvqK4O8k+I2rQbbK38P8Ah1XGPMnmkvpk99oVEz/wJhXdqCFAY5bHJxjNAGbba9pdzr95okF5G+q2cSTT2wzuRH+6fQ/h0yM9RWnXHeNTb6Hq2h+JJGW3tba4e3v5QAqiGZQu+RuyrIkOSegGTwKs6f450TUvEMWk6dNNdGUOEvIoi1q0iDLRLL91nC5JAzgA5weKANbX9b07QNPN7q1ysEG4IvBZ5HPRERQWdj2VQSfSuUh8eX2rXfn+FPD13rGjQfu7qbcLWbzj/BHHNs3bMfPuK43DGSCKseGIYfEviW88UzKs1rblrHSCwyFRTiWdO37x8qGHVEXsTXa0AcTP4l8WNKDZ+BbryY/9ctzqNskj56eUFdlbH8W9kx23VRl+I2oW1vLe3ngTxNFpyIxEipE0oZPv74942oOdr5IbBx/Du9EpssaSxPHIoaNwVZT0IPUUANt5o7i3ingYPFIodGHQqRkGpK8tvvAOuHSPs7az50ehpv8AD0MW6MiSM7ojcEHEhUARY6FSxIJbj0Pw/qkOt6Hp+qWp/cXkCTp7BlBx+GaAL9MimimGYpEcdcqwPcj+YP5V52LzxR43mvYtMksNO8HzTPbLqEcj/bZY4ztkaIY2qHYMqvnKgFhklcSXfgJ/Dt1Fe/DK10fR7qWM2t3FJEVhljIG2XCjmSMjIB4YM4JGc0Aeh0V51pniuPwkms6R4q1ia/v7CRHs2ljVbq/ilUFAiKAJG8zfH8o/hGfWt7wX4tj1+2mg1GCLSvEFmSL/AElrlZZLXn5SSANyMMEOBg568UAdPXP+I/ETaZe2mm6dYS6pq90rSJaxSKgSJcbpJHbhFyQB1JJwAeccbHpviL4gWnmanqFivgnVmE/2OOJ4rr7OrfJH5ityJAFdm4IyVHByO08LeGLTw6twYLm+vbmfaJLq+nM0pRchE3H+FcnA9SSckk0AYFz4n8WaRcifV/Cj3ljcRloodGlFxPbMuCRMZCincCSNvQqRzkGu1029g1HT7W+s38y2uYlmibGNysMg4+hqxXm3hrxdofhOC90DX9Tgsbmz1OW3t4JWJcwyyF4GAAzs2uF3/dG0gkYoA9Jorz3V9X8XatrF4fBR01tMs5f7Pka6B/eTEfvJkYdRCSgKY+c+YuQVFMXVfHWjtZ3Wv2FpdaXaN9mvP7Njee5ugV4u1jAGxQwXMShmwzEZwAQDsvEWt2mgaY17fGRgWEcUMS7pZ5W4WONf4nY8AficAEjmT4+nF1/ZZ8La3/wkJO4aeETaYsZMouN3k7e2N+7d8uOc1Z8K6XdalqsnijxDbvFeyApp1nKc/YLcjuO0z9XPUDCdjnsKAPPNT13xNpkkHiPV1t9M8OrOkFxpkqo80MLkL9olmViqlWIJVcqEySSenfWl1Be2sVzZzxXFtKoeOWJw6Op6EEcEe9SMoZSrAFSMEHkEVxvhJT4c8Q33heRFSxl8zUNKZeF8pmBlhx2KO4IH92RcfdNAHZ0UVwF9FqvjC71C60vUrqwsNMZ4dO+zymMXd2n3pJCOHiVh5ew8MQ5IOFwAd/RXBS+Mpdd0TRbXw1LHDr2sJlgVEp01F4nkkXpmNsxgHgyFR0zVjw3rmvWesHRfGUemiRLF7uLUbWZgs6ROqO8iMoER+dGwGYDJ54oA7WmTSxwwvLM6xxRqWd3OAoHJJPYV55dePtTu7eTVtB0OX/hGrICe7vtQR4muoP4mtYwMsAvz7mwCMAA5yL3jK7tfEN/o/hiyuIblbyVLzUI423j7Cg3/ADEdFkfy0AP3gW6gGgC94Z8a2evagLRbO+sjPEbmwkuowq38AODLFgk45B2ttbaytjBrqq5rx1pN3f6daXmjRo2s6VcJeWaswTzMcSQ7iPlEkZdM9AWB7VSlu/FXiJDb2Wny+F7RgBLd3rRTXXuIY42dAf8Abdjj+4aAOntdTsLu9u7O0vbae8syouYI5VZ4Swyu9QcrkcjPWrBmiWdIWkQTMpZULDcQMZIHoMj8xXFXHw5soltzoWo6ho1yInt7q6tWVp7yJ23v5kjgnzC2SJB8ylmx1rL17wlb+HNEuPElzeXeq6zpLR3Ueo3eGuIrSFstApUD5TF5gY9XLFmycYAPTKKztf1i20TRp9SuVllijC7Y4F3ySsxCoiDuzMQB7muVj1Xxxqt413pOjWGn6UY/Kjt9Zdo7kyHkzERbwFHTyzgtgncoxQB3E80VvBJNcSJFDGpd5HYKqqBkkk9ABVXSNV0/WrBL3SL62vrNyQs9tKJEJBwRkcZB4rk18NeI9Ra303xNq1lqOhwTLPJItv5dxe4O5Y5VHyKitgnbncFUHHzbrWt+Clm1N9X8PaldaNq5dZm8t2a1ncDbmaAMFfK/KTkHGDnKggAt6j4wsLHxJFo7w3cjlokmuYow0Ns8pIiSQ5yC5GBgHGRnG4Z6SuNvvCkkXgDW9NS5a41W+jmuZbvbtMl0wyHC5O0AqgUZ4CqMnGabrHie81HSdEh8IG1Or61bi6t3ulZoreDYGaV1XBI5VAMj5nHYEUAdpRXn9z448Q2Sot54A1suoWSd4JoZUWMcSsm1yWI6qmAzg8AHIFWbQr/xFp934q8m8g14MLjRraWV4Wt4o8FI3QnarS4bfuHSQKfu0AelUV5trPxHu5U/szw7oF+nimcK9pY6vAYEkjGTI+4Ejau0r1+8ydQwJ6vwt4psfEZuI7eC/s7y2VGntb+0kt5Yw4O04cDIyrDIyMqeaANm4uYLbyvtM8UPmuIo/McLvc9FGepPpUtcE+jweOzq1/eBWsTFJY6S5UN5eOHukz0cyABW7LErKfmOek8Jap/avhbTtQmLJJJAPP8AMG0rIvDgjthg35UAbNFcCureMPEto03h230vStOmLTWeo3UjXDzRA/JmEBdokwG3bmwjDjd0cNAu/G2Lnxpp8lhbQrttNMW4DGKbGDcl0ON4ORGQflHzcM2FAO8orgorrx/a2YtF03TbqTTxl72afnU0XosaAjypWA5ZztVugYHiqNO1rULtvGVlpssGsrMsdtp15P5DvYhdrQy7dyqS7PKOCQQgOOaAPR6K4xrTxL4haOz1uJdEsoW3zy6ZfsXuz/CsbgK8aDqxOGJAA4yTE2neOXtU0+PVtOtktiWTUwplmuwM7EkiZNqZ43srEnB2hc5UA1tY8W2Ok6qLO6guvITZ9pvlRfs9oXOEErEgjJ9AQuQW2gg10VYXh/RpYNGuoNeNve3moPJLfALmFy427AG6oECoM9QvPWuXuftHw6urW6udS1rUPC3kvA8TQC4GnhcNG2UTzCoG9S7FsDbk8ZoA9FopAQwBUgg8gjvS0AFFFFABRRRQAUUUUAFcLrXjHTr2S6tLLU/KtLVWku7q3YM7KvBjixn5i2F3ccnauWPy6Him7tb2e70m71EWFja20d3qEgcIzwuzgIG/hU+WwYjnHAwTkcBod+uqSR3eh21kvhq1kSLStJtrTyUlv9x2F2xkiNRubAAVgepSgDrfD+gR+fcRypcR3V/tuNQElw8xgh/5Z2odieuCWwefnPG9a7qNFjRUjUKigBVUYAA7CuV0/wAH6SZbm7uX+2a5Kwa41EPiZZAMDZj/AFYAGAo7DnPJOva3lyNNvBIFnv7PcjBB/rGC7lOOxYFTjsTigDVoqK1nS6tYbiEkxSoJEJGMgjIqWgDJ8RuJbaHTlk2y38nkcMA2zGZCP+Ag/iRUfhsfaWvdSZAv2mUxQ/Lg+TGSqfgTvcez1n6tcvPeXzwMFkTbpto+cjzZMGRuOflG3/vhq6W0t4rS1htrddkMKLGi+igYA/KgD83/AIo2WrxfErXrfWYZjq8l/KZAQT5pZyVKDH3SCu0c8Yx6V9WeDfhHqV18M9FHijWddk1a1tMwaY14YbeAHOISIwH5TCNljgEgYxXuzQxNKsjRo0i8KxUZH0NPoA8z+Hnhfwn4ab7VomiWdtHJaG+srry8zGB9rPGznLEo2Op4V1HY57PwbbLaeE9HhQsVW0jOW68qD/Wueu7Jbbw9qr+ekQ0ya9Z3k/hgkVpGQHsAHQj/AHAK6nw5/wAi9pf/AF6xf+gCgDRooooAbIiyIySKGRgQysMgg9jWJr3hTRtd0q302/s8WdvIJIo7eRoNhAK4BQggFWZSOhDEVu0UAR28MVtbxQW8SRQRKEjjjUKqKBgAAcAAdqkopGG5SMkZGMg4NAC0UDgUUAFefDwhroS60CHU7e08JPO8qNblheCJzua1BwFRNxbDgltpCgAjdXoNFAENnawWVpBa2cKQW0CLHFFGuFRQMAAdgBU1FFAEE1nbTXMFzNbwyXEGfKlZAWjyMHaeoz3xXNeMfBkfibUrG6OoXFiIoJrO7S3Vc3drKULwsx5UExryOQNwGM5rrKKAGQRRwQxwwoscUahERRgKBwAB6U+iigAqnqel2OqWt1bahaw3ENzC1vMrrnfG3VSeuOTVyigCppOnWekabbafplvHbWVsgjihjGFVR/nr3q3RRQAUUUUAFYPivQZdZFhcWGoPpup2Eplt7pYhKBuRkZWQ8MpDe3IB7VvUUAeZw+KtUnsZfCZu4n8cCeS0eRIgnlwZyt8UyQqmMqQMkGQ7fXHoGjabbaPpVpp1imy2to1ijB64A6k9yepPckmrIijExlCL5pUKXxyQMkDPpyfzp9AFKx0nTrC7vLqxsLS2ubxw9zNDCqPOw6FyBlj16+tUvEnhbRvEptDrdkt19lZmjBdlGGADKwUjchwMo2VOBkHFbVFACbV2bNo24xjHGKztD0HSdAt3g0PTLLToHbe6WsCxBm9SFAya0qKACiiigAqK7t4ru1mtrlFkgmRo5EYZDKRgg/galooA4Lw7oXiKSbS7DxH9k/svQtvkTxSl31GRV2xyuuB5e0clcnL4IOAM97RRQAUUUUAFY2g+GdH0Ce7m0ixS3lumzKwZmOMkhV3E7UBZiFXCjJwOa2aKACiiigArmvEvhmfV79bmy1a40wyW7Wd2YI1LzQk5AVj9xhlsMM43HjOCOlooAhsrWGys4LW0iWK2gjWKKNRgIqjAA9gBXK3Xg2ae6vrddZuIvD99O1xcadHGAzM3MiCbOVjc5LKBn5mwQDiuwooAbHGkUaRxIqRoAqqowFA6ACnUUUAFFFFABRRRQAVFdQR3VrNbzLuilQxuPUEYNS0UAcL8NfEMV/pulaRaMLqTT7ERX8wfcYJYyIljf/po21yR1G3n7wz3VRwwRQGQwxRxmRzI+xQNzHqxx1PA5qSgAooooAKKKKACiiigDE8U/ZbWxbUG0+2vNQixHZiSNWYysQEUE8gFiMkdBk9q8s+L76loHwx8R3GhST/adJtI7RbmNsuJJpEa6mHUhtrD5s5G5jxivR/EM8Umv2STgNbaVBJqs4CksGAKR4HfIMx+qCtHR9MjXQzbX0KTfaw8l0ksYxI0mS4ZehHOMegoA/Pj4OeJZvCvxJ8PahbXbWdubmOG+d3/AHbW7OBJuA/hCHPOcFd3YY+9/B+t6JrN3rFxomradqHnXIcm1uElwFijTnaT3U/nUHhL4c+EfCN9JeeHdCtLK7kBUzLudwCeQCxJUewxVSXwL4R1u91ePUvDmlTTLdBjN9mVZTujRtwdQGHJI69qAOisn+watNYSECGfNxa8d/8Alon4E7h7Mey1rV5/c/DCzijiPh/X/EmiywHfAIdRkuIkfBAJjnLqRyQQMZBIqnpa/ECAvar4i0TUNThAMtrqenNAWXpvSSF8FCQcHyzjocHigD0KWwgkuracqyvbs7oFYhdzDBJA4JwT19TVquEfxN4x035tZ8FJcW6DLz6RqsUuPfZMIj+prLn+MOjSWaPDb6lYM8rQtc6lp8y20BHUtIgKt7BW59QOaAPS/Pi+0i38xfPKeZszztzjP0zUlct4L1fw3fxyvoevWGr3c533E8VykkjntkKflA6BcAAVp6prP2a9SwsbWS+1FlDmGNgqxITgPI54UHBx1JwcA4OADLuLYSQ+M7aUKY7gF9vs1siHP/fBra8ODb4f0wDGBaxDjp9wVhvfC0tvE8t9E9veJbm6kiLB08sRFQyMAMj5GzkAg54wRnU8HX0OpeFdJurYkxyWsfDKVZSFAIIPIIIIINAGxRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBxMnmag/iKeTHkyala2MJPGYkaIMP8Av48wrtq4rRpY18NXzPHtWLXpywHP/L+Tu/ka7WgAqhNDPHq8NzApeKVPJnXcBtAyVcfiSD/vD0q/RQAVU1HTrbUY0W6RiUO5JEdo3Q+qspBH4GrdFAGOPDWjtN501hFczZz5l1mdvzck1rgBQAoAA4AHalrHvday3k6RbPqNyTt+Q7YU9S8uMDHoMt7UAYXxB0bwzc26f2p4d0rVtWumMVnFPbo0kknXO/GVVRlmbsAe+AeZ8HeAvC628q+EPF+oRaih/wBNl0jVxKrSYx80TGRAB90AjIAAycZrJ/aOsdasfhLql7BO9zqVy0dvf3EKlVgtC2XRFGSseQobqWGd2RwPnH4A29/bfGrQ4/Dl4LhluQs0kYZUltdpMzEEfd2jjdg5K8Z4AB9IePbTxppCapDa+KbfWF/s3yhBqOmJ5knnyiJU3wlOSeASuB6Hk1d+HvizxWNKu5T4Oi1G2N9N5kmk6jGSpJBIEc2zgZ/vZPoKsapqb3/irwzCgD3ev6mLqND0TTbNWdGJH96QrIuf+emP4a67wHa29tfeLTZh1hk1l2wX3KG8mHft9Bu3cdjmgCj/AMLO0a1hMmvWGvaEoO0tqOlzLGD/ANdEDJ+O7FddpGqWGs6fFfaRe219ZS52T28gkRscHBHHB4q5VPTdMsNMWddNsrazWeUzSiCJYxJIQAWbA5JAHPtQBcorz/xhd+L/AA9c6rrNjLp9z4dtVW+kgmDNclFUCWGPGFUbVLhiWO4kYweN3xV4hksDa6dosUV7r+oAmzgdiI1QY3TykciJcjJHJJCjk0AdHnnHesPSPFOlavrmpaTZTO15YHEgaMqr4O1ijHhwrAq2M7W4PNYMfw8iuHGpatq15N4q3AjWbULBJEAMeVEnzKsWCcowbJJJycEQ6rYWXhHXPBMtoFtdNiefS5ZZHzgTJvXex5JaWJPmPVm9WoA9Aorz651zWfGM8th4ZtJbXQGn8iXxAtyqmREP70W6gFiSQUEnA+8w6AnOs/EmqpaS+C4LqWXxfDdNZrcyoHZLPO5b1+MHETKOfvSjHrgA9RZgoyxAGQOT3PSlrz65+FWiz6fLYyXepzWIR2t7W4uWljt7hlINypPzGTJLAliFYsVAJzWjo/i+FPhtZeIdVEnmi3VZoUXMj3IPltEq93MgKgetAHYUjMFxuIGTgZ9a8oi03VvB2paZ4pvbTVtW1DUIpYdbhsN07eY5V4NsWduyLa0QK44fce5rQm8Max42upJ/G1jaadawQMum2tvcmeSCdyCLhzgKJUCqFwWAJfBweQD0iiuV0PxQG+HMHiLVsRtDZNNdj7v7yMESAf8AAlOBWL4NvdX0fXorPxVqMssmtWI1GOO4Khba4Unz7eMjoio0WFOT8kjdzgA9Eorj/EfiHUri9tNM8Ff2ddahLb/b5Jrks8Edvzs5QjJkbhSD0V2wcYOr4S8SWPibRbe/spofMaNWuLdZQ720hHzRvjoykEHOOhoA26j86LyWl81PKXO59wwMdcn2wa4W+8TReNGTRfCFzNLBM3/Ew1KJHjS3t+4jkIAaSTlVK5wNzZ4GZH+Gulo7WllcT2fhydg93okKoLa4dQACeNyg7RvUHD/xA5bIB2trcwXltHcWk0U9vINySxOGVh6gjgipa8zs9P8AFGhXmr+HvCml2ltps1011a6lcOFt7OKUAukcK5LusnmsF+VORkjOKbd2tz8L3l1HTLefUvDdwI21Lzr1mngm37XuhvyH3BgWUFeUBHU0AenUE4GT0rmNd8aafo3iC10q4t7yUyeX9ouoYw0Nl5r7IvObIK73BAwD0ycDmqXiZn8Ua2/hS2dl06KNZdalRsExt9y1BHQyDJb0Tj+MEAHRaJr2k67FPLoupWd/FbyGGV7aZZAjjkgkH3FWY9QspJYIo7u3eSePzYkWVSZE/vKM8jkcj1rn9X8CaHql4J5YriBWhS3ngtbh4YbmJM7I5UUhWUZIAx0OOnFYms/D/SdEtDq3g3QoItatLuO9iWBtrMob97DGWO1FeNpVCDamXzgHmgD0Sisfwtr8HiPSzeQW13aOkrwTWt2gSaGRGwVdQSAehGCchge9c5/wluqSarBfwW1q3hR79dLEmGM8kjN5YnUg7RH5uI8YyeWyBgEA7uiqWs6naaNpV1qOoyiK1tkMkjH09AO5JwAOpJAFc74X+IWha/c2lgJ2stbnEudLusC4iaJirqwBIBGM4zyOR0OADr6K4C6+JllY6neSahZS2/hiCZ7Ma5vDRNcoPnjKAZC5BQPyC6leDjOhD45tpfBup641jeWdxYlopdOvFCTpNgGOJgpYZffHjBP3xQB1UdzBLcTQRTxPPDt82NXBaPIyNw6jI6ZqWvNdM0J/Cus+EbyQQ/2lqTz2us3QA3XM0kTTZJ74kj2r6Kdo4Nb3ia5uNW1y28M6bPNbhoxd6lcwOUkggyQiIw5V5GVgCOQqOeDtNAHWUVwOs6P4v0aCe80DxHLqFrar50el3lqkk0+05aITjBwVyBlS27GWxkVq+GfHWh+IPIiinex1GV5UGm6gogu1MeC2Yidw+UhvoQaAOpoqhr2qwaLot3qVyGaG3jMm2MZZz2VR3YnAA9SK4yHRPHZkiuo/EdvC2ow/6dBNAHFg+cg2oxgkKSuJMglQxzkggHoVFcJpXi2+0maz0fxXpuqNdi4+yPq6Wy/ZJdzbYZGYEAGTKAqF+VyQQFwT0niHxHpPh63aXVb2CF9jPHAZF82bGPljQnLEkgADuQO9AGvWT4n8RaZ4Z05b7WZ2hgaQRLsieVmYgnAVASeAxOBwFJ6CuP0+z1HSfE2gaxqk8x1DXJJbW/hadmhgBieWGNEztGzyyu4DLF2JJzxr6aF1/wAd3mpMN1loYawtDnhrhwDO49do2Rj0IlFAHWQTR3EEc0EiyQyKHR0OQykZBB7jFPrz3RNYh8JeH/Eun38kdvHoErG1VyfmtpRvtwCfvHJaIAckpiqehalJ8PoFj8WTXq6ffW8d39pk826EF5t/0iJmG4qCcOo+7/rMYwBQB6dRWRdeJNHtdS0nT59QgW71YMbGPOfPCruJUjjGOeevarWk6tp+sael/pN9bXtk+4LPBIHQ4JB+YccEEUAXaK4KOPXNb0q78SaTqt1DcPvk0uxIX7NJCv8AqxIpGT5uN27IIDjGMc25/iR4cttI0++nupH+2WwuRDawPcvEpHVxGp2DcdmWwN3HrgA7KivP28e6lplsH8R+F762kZEui1qTNDBanl3llZVVXjGdyDJPG3cMkaXjDxTeaTdCDR9PXUZLWI3uoguV8i2H93AO6VsMVXvsbJHGQDrqK5/UfF2j2mkPf29yuoKGijSCydZZZJJSBGijI5bIxkgY5JABNZ+g+OF1XXYdNm0PV9LEsbhJtQhEIadMF4VGSWIU7g65RgGwxwaAOworg5vHMtrq0t5dQW6+DvNayj1CPzHk+0KOWKhSPKLBowR/EvowqfQ9W1yPW7GTXGCWOuNKtpZtCEksmRS8aMc5YvErs2fusuBQB2tFcrqXjzRbHVjp6SS3k0MqQ3jWgEiWJZgqmds/LlmAxyepxgEjotRvINOsLm9vJFitreNpZHboqqMk/kKALFFc54NuPEVxDPJ4lgto1m2XFr5KlGhRwSYJFJOXTAyw4bd0GOejoAKKKKACiiigAooooA5hrYw6xremhwP7ViN5b7jkB1RY5AB6DETfVzW9plz9s062ucoTLGrHZ0BxyPzzVXXrSe4to57HH2+1fzoM8B+zIfZlJX2JB7VT0i9hjmjaF86fqDNJAzE5jmyd8RHbkMcdiGHpQBv0UUUAFFY9pdzXNxaKjOFmL3LBwMrEPlVRj1JVufRq2KACiiigBGUMpVgCpGCDyCK8p8f+CNIu0XTvB9hpega7FuvzqttbrALRcFT5hj2lhKCyEE427m52gH0TW9Rls0igsYRcajc5WCI5CjGMu57IuRk+4A5IrnpdMinuh4f86S6aci91m5YcyrwFiPYByANnaNGHcEgGP8M2svGugXWp6nZNY6m8iwSWKM0UulrEuIo0YbWXKsZAwxkTemK77RdKs9E0yHT9NiMVrFnapdnJJJJJZiSxJJJJJJJrnfFmmXenamninw9btNfwoIr+zj639sCTgDvKmSyHvlk6NkdNpd/a6rp1tf6fMs9pcIJIpF6Mp/z0oAtUUUUAMmjSaF4pkV4nUqysMhgeCCKxvDXhPRPDXmnRbEQPKqo8jyPK5ReFTc5JCrzhc4GeBW5RQAVW1GwtNTsZrLUrWC7s5htkgnjDo49Cp4NWaKAI7eGK2t4oLeJIoIlCRxxqFVFAwAAOAAO1PCjcWwNxGCcc/wCeTS0UAFcpaeBNItvEz6yj3j5ne7Sxkm3WsVy4IedI8cSEE85wNzEAEknq6KACiiigDzm28Oa1JrMuh3ltH/wikeovqgufNUmcM/mrbeX1AWYliTwVVQOpx2niDQtK8RaebHXdPtr+03rJ5Vwgddw6Hnv1/AkdDWlRQBjeGvC+ieF47uPw/pltp6XU3nzLCuAzYxwOwAGAowB2ArI1vwFp+papLd21xPpkd5GYdTgslSNdQQtuxIdu4HJYblIYh2GeeOwooAZDFHDCkUKLHFGoVEQYCgcAAdhT6KKACqmr6dbavpd3p18nmWt1E0Mq5xlWGDg9jz1q3RQBz2meErCz0K+0yaa8v/t+77XdXku+eclduWYAAYUADAAGBgVb8MaBa+HdMNpaSXE7PI009zcv5k1xK3V5GwMtwB0AAAAAAArWooAKKKKAOA1nS/EkPiTWLbQogmna8kTy6j5yqdPlVfLlYIeWZo1j2Y4DA7sDrt6/pEdn4Gl07SbRnSxt0NrbpksTCQyKO5bKD8a6SigDitKtW8X6zFruq2c0Wk2bZ0mzu4ijs/8AFdSRtyrfwxhgCo3N1YbbHiPwLp2qWc66a7aJfzXqag1/YoqzGZQVLEkckqWXn+8a62igClpGlWWkaTa6bp8CxWVsgjjj64A7knqc8knknk81z974MS78aJrTX0i2H7uebTVjASe6iyIp2fr8qkDb0JRD/DXW0UAYPjbR7nWtEEemyQxalbXEN5aNPu8vzYnDqr7edrYKnHOGNO8KaI+j2tzLezrdatfSm5vrkAgPJgAKoPRFUKqj0HOSSTuUUAFYOueDvDmuvM+raLYXUkzRtLI8I3ybM7QzDlgASMHjBI6Eit6igDznw5p2psmmeF7zSp4NJ0SXfJdSFfJuY42JtUiwSTgeWzZA2mMLznNejUUUAZPivSTrnh+7sI5FimcK8MjLuCSoweNiO4Dqp/Cs3w74ZMc0mq+JRZ6hr87q7TLFmO3C/cjh3ZKquSc8EliT1wOoooAw/GGi3Ot6ZDHpt8un6jbXEdzbXLw+csbqcHcmRuBUsuMjrVrw7o9voOj2+n2rSSJHuZ5ZTl5ZGYs8jHuzMzMfcmtKigDI1Dw3o+oa7Zaxe2EU+pWSlIJnydgzkfLnBIPIJBK5OMZNa5GRg9KKKAOLg+GnhtdOurG7gub+1nEUapdXDsbeKI7o4omBDIinPAOTnBJHFQar4W1BL++sNFS1t/D+srGt6EkML2u1QjmJVXBMkYVOo2lc89K7uigBkMaQwpFCipEihVVRgKBwABVax0yw0+W5lsLG1tZbp/MneGFUMr/3nIHzHk8mrlFAEdzBFc28tvcRrLBKhSRHGQykYII7giqGgaFp2gWjW2lW5hjdt7s0jSO7YAyzuSzYAAGScAAdBWnRQBy0XgPQbfxNZ61ZWv2KW2RgLa1xFbyOc4leNQAzqGcKx6b29saviLQdN8RWKWmsW5ngSQSoBI0bK4yMhlII4JBweQSDkEitSigCO2ghtbeKC2ijhgiUJHHGoVUUDAAA4AFZPi3Rp9a02KOxvfsGoW06XNrcmLzRHIv95MjcpUspGRwx5FbVFAGHY+GrK28KNoMpe4t5YXjuJHOHnZ8mSRiP4mZmYn1NYVrYeIdXaw0rxBaRx6dp8ivdXRmDf2kY/wDVFUBJVSQruHxyNoDAk13NFABRRRQAUUUUAFFFFABRRRQAVy/iHS7m3le70u1S7tLh86hp+drTDtLEcgLKpAPUbsdQQDXUUUAc7omtwmyR5Lsz2e7YLiVdkkLf8851OCrZ4yQPQgHGdHxBKyaXJFGV8+5/0eIE4yz8dvQZP0BqPVtEgv2aaKR7S9KbBcwgbiP7rAgq6+zA+2K5q30y60C8FzNpVxexpvVG0u5cIgbAL/ZXcKrdR+73Hk4AzQB02ixoXurmMARMwghCtkCOPKj/AMe3n6EVqVxFj4uhtUS0WOyiji/dxLc3TWspVemUmRTnHXBP1q7c+MY7aMNPZBMkKrNf2qqxPoTL/SgDqqz9T1SKzZYIx9ov5B+6tUI3t7n+6vqx4H1wDzVx4nW4nEL6pbQM3IttLU31yRz1KqQn/fJ+oqbTrbVLmNk02y/sC1kbdLc3O2a8m98ZKg9fmcsR/doAkBvLS4uBD5V/4muo1EhBxBZx5O3PcICWIH3nIPQfd29D0uPSbLyUkknldzLPPKcvNIerN+gAHAAAHAFLo2kWej2zQ2MRUu2+WV2LyTP3Z3PLH3J9ugFX6ACuMuDH4J1eS5wU8N6lODOc/JYXLnHmf7MchI3dlf5ujMR2dRXVvDd2s1tdRJNbzIY5I3GVdSMEEdwQaAJaK5Dw5NN4c1OLwzqMjy2jKW0m7kYs0kajJt3J6yIOh6snPJVjXX0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAyeGKeJo540ljbgq6gg/gayj4W8P7tx0LSs+v2SP8AwrYooAjt4IbaIR28UcUY6KihQPwFSUUUAFFFFABRRRQBn67pFnrmnPZajGXhLB1ZWKvG6nKujDlWBwQR0rQoooA848Z6drVza6x4iuJp7KbRUebSbW3um2P5WWMswXAcyAbdhyFUn+InHokEqTwxyxndHIoZT6gjIpLiFLi3lhmXdHIpRh6gjBrzHTZ9Vv8ARU8BRQXsF3Zr9h1DUniZI0s1+VHjcjDyyx4A2/dJcnBUAgHT6T4/0DU31PyrmSGCxhN01xcRGOKaAEgzRseHjBVhuHp6EE8/a+ONR0MDVfGcE0Wh6nF9qs2t7GR/7PGf9VcFQSCYyshZgACJB2FdXqPg3w/qUulyXumQyHTFEdquWVUQbSEKggOoKqQrAgEA4zWlrml22t6Lf6XfBjaXsD28oU4O11KnB7HBoAu5G7GRk84pa8xu/BuqaS9r4nuNRuvEHiawmjLyxxCEy2YBWSCOINtyQxkPOWcDp8oGlc2+peO7hVmXWdB8OwqWGJGtLu8l/hbA+eONOuGwWbGRtGGANLxpq2opcWOheGpYItd1Dc6zzRGWO0gTBeZ0BGRkqgGRlnHYGtHwnra654W0/V5FWBp4A8yE8RSDiRST/dYMPwqLwx4dOjvdXV7f3Gqatd7VuL64VEZkTIRAqAKqjJOAOSzHqa4J55JbjxB4Cs55ft97qsskhjzm2sJws0sucYAJkkjX/aPHQ0AafhDxVqy3sN14nu7b+yNbiuL7Tm8ryvskcZ3CNm/j3Q4lDHBG1+2MP8JapqLeJLC/v7u9Nn4mgmnt7K4wEtPKKmFUGMqXhYswJPzKeldXrvhXQ9e0y007V9Mt7qxtJElggcYWNkGFwB2wSMdCCQcg0ninRJNZtbT7Femwv7K4W6tbgRiRUcKykMhI3KVdlIyOvBGKANuiuEbSvFmhXyalY6hL4kluQY72zupltYlP/LOSABSIwvIZeSwOclhy2/8AA974hsrq48Ual5mrtERZLZM8dtpz4+V4xnc7hsEu3XGAFGQQDr9Z1fTtEsTe6xe21jaBlQzXEgRdzHAGT6mroIYAqQQeQR3rhNO07V/FV5Y3HizTfsFlYQun2KR0kNzcshjeY7SQIwpcIOCd5JAwBVPS9f1Xwpo17omtWdpJeaRp0J0+a3uGcagCxijBUqCjlhEpGWGX4NAGzp/jRL3xtLogsitkfOit7/zQRPPDs86MJjI278ZzyUcY4yaXilNY8SeI5dM8O6xNpf8AY0S3Mk0Yykt23MUMo6tGEBZ1BGRInPFS3ngqQ+A7HS7O4h/t3T2W8tb6VTj7aCXaRsc4dmcNj+F2Fb3hPR20bSRHctHJqFxI11eyxg7ZJ3OXIzztH3VB6KqjtQBxreMdX1ywXQdKNpp3jKS6ltbkxH7XFp6RH57gghcqQUCBgMtIOoVq3PBXjKPWofsmrWl1pGt2yQi5tr6Lyd7vkbosn50Lo4BHXFdNbafZ2t3dXVtaW8N1dFWuJo4lV5iowpdgMtgcDPQVheN/B+meJ7C4a4sLOTV0tpIrK8ljHmWznlWR8ZUhgpyOmPc0AdNUN1cw2ttPcXEqxwwIZJHY8IoGST+Arhz4z8RyWxFr4D1lrjy/L3TywRoLn+6fnz5XUmQA+wNVx8L4ZUWabV7yLUL5WGuTW4Uf2orEExvkEqgxtXbgqhK55zQBv+HPGlhrTSpJb3mlyrCl0keoqsRlgY4WVcMflzgEHBUkAgZGellkSKMvK6og6sxwB+NYviXwpofia2hg1vS7O8WAN5BmiVjCSMErnp2/IegrmrLwlqXiK0gtviDHaXFlZw/Z47OKQyx3UgXabmXKjkjlUwdpJOScFQD0EnAyelcdY+MprvUbKYaZs8N30xtbXUWm+eSXnaxi28ROQVV92Sdvy4YGsG31i41XwXpPhdLnfr12X0q9cEF4UgJS4mYdshePeVMV2PinTFfwfd2dhAA1tAJLSKNfuvFh4go9mRcUAb1FcTrutReJNM0jS9CuW3a9GszyRMQ8NjgGWTI5UkYjB4IZ8j7pxjHwl4q0IWl1pms3GoW2hts07SY38v7VasfnjuGdsSSKuFjYkAbATyzGgD0+iuFgtfHsuNUj1HTLea5Y50e7g3w2cf8ABiWPDvKMfNk7CWIXG0Ma0+leNtMmktLHVm1ePVI9s19deXF/ZkvO6SKMDJQqcKmWKsoySGY0AbPhrxgNb1qe0/s6W3tGEr2F40isl4kTiORgByuGIwD1U5rodSvrXTLGe9v50t7WBS8kjnAUVyms6daeH38FtbBorHTrtbL/AIBLC8S7j3zIY8n1Oataqw13xXa6TGwaz0spfX2BkNL1giP0IMpHUbY+zUAb2kanZ6xp8d7p0wmtpMgNtKkEHBBBAKkEEEEAgipku7eS7ltY54muYlVpIlcF0DZwSOoBwcfSuOu9M8SaL4g1OfwvBYXVjq7LK6XczRixuAu1pQoU+YjBVJUFTuB5+YkIPAw0yK11DQ5YT4ogkMs2oXIIN/v/ANYkxXnaeCo5CFUwMLggHcVxo8UX58Q7zb2y+G/tp0vziH8/7R03/wB3y/M/dY67uc44qG50DxRrdwIdf1azh0aciSe100ywzxlDlUS4DKxUnBY4U8YHBNbGq+Hbf/hCrnQ9JiNvGtuVtlVzlZB8yHcTkneASSck8k0AdBWV4p1STRtCuby3hFxdDbHbwkkeZK7BEXjnBZh+FYt14mOqaBpa6Kxi1TWP3cakAvaY4ndl7GLkc8b9qnrT9K8M6jFqNqda1ptWsNPO+xSeBRP5hGN8zj5XZQWCkKv3iTk4NAFbQ/H1nLqNpoWuxvY+JmkME9skMrQq4UkMspULscLlCSCenUEDta5r4iIB4VuLvBLafLDfggEkCGVZCQB/sq351D4n8WR211/Yeh5u/ElzEHt4lid4oVY4EszgFVQYLYJBbGBnNAHV1laJ4i0nXJbuLSb+G6ktWCzCMn5c5wR6qcHDDIODg8GuWbwx4weI2l54uj1C0vI/IvmexSB4k7m32dGYEg7icZDLjGDsa94TS+jsTo99NolzaRG1SezRN32Y4DRYYHA+UFSOVIBHcEA6YEHpzRXH+GrK08Ja1c6DZotto00H22yi4CQlSFnRSTnGSknPeRqgi1TxbqNqb/SLXTJbC/yLMTM0UlqnISd/vCUMMPsAUgEDJySABPEGtawtzqOqabcxR6NobqtzAYdzXYADT/OfuhEYbdvV1YHjiuu1DUbTT9Mn1G8nWOygiMzy9QEAzkY68enWq2naLbWWgrpJ3TwGNklaQ5aYvkuze7FmJ9ya5LRYtU1W30rQNS0+6gg0lk+33MqbYrpov9UIic71Yqrk9ABtPJIAB2ejapZ6zpkGoabN51pOCUfaVPBIIKsAVIIIIIBBBBANXa4jUTqumaxqunaJaXCy6xIlxb3vkmWC1cqEmd+QBtCK4Qkb2bA7kRzw+L9OC61qWpRXIsyqTabYQAxXNuP9ZLhhvE38QUMVAXb8xOaAO7ori5/id4UhnhA1LzbORfmv4Y2ktonIysbygYWRucIecjHUgHOgv/GFldya0mlX+rW+rA+VpHmQwHTgpHlklyuC6bmcEsQ+1RxzQB2fiDVo9F01rqSGa4kLCOG3gTc80jcKij3Pc8AZJIANReFtZOuaV9omtjZ3sUjQXdoZBIbeZThkLDg9iD3BB71S8PxatqGpNrGt2v8AZwEJgtNP81ZWjUkF3kZfl3nCjCkhQvU7jisuoW+geMtXj1K4htbO/t0v4ZJDsUvEuyfJPGQiwn6ZPagDraK4m3vfFHimFZtPjbwvp5G5JruGO4ubhT90iMNtiGMH58tk4KjByLofirTfNsNG1xZ7KfDi+1Um4uLVv4gqAKJFbgjLLs54IwAAdtRWdon9rmBzrn2ET5AVbPeUwBy2W5yTnjtwMnrWjQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFIFG4tgbiME45/zyaWigAooooAKKKKACs3UNC0zUdU07Ub6yhnvtPZmtZnXLRFhg4/IfkD1rSooAKKKKACiiigAooooAKKKKAK0NhaQXk93Da28d3cACaZIwHkA4G5gMnHbNWaKKAKdhplhpz3D6fZW1q1w/mTGGJUMjerYHJ68mrlFFABRRRQBV1TT7XVdPuLHUIVntLhDHJG2RkH3HIPuOR1FQ6Ho9nolkbWwRwjOZJHlkaWSVz1d3YlmY8ck9gOgFaFFABRRRQAUUUUAU7bTLC1vrm9trK2hu7nHnzxxKry46bmAyfxq5RRQAjKGUqwBUjBB5BFZ+haJpmgWIstGsoLK13F/LiXAJPc+vp9AB0ArRooAKKKKAMvXdA0vX47ePV7NLlIJPMjDEjBxgg4IypBwVOQe4NaaqFUKoAUDAA4AFLRQAUUUUAFFFFACbQBgAYzn8aWiigAqvfWNpqESxX9rBdRK4dUmjDgMOjAHuPWrFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRTXkRCod1UscKCcZPoKdQAUUUUAFFFFABRRVHVdX07SEt21W+tbNbiZbeEzyhPMlb7qLnqxweB6UAXqKKjmnhhMYmljjMj+WgdgNzYJwM9TgHj2oAkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorlPEfiGFLiWzj1S10q2hIF5qdxIirESOIoy52mQjk5yFGMgkgUAa2r6/YaXKkE0jzXsgJjtLdDLM/0Qcgf7RwB3IrnZ9R8UarqZtbL7BolnCu+8mmH2ieEEZVRgiJZCOSPnCrgnqBVrRdW0i1twvh7TtRv45f3j3UNuxEx/vtNJgSE+oJrF0rVZ7rUptM1S1l0m2uL2S73XcXktLHuG2Lfkq7s3JCk4jAB5PAB2EPh3TFXNzbLezEfNPd/vpG/Fun0GAOwFR6TdC31q90WWbe0UaXVuHfc/ksSuD3O1lIz6FavapfrYrbZXc086wr2A6sxJ7YVWP4VzWoiO48VzanpKR3OoafaQCQx8s8Lu5aIEdSVw4HqqeooA7KiobO6hvbWG5tJVlglUOjqeGB6GsnxV4ls/DtvB5yS3V/dMY7Owtl3T3Tjsi+g6ljhVHJIoA2ndUGXZVBIXJOOScAfmcUk80dvBJNM4SKNS7seigDJNcfpfha61a+tda8bmG51CBxNaadCxa1sGBypGf9ZKMf6xhwfuhR17OgDM8O67pviPTE1DRbpbq0Zim4KVKsDgqysAyn2IB6Vxt3o8Hj7WPEsk7KbC2tZNFsJ9ocRzMM3EyA8EhvLQHsYnHc1q674U1GfV7u60DW20mHU1VNSjWHe77QF82F9w8uXYAm4hhgKcZUE9NpWnWmkabbafpsCW9nbII4ok6Ko/z170AcjomseKLDxFpul+MI9GMWoQultNp7SkmeJQzB94A+dNzAD7uwjLday7vQofiJ/bGsBlaOONrPQJ5VytvKhJa7j9CZQoDdSsQxw3Pb+JfD+m+JdLbT9Ygaa2LrINkjRujKchldSGU9sgjgkdCa0LO2gsrSC1tIkhtoEWKKNBhUVRgKB2AAxQBwafEKaWBtKTSHTxqriBtHaVWCEqG89pFzi3wwO/Gf4cbvlq9oHi2S31h/DvjG40618Q7wbYwhoob+NhkNCHJO4EMrLuJBXPQiuxEaCUyhF8wgKXxyQM4GfTk/nVHX9Hsdf0m403VIFntZ1wynqp7Mp7MDggjkEAigDQpsjrGjPIwVFBLMxwAB3NefXHgjXNds0tPFniRpoLRcWbabG9rI0yj5LmZg53SKcMEGE3ckHgLQsdevPH2mWnhvy5ra6VBH4lk8to/s+3h4EJx80pB6E4jJPdcgD/8AhItfgS28Z3M0reFrifY2mxWwdoLFgRHdkgFy+7a7AZAjfplST2fhfxRp/iQXX2BLuKS2ZQ8V3bvBJtYZSQK4B2MM4PsRwQQNqONIo0jiRUjQBVVRgKB0AFc74j8NT3+qQ6ro2qy6RqyRfZpJ0hWZZoc7gjo3BKkkqeqlm6hiCAdDPLHBDJNPIkcUal3d2AVVAySSegFcv4e8Zw6xqsdodOvLOC7ha4025uAoW+jUgMygHK/eVgGAJU5xwcU4PhvpvniS+1TXdRSQq93b3d+zwXkgOQ0kf3fT5F2oQACpxWt410u7vrOyvNJSKTVdMulvLVJH2LKQGR4y2DjdG7qDjAJB7UAN8XeKo/D0ljBHp97ql9dMzLaWShpRCmDJLgkZC5UYHJLAAEms+0+JXhu7sdSure4ujHZIsm2S0kie4DHavkq4BkJcGPAH3uO4q94X0e8TULzXdeEP9s3qLEIoTvSzgUkrCrEAtySzNgZY9AAK1L/Q9L1HU7DUb7T7a4vrBma1nkjDPCWGDtPbP+FAFTwt4gGuw3Sz2FzpuoWkgiubK5KF4iVDKdyEqwKkEEE9x1BAzfGPjRPDmq2Fmli94r7Zr6VZQgsbYuIxMwI+bLtjaOcK5/hqLxPJfeHvFFvr1hpt9qVld2/2O/trKMPKrIWaGUKSM8s6Hn+JTwATUmj+GZL3R9bk8RoF1HX1IukRg32eLaVjhU9DsUnkcFyx70AbPifXYPD+mrdTQz3U0sqwW9rbgGW4lboiAkDOASSSAApJIANcsPi14WUp9onu7ZdrLNJPbsiW04BP2aRjwJyFbCck446jN7wr4e1pdQg1PxjfWd7f2UJtbNbVWEaqcB523c+a4AzjhRkAnJJ66aGKYKJo0kCsHUMoOGByCPcHvQBwtnpnjeXT4tWi8Qxx6ncKZn0m9s0azjDcrECgWVSowCxZucnaeBUtxF8QNRRLuCfQ9EliIKWDBr1J+zebLhCoxyAgznGSeldxRQBwXhazvvCvipdJ1DVrvVINXtnvBPdSFit3GV85UH8CMrqyoDhdjYre8R+JBpN5bWFlp13q2qTq0os7RowyxKcNIzOyqoyQBk8k4HQ4PF2i3WqRWFzpVxDa6tp0/wBptZZ4y8ZJVkZHAIO1lYjg5BwecYpfC2hy6X9svdTuEvNa1B1e7uEQonyjCRxqSSsaAkAEkklieWNAF/QtVtta0uG+s/MEcmVZJUKSROpKsjqfusrAqR2INX64h9VsvCXjDWV1a4Sz0zUoF1GGaXCx+bGuydAf721Ynx1OWIzg1XtdB1TxRAmv3er6toeoyktYxWzgLa256LJC4KO7jDMXUlTgDG3kAv674xuLDUr6LTdGl1Sx0uISancwzqpgyN2xEI/eOEG8rkYBXGSwFdZazxXVtFcW7rJBKgkjdejKRkEfhVLQ9Gs9E0tLCyRvJG5naRt7yuxyzux5ZmJJJPUmuG0PXLjwCLDw54vaxg0qG2lXT9VF0SZkhxhJIyg2P5ZHAZslGx2oA9KorzxbTx1ryNfRatbaPp2ooYxp8toTcWcJ+7KsgIPnkclW+VSR3U7pobbxL4Xa70rQrGbV9PnKtp11eXu/7CSMOk7O3mPGpG9Su5juK8AA0AbFx4y0yDxONFdLrfvSB7sRf6NHO67kgZ88SMuCBjHKjOWAPRCWMyvGJE8xFDMu7lQc4JHYHB/I1z1v4QsV8JPodw8somJlnu1OyaS4LbzPu7PvAYHsQOwrJb4YaJIRLPcajLfTblv70zhZtSjbAaK4KgBo8KoCgKFAwuASCATWPjn7Vqlu39lTp4cu5Ra2msGQbZ5iSF/d/eEbEYWQ8MccYKk2vEHjKHR9Ua3Fjc3VrahH1K7iK7LFHOFLAnLf3iF5VfmPGM7eqaNp+q6NLpN9axyadKgjaAZUBRjGNuCuMDBGCMDFV7Pw5pVnodzpFtaKtjcq6zozM7S7xhi7sSzEjgkkmgDWJCgliABySe1cFba14naT/hILW0fVdBut6wabbJHHPHGP9XOGkZd+/BJUkYDLjkHMNnPq+uaDbeFruw1K3nWP7JquoTwlI3iUbXMTk/O0oGAVztDEnBAB9CijSGJI4lVI0AVVUYAA6AUAcXq+q/8ACVRaNpmgX9zapqUIv7m5tzsmgtAOAD/A7uVUd8CTutbPg6/u7rTZbbVG36np8zWly+3b5hXBWTHbehR/+BEdqvaZo+m6VLdyabY21rJdyma4aGMKZXPVmx1PX8zWJfuvh/xemoSsqabq6pazueBHcrnymJ9HUlPqqDvQB1VZniPV00XS3ujEZ52ZYbe3VgrTzMcJGCemSevYZPQVi3Wv3WuXtxpnhGWImBvLu9VdfMhtm/uIOBLJ6jO1f4jn5TLpHh/U21G3vfE+qQ6nLY7hZCG28hVJGDLIu4hpdpK5GFALYA3GgBfDfiOea/m0bxItlZeIIcOIYJi0dzGwJEkJYBmAwykY4KnsRV+38S6XceIrjRIrhjqEC5ZTEwQnAJVXI2swDKSoOQGBxUPi7w+uu2lu8Bt4NVsplubG6mh80Qyqe4yCVIypAIyDWNrWhf2H4Stbm0Mlzf6TdDVJJ1jLSXDbj9oO0ZJZ43lAAz1AGcCgDe8UeI7Lw5axTXq3ErSsQkNtH5kjADLttH8KqCSew9yAdaCaO4gjmgdZIpFDo6nIZSMgiuY8Mo2ualc+I7qCWO3mi+y6fDPGyMLfOWkZG5UyNg4IB2qmQDkVRs5v+EFmNrq+tGbQ/sjyWYuVjRrcQ4/dKVAL5RhjOT8lAGj4kutWvNVj0bw5e21ldLbm6uLmWHzvKXdtiXZkffIfn0jbHJBD/C/iy21e3livYptN1W0hWW9tLuFoTF1BZSwAePKsA6kjjrVjwnZzxWUt/qEZTU9Sf7TcKRzECAEi/wCAKAvu2496TxL4X0/xC9u98bmNogY2NvKY/OibBeGTH3o2wMj24IoA0tJ1Ky1jToL/AEq6hu7Kdd0U8LhkcdOCPcEVbrl9S8EaVe3s11HPqllLMxlZbK/lgj83AAl8tW2bxgckYP8AEDVSXw34kXbeJ4ruLnUbZswRSQpDayp3SZFBJJGRvGMHBCjkEA7OsoeIdLbxG2hC7X+1Fi87ydrYx6BsbS2MErncAQcYINcm3iTWfDOpI3jB4potTR2tLXT4WkMNwpULaowUGQupLbmC8q3QdNC18KTzeHALmcWuvy3f9qNdIBJ5F0ew6bkVP3OOMoMZGc0Aa3iHxVonh2WCLWtRitHmBZA4J+UdWbAO0dsnAzx1rP8ADvjJdW1GO1u9Kv8ASxdq8unyXgVftka4yQASUbBDbGAbac44IGl4f0V9Ne5ur68a/wBUuiPPumQINq/dREGdiDJwMnkkkkkmpPEmhW2v2KW9zJPBJFKs8FzbPsmgkXo6Ng4OCQeCCCQQQSKAIYfE+mS+I5tE8yVLxPlVnjKxSuFDMiP0Z1UqSo5APscbZOBk9K5648Jae/hg6NFvQKTNFcuxeZLjcWE+48mTedxPfkdDis37D4h8RwJp3ia0s7HTUIF59muDL/aGP4QNo8uJjywOSR8vQk0AdhDLHNEskLrJGwyrIcgj1Bp9Z+i6NYaHayW2lW6Wtq0rSiCPiNC3UIvRQTzgcZJ9a0KACiiigAooooAKKKKACiiigAqG9uoLG0luruVYbeJS7uxwFAqauO1bVoL/AF4WjI9za2TjZbQ4L3d0MHAGcbI8jLEhQ5AJBSgC79l1TX1Ml1cXOkac3+rt7c7LiVfWR+sef7q4Yd2zwI9I8D+EdJljWw0LS1uYiZVkeJZZgSeXLtlySepJyapG71LWZjGN8wDFXhsbgxW8R/uyXONzNz0jHHQjvV/TfDlxaqPJurbTsrh10+1QFu/zSSBi31wKANJp9ZG4jT7AgHgfbWyR/wB+uv41BJq0D2o/taxkjgk43bBcQsPqmcD/AHgKWTTtVgUvZazLM4BIivYY2Rj6ZRVYfXnHoelV7SGzubSWePztFuLVnFwsLiNY3wGZiCPLcEEEOVPB7cigCDU/BWh6rbjyluLPkvHJYXLwbWKldwVTtJwzDkHrS6EkHhO0s9Intre2tCwit7m2i2RMcYUSD+FzgDJ4Y9CCQtVD4mmgulhaaS5t5w3lv9ke2uAP70YkXZNjrhecchWrl77xle+IpLnwzpU1nLb7vs134kMW+yRWH+rUH5GuOcbclFJBJz8lAGtrniYeHPFZ8P8Ah6FNS1TVAZorHzAkVnKcs0kz/wACOAWCgFmZWwDuOOi8KeG30qWfUdWvG1PX7pQtxeuu1VTORFCnPlxA9upPLEnmvPpLOH4aaUdJuFWW3e7ivbHWLr5pbuYShnhuHxzMVyqNxuX5QAV59koAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooArX1hZ6gkSX9pb3SxSLNGs0YcJIv3XGRww7HqKs0UUAFVr2ws78wG+tLe5NvKJ4fOjV/LkHR1yOGGTyOeas0UAFFFFABRRRQAUUUUAFFFFABUF7aW1/aS2t9bw3NtKNskMyB0cehU8EVPRQBFa20FnbR29pDFBbxjakUSBVUegA4AqWiigAooooAKr3tjaXwhF7awXIhlWaLzow/lyL911z0YZ4I5FWKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACimTSxwwvLM6xxRqWd3OAoHJJPYV5hqvjGLxFFJKljqR8KROFkm8gx/2h02qhbBaN2KqAgJcnBwucgHTa74kjvoJtO8KatpjaqyFpLgyLNHYRD700ig9v4VJG5vYMRmeDvC8aaYsEMl2NKKKrXFwx+16jj+KRuNkZycKACcknGTupWU+mWWrDSdduLG21K5SG91NAQqckrBbKenlrsYc4Bx0PmGvTKAGQxRwQpFBGkcSAKiIMKoHQADoKfRRQAhIUEsQAOST2rjreQajdWnmsfIvZH1WffgqIIwqwqT2BOx/wDgL+9XvH+tWWi+H3fUr+KwguHEL3EjhQiEEuRnqditgDJJxiuL0DTb34j3tzrOqF7PwTcFEs9L8sxy38UeQpuPSLcXZYxjcGG/j5SAX9Skl+KG/T9Nd7fwYjj7TqKrh9SZT/q7Y/wxgj5ph16J3atrR7SHwlZQ+HDarLowhaPT1SNcsApJt3HALkAkMfvc55BJ62KNIYkjiRUjQBVRRgKB0AHYVW1Wxj1GxktpGKbsFJF+9G4OVdfcEAj6UAcva2lpq+lX3hyaT7Rpl1bedYzv8xERONvzc7om24zyAUzyDW14O1WXWvDVjfXMRhuJFKyoezqxRvwypNY/hmdRqcEjxRbb5ZWIVci3vI223CKewYrnHco5PWtD4fo6+DtMeYsZJka4cnqTIxc/+hUAdDRRTZHWNGeRgqKCWZjgADuaAHUVys/jzQW8MnW9KvYtWgeX7Nbx2Th3ubjOBCg/vE+vQfMeOas+DtdvNWjv7bWbKGw1iwn8q4t4ZvOTDKHR1YqpKlWxnA+ZWHagDoaK5TxX4j1Gx1KLS/Dmmw6nqYt2vZ4pZzEscCnAwQpy7sCqjplWJIAq5N4w0K18M2Ov6jqMFhpl5FHLFJdOI8h1DAY9cdR2wfSgDfopsbrIivGwZGAKspyCD3FMtbiG7t0ntZo54HGUkjYMrD1BHBoAloqI3MAuxameL7UUMoh3jeUBALbeuMkDPvUtABRVK31XT7nUrrTre+tZdQtQrXFskytLCGGVLqDlcjpmpLa/s7q6urW2u7ea5tSq3EUcis8JYZUOoOVyORnqKALNFVbXUbK8ubq3tLy2nntHEdxHFKrNCxGQHAOVOOcGrVABRXIXfxL8HWsyxt4gspVyRJLbsZooOduZZEBWIZ4BcgE1taZ4k0TVZYItM1jTruaeIzxRwXKOzxg4LhQckA8E9jxQBq0VlQ+ItIm8RTaFFqFu2rwxiaS1DfOqnH64IOOoDAngitWgAooooAKKKKACiuVh8b2E3iJNNS1vPsrztZx6mVUWz3KgloQ2d27hhnG0sCoJYYrpbq5gs7eS4u5ooIIxl5JXCqo9STwKAJaKRGV0V0YMjDIIOQRS0AFFBOBk9KRGV0V0YMjDIIOQRQAtFFFABRRXMan488N6VrU2mapqcNlLCgaSe4/d26NgHyzM2EEm0htmd20g4xQB09FNZ1VC7MoQDcWJwAPWodPvrTUrOK7066gu7SUbo5oJBIjjpkMODQBYooooAKKKKACiiq8l7ax3sNnJcwJdzKzxwNIA7quNxVepAyMkdM0AWKKKKACiiigAopCyqygsAW4AJ60tABRTUkSQuEdWKHa2DnafQ+/Ip1ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBx3jK5hbWLOx1iyvLnRngaby4Ld5luZ1ZdsThQeMZIDYVu/3a4fR21fxBrcut6payWmqwXMum6bYz3InhiuM/NMEQ7NsUYxnli3mcj5RXq3iW/k07Rbie2G66bbDbrjIMrsETI9NzDPtmsrwzpkVnqH2eBnaHS7dbRXOMPK+JJXPJ+Y/IT/vGgDX0vR7TTtOazRPOSTJneb53uGIwzSE/eJ7/l0AFVdKhkgOp6UkzLFDg2z7tzRRupwv/AWDY9to7Vt1yF34i0vw5ceJdV8QahBZWMFzDb+ZLwB+5RgB3YkueBQBveHbt7vR7ZpixuY18qcMMESr8r5H1BP0INVPFniay8M2Mc12s1xdXD+VaWVum+e6lxkJGvc8ck4AHJIFcNefE3Q4dRgn8I3lt4huNbAihsbWcArcAhVklJ/1SEMqsWGflTAJNdX4U8LS2N62t+IbpdT8TTx+XLcqpWK3jJz5Nuh+5GDjJOWYjLHoAAcc2i61rGpT6z41itV1CJorbRbBcvBYTSgFpA2P3sigqfMwACjBcda9Vs7aOzs4LW3BEMEaxoCckKowOfoKkeNHaNnVWaNtykj7pwRkfgSPxp1ABRVX7fAdS+woxe4CeY4UZEa9tx7Z7Dvg+lWqAOUghDXfiAHfGbLUEvISqFusEZYBRjO4mQf8CNaPgl1l8G6DIgYK9hA4DDBwY1PIp1i2PE+rw4JUwW8pz0yfMX+SCuU0r4gaTHpGnad4dhuPEepxW0Ub2ukhZVhYKBiWUkRx8j+JgfQGgD0Oqd5DZavZ3lhceVc27gwXEO7IwRyjY6ZB6ehrlE0zxjr53azqkHh6xb/ly0nEtwR6PcuMD6IgI7NWx4Q8JaR4RtLqDRYJUN3Obm5lmneaSeU9Xd3JJJxQBbj8P6RHrP8Aa0emWa6nsEf2kRAOFAwBn6cfQAdBWR4p0nWE1e313wp9hOprCbS4t712jiuYidyEsoJDRtuK8Hh3HGcjq6KAMPwtoH9jQ3M13ctfateuJby8ddplYDAVR/CijhV7DPUkkt0zwf4f0y+lvLLS7dLiTf8AO2X2B8llQMSI1OTlVwD6VvUUAeZaToevT2sPg+8tZbXw1psrRve+coa+tBzBboFO4YUqsjHbkIQM7iRoSeCtZ0oTReCvEaaNphczxaa1hHLDFJ12IeCkLNksoBPJ2la72igDzPXPDlzp3hnUPFOptbP4vtM6k13aqcRpEM/ZoyfmMRjDIQfvFmbAJ47DxT4ih0TQvt0Sfa7m4KxWNsh+a6mf7iL9epPZQSeAa23VXRkdQyMMEEZBFc34f8EaHoN8l5YwXDTxRmG3NzdSzi1jPVIQ7ERr7LjjA6AUAZNr8PIRpWnmTUr2y1+NpJrrVNOZUlneU5mUllIKE4wCMqETBGKsT/D+ytxby+G7680K+ijMMl3bbJJLlGOT53mBvMbJLB2ywJJzyQezooA8+1TwrfeGDDq3gS3tJLq3tXhu7W7Llr9dwkDbwcmbcGwzZB8w5p82pyfECSPT9IS8t/Dg51K7mhe3ef8A6dYwwDc/8tGxgD5Qck7e+ooArWGn2enweRYWlvaw/wDPOGJUX06AYrnfEHgmwvkWfRfJ0LWEuhdpqVnax+b5hyHLZGH3KzKd2eue1dXRQBw+veHBonh/TJ9Ctri6udIvVv3wd9zdg5W4JY8vIyO5x3IA9MZzaPqPi+W78S25l06/gdBoAvopEESJy7SxZVgJiWVgQG2Beh4r0migDzoeNvEFzp0F3Z+GbiJLFUfWVu45I2Ug4ljtlxmZlG5gw+UgAAkt8rLm88Waxcx+JvDkcp0+3kEVppFy4thqEDDEk8hZSyHJUoDjCoSR8+B6RRQB51/bWveMki0i10bUtCgOU1e/mJiMJU4aG2PDSM2CBMAFVTkHdgCW58Hatpd5PZ+Dby303QtRjVLpWd/MsnXhpbYYI3OvByQAyh/mJIPoFFAHP6l4Wsp/CJ0CwUWUEUai1ePrBIhDRyA9SwYBs9Sc561k2elaz4murWXxrp9jbWNkMjT4pftEd1PjHnPkAbF5KIQTk7jgqK7aigDz240278BTQahp+oX9z4YjlaOfSRAsiWUD5PmRbE8whH/hywCMQANoomGv35fxXE2pQJbSKbTRwSPPtAf3hki7yupLKDyu1BwSwr0KigDh7u4m8dTw2Npa31t4ZBEt7c3MDW5vQMEW6I4D7CfvsQAQNozuJGVP4dl8Bazpuq6G+vXuieZLBd6ZDI9wltC43R+TAOio4A+UFgrY+6MD02igDz3+1PEEGq2niPUXlstBublbE6VcIoaCJ/ljuXYciQy7QVztCPzhgav+KvF1s8lz4d8OalbS+KpHW3WCNg72u/lpnXsqJlueM7R1YA9ZfWlvf2c1pewRXFrMhjlilUMrqRggg8EVV0PRNM0GwhstHsobS2iUqqxrzycnJ6kk8kk5J5NAHFR+IbjwedR0HULi81XUQVbRPtJDTX6uoHlllAyUk3bmxwhVj610+i+GLK00G2sNSgttQlVzczyzxK/m3LZLy4I4JLNj0Bx0rfooA8+0zwnrM0dvoWtzWzeFdOYrCkcrtNfxj/VJPkAKiDAZQTvKjOFypTxD4d1LQJL7WvDWpz22nW+2/fRLa2j2TyJxKA2MgPGD8gA+cBs5JB9CooA4+/8AEt1rFxBaeBZ9NvZRGLm4upSZLdExlI9yHh5Ox52qCxU5UGuni688QCCw8KwpBqw51A30DvHp2OscgBXdITwoB6ZbpjPY2dnbWMPk2VvDbw5LbIUCLk9TgVPQBxcXjWaaJdOg0qeTxUp8ubT9rrFC3eRpiu3ye4YZLAgAbsgSDQfE2pKY9e8Sxw25zmLRbU2rMD2Mru7DHT5dpOPfFdhRQBxU/gu4tWTU9M1e7ufEUDfu7vUpS6yRdDA6IFUIQeoXIbDHJHMd34VvZ9LvtTvPs83itpFureSLlYDEcxwRswBCEAqx4z5jnAzgdzRQBw8Pje51qaGLwfpUeqEIPtss92IEsZD92NxtYlwQdygZUAdcinnRPGsu0N4ttIcMLgNHpqsd56wkFuYR26SdPn457NEVN21VXcdxwMZPrTqAPOY9XvvCmsXmh3WoXmu6rfwJd6bHOgUySkssqAqAFiQhHOfuq3U8VoaNfa7omq7PG+safcR30LyQm1tjbwWzRDLKCzMzbkJfLHjY2OK7bHOe9VNT0yx1W3WDU7O2vIVdZVjnjEih1OQ2D3HrQBy1voEXiizudX1RJIry8G7TpCMS6fEP9Uyf3XJ/eN0OWCtkKBTV8WPdaBb2drJF/wAJVcE2bWoILW868SSOozhE5fPQjbj7wz21QR2dtHeS3cdvCt1KoWSZUAdwOgLdSBQByE2gN4SW21Hw6ZPs8KompWoiEj3qA/NOSBuMy7mYkZL9Dk7cOu5V8eeXZ2qXieGwd91ckSWzXRH3Yo/uvtB5Zxj7oUE5bHaUUAcCyeL/AA59lvb2+bXNMtWNvJZWdmDcTREfLOzFstKDtBVcKVLHGcYWDUta8MH+0vEv9o31nqCtJLBa2/2g6dNnKRKsSlmQqQm75vmTPAfjvaKAOQ1S6h8WXWn6Xp85k0maFNQvZY8gSwN/qos448wgkjg7UYfxVa8MZ0nVL7w+7HyYgLrT8npbscGMc5PlvkeyvGK0tB0HTNAguIdHs0tY55muJFUk5dup5JwOwA4A4AApmv6Fb60sBlnu7W4t2LRXNpMYpUyMMMjqCOoORwD1AIAMaazTxbrt6t3JI2i6afs8aQTPEZLrrI5ZGB+QFVGDw3mdwMJp+tf8I5fxaFrr6jKJZxFp9/JA8qTI33UklUEK4bKZfBb5TySa6bS9PttLsIbOxj8u3iGFBYsTk5JJPJJJJJPJJJNN1jTLTWNNnsNRjMtrMAHVXZDwQQQykEEEA5BB4oAswzRToXgkSRNzLuRgRkEgjjuCCD7in1BY2lvYWcVrZwpDbxLtSNBgKKnoAKKKKACiiigAooooA5XxPPG2v6atz/x5aZDNq1wRkkFF2RjA6/fkb6oK1vDNo1ro8JmUC5uCbmchduZHO5sj2zj6AVzUztPd+N72Uqqx+TpsZI6osQc/m1ww/Cu5oAK+X/2uLXULUwX2nxtLawSpd3KMnmRqzxmFJSpGPl2AZPQsvqM/UFUNRsDdXNrOjqrQlkdXUsskTjDoRkDnCkE55X60AfMv7JPh55dU8bS2ySy+ELgC0ilmUq1yyu2xlYAYKqSTjGC69xX0ZZahLpk0ena1ISThbe+fCpceiseiy+3Ruq9wuzbwRW0CQ20UcMKDCxxqFVR6ADpSXVtBeW8lvdwxTwSDDxyoGVh6EHg0AUNR8RaNpsxhv9VsoJxj9y8yiQ56YXOT+Aqi+p6hrDm30W2ubO3/AI9Ru4NmB6RRv8zN7sAo6/N0PiP7VnjS48GaVpegeD57fTLjUjJJetYlY50RdgUfLyoYsfm4J2YBxmuf/Zd8QeOfEn9u6TputpDotqUl+0alG97cW+8sFSI7lXkKSdwIBGQvJoA+mB/ZHhTSJZ7u6gsrRTvnu7uYKXc9Wd2PLH39gOABXIW/xJk8TXs9h8PtHm1WWJVaTUL7dZ2UYYHadzKXkz1AVMEc570278Habpt7bXF4LnxV4quGP2WfWX85IOm6QRgCOJF4PyKCcgZJIrudD0xNJsfIWR55nYyzzyY3zSH7ztj8gOwAA4AoA86bwbdanq+py/EXVp9QSW382OxsJHtbBoUHKvGG3uVZiTvYqQ68cYHVfC2ayk8CaRHp1mbBIIEiktTEI2ikCgsCo45yDnnIIPeqPxIuRFBfGNwLhdJuII89BJcPHHHu9tw/Q1Y+Gcpex1RJo1guY7zZLbht3lFYo0xnuPlOD6UAdjRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBw0ss8+m+OILuRQbS9LpgciLyIZB/7MPw9q7hWDKGU5BGQa5m/gjs/FyvMm6x1u3+xzBsbfNjDFM/7yNIP+AKO9X/Cdy0+hwRy4FzaZtZ1znDx/KfzwD9CKANiivnn4nftJW3hPxzLoek6Qmp29jJ5V9OZ9h8wfeSMAHlehJ75GBjJ918O6xa+INA0/V9OLG0voEuIt4wwVgCAR2Izg+9AGjRQSB14ooA5nxl4E8NeMrRrfxHpFvdqzK3mYMcoK5xiRSG7kYz3ql4c0Sy8J6Y2i+BNAWygDktNOGSLd3Zix8yU8ADseBuArs6KAMzR9JTTzLPLNJd38+PPuZer46KAOFUZOFHr3JJOnRXO+JLv7S8mlxXAghWMzajc5x9ngweAezNgjPZQzemQDjNd1Ka48Q+HoYADceIdVjlDOm+OPT7UGRcnoC7AMue8p/u4rqvCFpbReI/GN3ZoircahGHaNsq7pbxBjjs2cg+49c0/w9pUOoWF3e6jaqF1III4GXHk2yDEKDoVOCX9VZzjoK29H0uy0bTorDS7aO2tIs7I06Akkk+pJJJJPJJzQBdpk0scMTyzOscSAszucBQO5Pan1BfWltf2k1pfW8NzazKUlhmQOjqeoZTwR7GgDk7/AOJPh22vNLiguJL+2vgrG+slEttbI0nlI8sgOFVpMoDzyDnABNdVqd/a6Xp1zf6hOlvZ20bSzSv0RQMk1hweBPDNrpOtabZ6Pa2tlrG43scK7RIWXaT/ALPHTGMHkcmsyx8G6rdTWaeLfELaxp9gytb2iWwgEzocpJcnc3muMA4G1NwDbScYAIIvifp1q0q+I9PvtClkiFxp8F2FabUIzwBEiEnzckAxffG5Tjk4m0bxTrkWvafaeLdMtNNttYDnTvKlLvFIo3eROcbfMZMsNpx8jjnAJ7Z4YpJI5JI0aSMkoxUEqSMEg9uCRVHX9F07xBpkmn6xapc2jkMUYlSrA5DKwIKsDyGBBHY0AaNFcI/wx0mBg+i6lr+jyK4lQ2mpSsiyd5DHIXRmYZBLKcg+vNVBH8Q9BaK9vL2x8Q6dZt5UljaWgiu7uE/8tt7MEEy8fIAFYBsEEgAA9Gory7WJ/E1tt8cXst/YWdpNGH0BSJFWwLbZZZVTOZgD5vyk7RGFGctnW1Tx5pup+BJdU8L3P2ya+lfTdOXa0bS3RJQDDAEAEFieyqT2oA6Tw94l0bxH9s/sPUbe9+xzGCfymzscevtwcHocHB4qy+saamsx6Q9/aDVJIjOtmZV85owcbtmc49/Y+lcbdeFtW8PjQbvwdHY3N7Y6euk3MN5K0EdxCANkhZVb5kcFsY5V5BkEiqvibwqdH8DXmqRkXviezmTWZtQEeJJposFwo5wpiDxKnQKcepoA9KrgbHxlqc2uQXElnZf8Ireag+l2twjt9oEqbl81h93y2kjdABz9087sDU8VeIiug2a+HpYp9V1pRHpnPB3LuMxHXYineT7AdWFSXPg+zk8D23hqC4uLeG1ihWC5jI82OSJlZJeRgtvQMcjB5z1oAXUfGel2Hiq00CUXL3M+1Xnjj3QwO4JjjkfPyu+1tox25xlc9LXD654Sng8B6hZaZLJfa08yag1zOVWS6uUkSQEkABSfLVVAACgKOgrX8JeKE8RvfxnTNR0y4tGQNb36KkhV13K+1WbAPzDBOflNAHQ1R1HV9O02ezh1G/tLWa8k8m2SeZUaZ/7qAn5j7CuU1XxzPaavO1lo89/4esJvsuoX1tulkim7iOFFJkVDgORyC3AO1sLpPh3/AISWPVNV8W2G2TVIfssNlLjdaWmcqpx92Rid7EHIO0Z+QGgDt2YKpZiAoGSTwAK5/wAHeLdO8W2tzPpi3MawS7CtzF5bOpG5JVHdHUhlPcelc8vw91Fo2tLzxlrN/pl2oTUYLsK7XKDoiMMCFWX5XCr8w7gkkyeK7W68MeIrLxPpt7FbaTI1tYarZPEojaLeUjmD8FChlGccFRz0oA76snxJr9h4eskudQaUmWQQwQQRNLNPIQSEjRQSxwCeOgBJwATXIaguofEF79tE1W503R7DdHY3Vs5QXl4v/LQkffgjYbdo4c7uoUZ2PDei6pc6x/wkPi1bQaokRt7S0tXMkNlGcbyGYAs7kDLYGAFUdywBlP8AE61huUurzSr+x8Ml/s7atfRtb7LjaW2GF1D7eNm/pvIUA9aq282t2+o6V4s1O5v7eDUr5LJtJkfEVvaS5SDMfQTeYYmZvvAOy9Fr0wgHrzWT4p0f+3dEmsVuGtZi8c0M6qHMUsbrJG209QGRSR3GRQBrU1ZEaR0V1LpjcoPK56ZFcVYeL7u28H317rUFvPrNneS6f9nsdyrcziTbEqBiSN4KHBJxknOBWR/ZA8DT6V4m1CSNry4laLxFequFdZeVkb0SKQRopP3Yy3QZoA9IvLq3srWW5vZ4re2iG55ZXCIg9STwBUqMrorowZGGQQcgiuEWS2+IuoWskAS68HWT+b5jDMepXAyFAB+9FGcsT0Z9uPuHNHToNV+HNzZ295f3OqeD2V7eGOHT2eTTADuiDGPc8ikZTO0YwnTJyAeg31/Z6eIWv7u3tRPKsERmkVPMkb7qLk8sewHJqzXnGr6PcfEK31C6ubGS206OynttJhvYzHI88ikfamRhmPHCpkBgC5IGRTbb4iahp5WPxP4av9PkuYQNMiDLLPfTqMSRFUyqNuIK5YgpliQFOAD0Xz4vtBgEqeeF3mPcN23OM464yDzUleW3XhqXw7pcPjC6hjk8T2919v1WeFd7PbPxNAp6tHHHgqvTMSnGSa6HxXew6/cWPhnT7gyjUFW5vZLaUjy7EHJO9TkeacRjByQXIPykgA7GivPre71/wlLPoVjouo+IIS3maXcPOFSOIn5oZ5nJIKc7SQxZSo5IJpl3efFLaRb6V4UTAd/M+1zSE/xLGE2LzgbC27GWDAADaQD0SuTm8c2MGsSWs9pex6clx9iOrMi/ZRcZwYid24ckLuK7d3y5zxS6h4oW88M2E+gOjalrCiOwjk6o5Hzs6+kQ3Fge67epFa+m6DYWPh6LRTAlxYrF5TpOocTA/eLg8MWJJOepJoAr6L4r0bW9VvtO0y8E91ZgGTCMEYEkEo5G1wGBUlScEYODW5XLeI9Hlsl0vU/DdlF9q0gNGlnEBGJ7VwBJAvRVPyo6543RqOASaz7i+m8dbNP0+DVNP0QHOo3M8L2ksuOtsgYBxk/fcYAAwpJJKgHc0V562j3HgW9sL6z1jVLnw8sq2cunXMiyR2cMhwjoxG87XKglmbCE+grb8Ualq7albaT4XazGo7Dd3El2jPHHCMhVIUggyMNoPOArnBxggHT0VneHtWi1rSoryJGiYlo5YX+9DKpKvG3urAj8M1yP/Cf3Vu8+pXuh3LeFWkZLfUbTMzKsbFXmmTA2RcFlYbvlUk4yBQB39FczrWsajcanHpXhdrFr0Q/abi4ulaSGCM8ICEIJZyDjkYCseeAc+PxJe+ILZNJ061vLDWGHl38kkDqlh/fKuw2ux52YznIY8DFAGm3jPRl1JbPzblsz/ZftItZTbCYnaIzNt2bt3y4z97jrxXR1k3Hh7TZvDTaCYNmmmDyAikgqMcEN13A87uueetcjHpniKIz+FGm1S602aXzDrtxOhkW1IG+HcMN5u7coIXARs5yMUAeiUV55C/iPwWjWyWEN94TspdwuDcyS3cdq3RFj2kt5RJ6sSYwAMsDU0eq+JvEF/JqnhG4sV0OJRBFBqVvJGLxurTq4G9VXIUDaQ21+gKtQB3tFcTDN440WWRbu1sfE1o3zLNbSLZ3CMf4fKf5CgP8AF5gbB6MRy2HQvGmozB9a8UwWNswJa10mzVWw33kM0hYnbwFdQh5JI6YANe98a+GLK+Flda/pkd59oFqYDcqXWUjIVgDlT0646j1rX03UbLVLUXOmXlteWxZkEtvKsiblOCMqSMggg1StvDOiW+mNp6aVZtZvEYZI5IhIJEJJIctkvkkk7s5JJPNcxqWoWHw+1y8uLkLbaJqcPmxxxoABeRqF8pAOryoF2r3MRxyaAO+org9JXVtD1nTL3Wry5k/t1mju7Z5fMhs7gruhSIfwqFV4yR95thPJNaHi7xJqGmajFaaLYRX8sFu1/exszK4t1O3EeAQZGO7aDgHY3tQB1lFVtNv7XVNPt77TriO5s7hBJFLG2VdT0INWaACiiigAooooAKKKKAKGu6amr6VPZyO0RkAKSofmjdSGRx7hgD+FczZ6o9pfzXlwjRToqprFsAT5ZAIS5QfxIQMEj+HryhFdrWD4o0GTVGtb3TLs2Gs2Tbre4A3I4P3opV43xt3HUEAgggUAfPXxE/Z31fxP42v9S0HU9Kj0LVLkX/mSySF4GcZl2IoKMGOGzkdFGQBz61o3wc8LaHpNta6ZLrNjLBEqtdWmq3EDOwHLlVfZknJPy456VoaRqEumXZhaylsrlgXn0hcOjY+9NaNwGHcoMHvtVuG1dR1yx1PTvsmlXtvPd3jfZ1jzl0z98snDLtXcSDjBFAHD2XhHX52tE0nx74hijmZr5k1GGC8CxhgIeSgIJwGxu/hPfmsvxV8SNS8Ea9Homr+NvCN3qDBSYrvS7m3Zd33d8kTyInHPIHBB4FereGY4pVutRhCbLpwkJQEAQx/Kg57feb/gVfEP7QOjah4c+LHiW51rT3u4tVLy6fczFtmH28rj7xRcoFPQ7T6ZAPruPxL42iSJ5vBVnqFu6hhPpWtRyBwRkFRKkeR+NWE8eTRELqPg/wAV2bdyLNLlR+MLv/Kp/hFpOpaF8M/Dmma2R/aFtZokqgg7O4TI4O0ELxxxWteaysk8tlo4S71BDsfGTFAfWRhwMf3fvH26gA47Xvi94Ys5I7BNSNhqk4G3+1LKe1SBTkeY5kRRgEEAZ5PHHJCaZqnh3XLu20HQta03U7IP9r1W4S7jla6f+FDgncWYAsAMBU28AgVtKJ2N5pmhXyXOsMyjUdSlUMIM9go43gZ2x9FzluvzPT4b+DRpsNlN4Z0i5iiGA9xaRySEnksXIyWJ5JzzmgDraK4aP4W+GbUu2kpqmku3fTtVuYB/3ysm39KB4L1uzTGj+Pdfi/2b6O3vF/Now/8A49QB3NFchBbeOLF4/M1LQdXgVWLK9nJaSudvADCR1HOMnbXS6Ub1tMtDqq26agYlNwtuSYxJgbghPJXOcZ5xQBaooooAKKKKACiiigArmNH8EaRpfijUNeh+0y3l3I0iJPLvitWcDzDCv8BcgFj1J9uK6eigAoIyMHpRRQBzvhnwXoXhq5muNIs2jmkXylaWZ5fJjznyot5Plx5Odi4HtwK6KiigArmdf8JnU9VbULHWdS0ieaAW12bIoPtEQJKgllJVl3Nh1wQGPtjpqKAKmk6bZ6Pptvp+mW6W1nbpsjiToB/Mk9STySSTzVuiigAqK7tYL21ltryCK4tpVKSRSoHR1PUEHgj2qWigBkEMVvBHDbxpFDGoRI0UKqqBgAAdABT6KKACiiigDnV8H6YPFr+IGa5e5bDi3aUm3SbZsMyx9BIUAQt6Dtkk9ERkYPSiigAAwMDpRRRQAUUUUAIQGBDAEHgg96zNB8PaP4ehmi0LTLPT45n8yRbaJYw7epx6Dgeg4FalFABRRRQBk6b4c0jTNWvtTsNPggv705nmRfmfnJ+mTycYyeTk81rUUUAFFFFAFbUrK31LT7mxvYxLa3EbRSoTjcpGCMjpVHw5oNvoUEwjnuru6nYPPeXbh5piBhdxAAwAAAAAPxJJ16KAOUv/AApcTajf/YtWksdK1JhLe20MIEjSbQrFJc/IHUKG4JyMgqSTXSwWsFvZx2kMMaWscYiSIL8qoBgLj0xxipqKAM3QtC0vQLV7bRdPtrGB3MjRwRhAWPc49gB9ABWlRRQAUUUUAFFFFABRRRQAUhAPBAI680tFAFHWtLtdZ06SyvlcwuVbKOUdGVgysrAgqwIBBHcVX8P6BZaGtwbU3E1zcsGnurmZpZpiBhdzNzgDgAYA7Dk1rUUARwQxW8Yjt4kijyTtRQoyTknA9SSfxqSiigAooooAKKKKACiiigAooooAq6np1pqlo1rqFvHcQNztcdD2IPUEdiORXOvoOpabepd6VJZak6goBqi/v0Q/wLcKpbHA++GPA5rrKKAPP01XxDppEU1pcWltnbGraX9sSJQPuhreQHaOgJjB45rK1nx7F9jaz1dtInhuP3DxTafessm7+Fo/KPX0Neq0hAPBAI680AeCWth4j0U2sfg46xruhtIWn0IQSWFvChHSC5mYOoGM+Xkqc4G3gV1/gzVH8ZwS2K3aeHorI7LnQrUGO9h56SuwBVT1zGoznhzXptc74s8H6X4laC4uRPaapbA/ZdSspPKubfP91x1HqrAqe4NAGzpthaaZZR2mn28VtbRjCxxrgD1P1Pc96s15+PEus+DmWHx0i3ek8KniCziIVOw+1RAfuv8ArouU552dK7u1uIbu2iuLSaOe3lUPHLGwZXU9CCOCPegCWiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopkzbU3ZwARn86AH0UUUAFFFFABRRRQAUUUUAIQGBDAEHgg964q78Fz6TK154Cvl0afcXfTpFL6fcE8ndEP8AVsT/ABxlT6huldtRQByGh+N4ptTj0bxLZSaBrzkiO2uJA0V1728wwsv+7w47qK6+qGu6Npuv6bLp+tWUF7ZSfeimQMMjoR6EdiOR2rkPsviTwSCdO+1+J/DwOTayyhtQtF/6Zu3E6j+65DjszcCgDvqoa9Z3OoaRdWllfSafcTJsW6iUM8WepXPGcZwex5qHw34h0rxJYm70a8S5jRjHKuCskLjqkiHDIw/usAa1aAPNo9cufB2p6h4cSDU9XvLiRZ9EhmkkkMqOoDq87A7VjcMzFiSFYYB4Fdd4N1qXX9Aivbm1W0uhLNbzwLJ5ipLFK0bgNgZGUJBwOCOBW3XB/wBn+LtF1XVrfw3aaNPp19dG+juL66kQ27OB5qeWqEvlwzg7l+8QcdaAO8orgX8I+JrOSO40jxjcte3BK37ahF58OD/Hbw5CxMvRV5XH3gx5NXWfC3iKy02bV28Ualquq6Uhm0+BFFukyr8zRzInyys4GzcQAOCoU5JAPSKK5PUfHWmJpmmz6MG1m91SPzdPsbN08y4XGS2WIVEH8TMQB06kA6Xh/wAT6Xrmm6Xd2t1EjajEZIbeV1WU7fvrtzklSCGxnBBoA2qR2VEZ3YKijJJOABXD6rcy+NtUn0bRtQubXRLMldR1Gwl2SSS8bbeKUdCPvOw5GAndsc+LPxJJFqPgOefV79Jp1L67dRhR9gdFMgDgBTKW8yMKBkAhjwOQDf8AC3i7U9T1u0/tK0s7fRtYjml0h0dvOZYyMeYDwTIhMiheiqc5qLV/GGrWeo6lqUNpaP4U0m4W0vXwxuG4BlnQg7fLiLAMpBJ2yHI2gHpPEXhuy1zRodPd57IW7pJaz2TCOW1dOFaM4IHGVxgggkEEEirmk6RZ6Xo0Ol20Za0jQoRKd5kzncXJ+8WJJJPUkk9aALyMrorowZGGQQcgilriovhtocMQhjuddW3Q4ihTWLlEij/55KquAExxj049Kp33g/U9BltdR8H319ez2shVNL1LUpBam3ZSGiU7WIIYqwZgxG3aCBwAD0GivO7nX7/xlbabYeGLuXS7qW0F9fTIFdrQ4xHASyldzSA5GM7Y26ZBrsPCupPrPhnStSlUJJd2sczqOisygkfgc0AalUNe1e00PSp9Q1B2WCLHCIXd2JAVFUcszEgADqSKqWPijSb7XrjR7a4Zr2ANnMTBHKkB1RyNrlCVDAElcjNY1greK/FD6jOoOiaNO8VihHFxdLlJJz2KodyL/tbz/doA1H8WaYvhB/EgadtPWMvsEJ84sG2+VsPPmb/k29d3FYvgzxVq2reILiLV9ObT9PvomudJSeJobjy42CSCVG6MSyuBx8rc9Kdb+D70+JJWu72FvDkd+dVt7NFIkNwwBw56bFk3SADqzAn7vOx4t8Mw+I4bQG8urC5tZS8dzalRIFYFZEyQcBlJHqDgjkCgCbw14m0nxLHdyaNdfaFtZjBLlGQhgMggMBlSDkMOD2JrZrgdQvdO8C+LPtV7tsdCvdOitllCMyJNAW2JwCQWjc49fLx1xVS/XxLrUR8U2S6lbfYpUk03RhJ5JuoAw80zocAySIWCK33MIeGLYAPSaK85bVPiJas2qzaVpk+kM63DadHu+3ww8gxKAdjy42vndjO5AOjVGfG2sXGn6lps9jFpXiiWeGCwg3ebtjuATHKwIwWjVZWdRx+6Iyc0AelVlah4h0rTtZ0/Sb29ih1C/wB32aFs5fb15xgegzjJ4GTVTwRqN5faRLBqsiy6lp9zJY3MoQIJWQ/LJtHC70KPgcDdiuaig/tfwt4o8QRhZLi7maeykxz5dqf9Hx7b0Zx/10z3oA7PxHq0eh6Jd6jLG0vkr8kSnDSyEhUjHuzFVHuag8Ja5/b+kC6ltWsryKV7e6tGcOYJkba6bhwwzyGHUEGsfUr+DX9Y8JWtrIHtrhW1pgD9+KNV8vI/66TRMPdKr+JPB+qDVJtZ8H65PpupTTJLLaTnfYzHaI3d4wN28oBjDAZRfc0AbMHi3S5/Fb+H4nma8RGJl8s+SZFClog/QyBWVio6A+xroK46+8Eg+HtKsNH1SfTr/Trn7VFqJjWaVpGDiZ2DcMziWTOcgFgcHAFUPC/j1fsF9aeIrfUbfUtGtDJe3E9oYY7po2ZHaHOA/KqflGP3igegAO4+3Wn2/wCw/aoPtvl+d9n8weZszjdt67c8Z6VYrzO70iXR9CsfFN+ka+IE1CK+vZiuWWKVhFJDk87EifAHTMYPWu58SaqNE0W5v/Ie5kQBYreM4aaVmCpGPQszKM9s0AadFc74Q1q91Bb+x12C2tta06RUuUtmZoWVl3JJGzAEqQSOeQysO1ZL+MdbvES68O+D7rU9MkY+VdNfQwecmcB1RjnaTyM4yvzDspAO4rll8eaAPElxotzd/ZLiNhHHNdYihuZMgNHE5OHdSygqOcsOvOMmbx7qloEXU/CGqWU1whitFLrMJrsf8siUyEUk/LI2AQrHAwM7Np4Qsn8HRaHqyJd5icTTEAsZXyZJFJHBLMxB69KANDxJrS6LZxOttLe3lxKILW0hKh55Dk4BYgAABmJJwApNP8O6zb65pSXsCvEQzRzQS43wSqdrxuAThlIIP59KpaFoFxa3q6hreonVdTji+zxTGEQpFGcFtqAkBmIBZs84A4AxWR4m8JXlxrs15oDWtpHq0H2LVmPyMYwciVQAQ0m0umTjAYHPy4oA2vDHinTvEjXg077QPszgZmiMfmo2dkqZ+8jYbDd9prdrifEy3nhS6OvaNpgvrCHT/s11ZxSrE0ccRLo6buCFDSAr15GPStPxV4v07w1bWk93Fe3S3OXVLKAzOsSgF5io52KGXJGT8wwDQB0dFY3hXXo/EOny3KWd5YyxTNBLbXaBZI2GCMgEjlWVhz0Yd+Kzbvx5oll4lfR72WW22ssIvZVC2zXDYItxJn/W7WVtvoeuQRQB1dFcTda94mu9Vvz4c03Tr3TLWU2I86Zo5GnABaTd93y0Y7CoG4lSQe1G7W/COJJ5NV8TW1yh8xY4kaSG47bQMbYm5GDnZgc4JoAu69fazeay2meGbizgms4Rc3UtzCZUZmyI4eCMbsMSw5UBeDurS0nX7S+8LW+uysLe1e3+0Sb/APllgZYH6EEfhSeFtNm07Tma/ZX1K7kNzeOvQysB8o/2VAVB7KKxm8HTy3rW9xqjP4d+1NejThCAzSM28o75+aIPlggUcnBJAxQBd8M+IrrVL+4tdT0xtMlaMXVnHJKGkltycbnXA2ODjcvONy85yB0lc94p0nUrqez1Hw/c2ltq1qskaG7iaSKSOQDcrBSG4Kowwf4cd64+X+3PHukGxuornTpdOt3W7eIy26z6koIURnhjCjDfnJVtyDnDUAeo0VleFNSGseGtM1ASLIZ7dGcr/fxhh+DZH4Vm6f4xtr3xNJpItLmOEySW9vfNt8m5miGZY1wd2V55IAOx8fdoA3dU1Cz0qwmvtSuYrWzhXdJNKwVVHuT+VPsby3v7OG7sZ47i1mQPHLGwZXU9CCK5vUgmueNrKwIElpoyi+uAQCpuGBWFT7qN7/8AfB9Kyo7vVPCNzqul2eh32oQ3Vw9zpT20YMEZkwWilIP7oCQu24jG1uORigDd13xx4Z0Gd7fVNas4blHVHt1fzJYywyCyLllXHJYgADkkCuiDAsVBGR1GelYHh7wxZ6ZootbuG2u7ueNxfXDQrm6eQ7pS3HKsxPynjGB2rnLzQtJ+H1zZa5pMUltZ+aLXU3kmeUtA3CO7uxOIm24J+6hYcCgD0OiqumX8Gp2EN5ZszW8w3RsyFCy54OCAcHqPUYq1QAVmWuvaTdatc6Xb6jayalbHEtqJB5qcZ5XrjBzmn6ZqiX97q9skbI2nXS2rknhyYYpcj2xKB+FeOeI4tC1X4qrc+IH1u4t7HUIYbe4ttNjis7a4+XbHLcD945LMvoAWA96APc6KKKACorv/AI93/D+dS0yVPMjK5xnvQAyFyygSMhJ7e2KmqqlptdW35wc9KkjhdBjzMjn+Hv60ATUUgBySTS0AFFFFABRRRQAUUUUAFFFFAHNeIPCFnqeoLqtlNPpOuoAq6jZkK7qOiSqfllT/AGXBx2wea2NIOom3k/tdbVZ/OkCfZyxUxbz5ZOf4iuCR0zV2igAooooAKKKKAMzTNA0fS727vNM0qws7u7bdcTW9ukbzHrlmAyeeeay7v4f+Ebw3ZuvDelStdy+fMzWy7nfOd2cZBzk8ep9TXT0UAQWFna6faRWthbQ2trEMRwwxhEQegUcCp6KKACiiigAooooAp6ZpdhpYuRptnb2ouZ3uZvJjC+ZK5yztjqx9TXCzQXngnV7mz8PWepXlpq0QWwhZnmtrK6DNuB6+VEVcOe37tgOcCvRqKAOUbwRZv4e0nTReXtvPpvzRX1q4inLsCJGzg/f3MW9znqAa6PTrK202wgsrGJYbaBBHHGvRVH8/qasUUAFFFFABRRRQAVQfRtOfXI9ZeygbVY4DbJdFAZFiJyVB9M1fooA4fxDpGux69ef8I+ka2euRJFe3JlCtZSINpmVf4y0eFAHRkUnjNdhZWVvZadb2NtEqWkESwRx9QEUbQvPsMVYooA5rwj4RtvDbyvHdXF5J5SWsDzhc29shJjgXAHyruPJ5PGScCuloooAKwdf8Lafrur6TqF81x5mnMzJFHJtjmDFTtlXHzAMiMB/eUVvUUAU9Y0+HVdJvdPuhmC6heBx/sspB/nXL6NpviLUr3Tn8ULawWulY2RwymVr24C7ROxIGxACSqcncckjaM9pRQByviXwk+s6sLqHUpLKC4tvseoRRx5a5hDFlUPn5OWcE4JIcgYPNdPBDHbwRwwRrHDGoREQYCqBgADsMU+igAooooAKKKKAIby3S7s57aYZjmjaNh7EYP865rwXoOpWDm98QzW02opbpYw/ZixjSFO/IB3OfmbjjCjnbk9XRQBxWrTaj4e8Tajd6fpF5qkerQxeUsBG1LlMriQn7iFSh39BsPfAOlaeGIpfCFzousSfaXv1lN7NF8heSUksynqME4U9QFX0ro6KAKmkada6TptvYWEfl20CbEXJJ+pJ5JJySTySSTVuiigAooooAKKKKAOB1rw9qOha6dW8E2Rlm1ASQXlvJelLeJ3IZbny2JX5WB3BAC27oTmtK/wDCJ/4R/SbPSbtbfUNKmF1bXc8PmhpcMJGkUFd28SSZwRy2e1dZRQBleHNFj0WzlQTSXN3cSme6upAA88p6sQOAMAAAcAADtWrRRQAUUUUAFFFFAHNeE/8AkPeNP+wtH/6QWlYGu+AdE1/Xr9n8S65Bc3EyXE1jZ6p5aCRAm1/LA4I2IQeoIB7Ct3wwpfWvGyqxQtqqAMOo/wBAtOa8W8O+C5bfXPD2nmDwdb3kc8N3HrFtqTtd3iRvuZ44y2WLhWBzleW9BgA+htLsxp2m21mLi5uRBGI/OuZDJK+B1Zj1PqatUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFQX15bWFpLdX1xDbWsQ3STTOERB6ljwBU9FAHNf8J94O/wChs8P/APgyh/8AiqP+E+8Hf9DZ4f8A/BlD/wDFV0tUtbvJtP0m6u7WykvpoU3LbxuqNJ7AsQB68ntQBj/8J94O/wChs8P/APgyh/8AiqP+E+8Hf9DZ4f8A/BlD/wDFU/4eeI38W+DNM1yS2W1e8RmMKvvC4dl64GelYlh8VvDd7YahqEZvV0yyjMrXjQfu3AcIAuCW3FiAFYAn8DQBsf8ACfeDv+hs8P8A/gyh/wDiqP8AhPvB3/Q2eH//AAZQ/wDxVZFt8U/D9zas0Sag18LpbNdPEG64eRl3rhQSMFQTuzgY5IqTUPiZomnkC8ttViMcKz3Ya0bNlGzlA0w/hyQemeBnpzQBp/8ACfeDv+hs8P8A/gyh/wDiqP8AhPvB3/Q2eH//AAZQ/wDxVZ1z8TNCt9aOnPHqLFL5NOkultWNvHM4G1Wk6c5H9cCqMvxJiuvF2i6Vo1pNNZ3V/NYzXs0RWJmjjZmETZ+YhlwSRj0zQBreAr+z1PUfF95pt3b3lpLqyeXPbyCRHxZWoOGBIOCCPqDXCeH/AIMXOnQW327VLK9vbW5sXtbv7KY5LaGCRnZEOTy2cdvfOBXtNFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFU9YsTqWmXFmt3cWZmXb59vt8xB3xuVh7cg9auUUAc94G8K2/g7QY9Isb6+u7OIkxC7ZGaMHnaCiLxnJ5yeetczF8H/DhbUnvpdQvpL63+zSSTvGrKu8ODmNFLMGVTufceOtej0UAcHH8MtNS3iU6rq5u4J1uLe8V4UmgZVK/LtjCkEMQdytnvRqPwx0vUiTe6nrUjTwLb3zG5XN/GrlwJjt7EkfJt446cV3lFAHGz/DzSJlvVM16q3eqRas4R0AWWPbtVfl4T5Bx196gsPhrpdjrtnqMGoaqI7O8mvrexMqG3iklBD4Gzdg7icbuDXc0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Generalized slow activity (theta and/or delta) is the most common electroencephalographic pattern observed in patients with metabolic encephalopathies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahram Khoshbin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_59_34741=[""].join("\n");
var outline_f33_59_34741=null;
var title_f33_59_34742="Fluoride: Pediatric drug information";
var content_f33_59_34742=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluoride: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?4/33/4632?source=see_link\">",
"    see \"Fluoride: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/37/6741?source=see_link\">",
"    see \"Fluoride: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F172452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Act&reg; Kids [OTC];",
"     </li>",
"     <li>",
"      Act&reg; Restoring&trade; [OTC];",
"     </li>",
"     <li>",
"      Act&reg; Total Care&trade; [OTC];",
"     </li>",
"     <li>",
"      Act&reg; [OTC];",
"     </li>",
"     <li>",
"      CaviRinse&trade;;",
"     </li>",
"     <li>",
"      Clinpro&trade; 5000;",
"     </li>",
"     <li>",
"      ControlRx&trade;;",
"     </li>",
"     <li>",
"      ControlRx&trade; Multi;",
"     </li>",
"     <li>",
"      Denta 5000 Plus&trade;;",
"     </li>",
"     <li>",
"      DentaGel&trade;;",
"     </li>",
"     <li>",
"      Epiflur&trade;;",
"     </li>",
"     <li>",
"      Fluor-A-Day&reg;;",
"     </li>",
"     <li>",
"      Fluorabon&trade;;",
"     </li>",
"     <li>",
"      Fluorinse&reg;;",
"     </li>",
"     <li>",
"      Fluoritab;",
"     </li>",
"     <li>",
"      Flura-Drops&reg;;",
"     </li>",
"     <li>",
"      Gel-Kam&reg; Rinse;",
"     </li>",
"     <li>",
"      Gel-Kam&reg; [OTC];",
"     </li>",
"     <li>",
"      Just For Kids&trade; [OTC];",
"     </li>",
"     <li>",
"      Lozi-Flur&trade;;",
"     </li>",
"     <li>",
"      NeutraCare&reg;;",
"     </li>",
"     <li>",
"      NeutraGard&reg; Advanced;",
"     </li>",
"     <li>",
"      Omni Gel&trade; [OTC];",
"     </li>",
"     <li>",
"      OrthoWash&trade;;",
"     </li>",
"     <li>",
"      PerioMed&trade;;",
"     </li>",
"     <li>",
"      Phos-Flur&reg;;",
"     </li>",
"     <li>",
"      Phos-Flur&reg; Rinse [OTC];",
"     </li>",
"     <li>",
"      PreviDent&reg;;",
"     </li>",
"     <li>",
"      PreviDent&reg; 5000 Booster;",
"     </li>",
"     <li>",
"      PreviDent&reg; 5000 Dry Mouth;",
"     </li>",
"     <li>",
"      PreviDent&reg; 5000 Plus&reg;;",
"     </li>",
"     <li>",
"      PreviDent&reg; 5000 Sensitive;",
"     </li>",
"     <li>",
"      StanGard&reg; Perio;",
"     </li>",
"     <li>",
"      Stop&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F172453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fluor-A-Day",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Mineral, Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Mineral, Oral Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adequate Intake (AI): 0.01 mg/day; supplementation is not recommended in neonates",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/33/4632?source=see_link\">",
"      see \"Fluoride: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adequate Intake (AI):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     0-6 months: 0.01 mg/day; additional supplementation is not recommended in infants &lt;6 months of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     7-12 months: 0.5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-3 years: 0.7 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     4-8 years: 1 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     9-13 years: 2 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     14-18 years: 3 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Males: 4 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Females: 3 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The recommended daily fluoride intake is adjusted in proportion to the fluoride content of available drinking water; see",
"     <b>",
"      Recommended Daily Fluoride Dose",
"     </b>",
"     table",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Recommended Daily Fluoride Dose",
"     </caption>",
"     <col align=\"left\" width=\"175\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Fluoride Content of Drinking Water",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Daily Dose, Oral Fluoride",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Adapted from",
"         <i>",
"          AAP News",
"         </i>",
"         , 1995, 11(2):18.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          &lt;0.3 ppm",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:2em;\">",
"         Birth - 6 mo",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:2em;\">",
"         6 mo to 3 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.25",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:2em;\">",
"         3-6 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:2em;\">",
"         6-16 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          0.3-0.6 ppm",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:2em;\">",
"         Birth - 3 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:2em;\">",
"         3-6 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.25",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:2em;\">",
"         6-16 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          &gt;0.6 ppm",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:2em;\">",
"         All ages",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dental rinse: See",
"     <b>",
"      Sodium Fluoride Dental Rinse Dosing",
"     </b>",
"     table",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sodium fluoride (dosage based upon concentration of solution):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     2% concentrations are administered by dental personnel only",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Sodium Fluoride Dental Rinse Dosing",
"     </caption>",
"     <col align=\"center\" width=\"80\">",
"     </col>",
"     <col align=\"center\" width=\"120\">",
"     </col>",
"     <col align=\"center\" width=\"140\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Age",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         % Solution",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dosage",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.05%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10 mL daily",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         6-12 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.02%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10 mL twice daily",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.2%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5 mL once weekly",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;12 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.02%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10 mL twice daily",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.2%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10 mL once weekly",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acidulated phosphate fluoride rinse: Children 6 years and Adults: 5-10 mL of 0.02% daily at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Gel:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acidulated phosphate fluoride: Adults: 4-8 drops of 0.5% gel daily or for desensitizing exposed root surfaces, use a few drops of 0.5% to 1.2% gel applied and brushed onto affected area each night",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stannous fluoride: Children &gt;6 years and Adults: Apply 0.4% gel to teeth once daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F172440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, oral, as sodium [toothpaste]: 1.1% (51 g) [equivalent to fluoride 2.5 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Denta 5000 Plus&trade;: 1.1% (51 g) [spearmint flavor; equivalent to fluoride 2.5 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PreviDent&reg; 5000 Plus&reg;: 1.1% (51 g) [contains sodium benzoate; fruitastic&trade; flavor; equivalent to fluoride 2.5 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PreviDent&reg; 5000 Plus&reg;: 1.1% (51 g) [contains sodium benzoate; spearmint flavor; equivalent to fluoride 2.5 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical, as acidulated phosphate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phos-Flur&reg;: 1.1% (51 g) [contains propylene glycol, sodium benzoate; mint flavor; equivalent to fluoride 0.5%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, oral, as sodium [toothpaste]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PreviDent&reg; 5000 Booster: 1.1% (100 mL, 106 mL) [contains sodium benzoate; fruitastic&trade; flavor; equivalent to fluoride 2.5 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PreviDent&reg; 5000 Booster: 1.1% (100 mL, 106 mL) [contains sodium benzoate; spearmint flavor; equivalent to fluoride 2.5 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PreviDent&reg; 5000 Dry Mouth: 1.1% (100 mL) [mint flavor; equivalent to fluoride 2.5 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PreviDent&reg; 5000 Sensitive: 1.1% (100 mL) [mild mint flavor; equivalent to fluoride 2.5 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical, as sodium: 1.1% (56 g) [equivalent to fluoride 2 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DentaGel&trade;: 1.1% (56 g) [fresh mint flavor; neutral pH; equivalent to fluoride 2 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NeutraCare&reg;: 1.1% (60 g) [grape flavor; neutral pH]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NeutraCare&reg;: 1.1% (60 g) [mint flavor; neutral pH]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NeutraGard&reg; Advanced: 1.1% (60 g) [mint flavor; neutral pH]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NeutraGard&reg; Advanced: 1.1% (60 g) [mixed berry flavor; neutral pH]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PreviDent&reg;: 1.1% (56 g) [mint flavor; equivalent to fluoride 2 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PreviDent&reg;: 1.1% (56 g) [very berry flavor; equivalent to fluoride 2 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical, as stannous fluoride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gel-Kam&reg;: 0.4% (129 g) [cinnamon flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gel-Kam&reg;: 0.4% (129 g) [fruit &amp; berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gel-Kam&reg;: 0.4% (129 g) [mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Just For Kids&trade;: 0.4% (122 g) [bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Just For Kids&trade;: 0.4% (122 g) [fruit-punch flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Just For Kids&trade;: 0.4% (122 g) [grapey grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omni Gel&trade;: 0.4% (122 g) [cinnamon flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omni Gel&trade;: 0.4% (122 g) [grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omni Gel&trade;: 0.4% (122 g) [mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omni Gel&trade;: 0.4% (122 g) [natural flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omni Gel&trade;: 0.4% (122 g) [raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stop&reg;: 0.4% (120 g) [bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stop&reg;: 0.4% (120 g) [mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral, as base:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluoritab: 0.125 mg/drop [dye free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lozenge, oral, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lozi-Flur&trade;: 2.21 mg (90s) [sugar free; cherry flavor; equivalent to fluoride 1 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Paste, oral, as sodium [toothpaste]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clinpro&trade; 5000: 1.1% (113 g) [vanilla-mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ControlRx&trade;: 1.1% (57 g) [berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ControlRx&trade;: 1.1% (57 g) [vanilla-mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ControlRx&trade; Multi: 1.1% (57 g) [vanilla-mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as fluoride [rinse]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg; Total Care&trade;: 0.02% (1000 mL) [ethanol free; contains menthol, propylene glycol, sodium benzoate, tartrazine; fresh mint flavor; equivalent to fluoride 0.009%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as sodium [drops]: 1.1 mg/mL (50 mL) [equivalent to fluoride 0.5 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluor-A-Day&reg;: 0.278 mg/drop (30 mL) [equivalent to fluoride 0.125 mg/drop]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluorabon&trade;: 0.55 mg/0.6 mL (60 mL) [dye free, sugar free; equivalent to fluoride 0.25 mg/0.6 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flura-Drops&reg;: 0.55 mg/drop (24 mL) [dye free, sugar free; equivalent to fluoride 0.25 mg/drop]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as sodium [rinse]: 0.2% (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg;: 0.05% (532 mL) [contains benzyl alcohol, propylene glycol, sodium benzoate, tartrazine; cinnamon flavor; equivalent to fluoride 0.02%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg;: 0.05% (532 mL) [contains propylene glycol, sodium benzoate, tartrazine; mint flavor; equivalent to fluoride 0.02%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg; Kids: 0.05% (532 mL) [ethanol free; contains benzyl alcohol, propylene glycol, sodium benzoate; bubblegum flavor; equivalent to fluoride 0.02%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg; Kids: 0.05% (500 mL) [ethanol free; contains benzyl alcohol, propylene glycol, sodium benzoate; ocean berry flavor; equivalent to fluoride 0.02%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg; Restoring&trade;: 0.02% (1000 mL) [contains ethanol 11%, propylene glycol, sodium benzoate; Cool Splash&trade; mint flavor; equivalent to fluoride 0.009%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg; Restoring&trade;: 0.02% (1000 mL) [contains ethanol 11%, propylene glycol, sodium benzoate; Cool Splash&trade; spearmint flavor; equivalent to fluoride 0.009%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg; Restoring&trade;: 0.05% (532 mL) [contains ethanol 11%, propylene glycol, sodium benzoate; Cool Splash&trade; mint flavor; equivalent to fluoride 0.02%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg; Restoring&trade;: 0.05% (532 mL) [contains ethanol 11%, propylene glycol, sodium benzoate; Cool Splash&trade; spearmint flavor; equivalent to fluoride 0.02%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg; Restoring&trade;: 0.05% (532 mL) [contains ethanol 11%, propylene glycol, sodium benzoate; Cool Splash&trade; vanilla-mint flavor; equivalent to fluoride 0.02%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg; Total Care&trade;: 0.02% (1000 mL) [contains ethanol 11%, propylene glycol, sodium benzoate; icy clean mint flavor; equivalent to fluoride 0.009%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg; Total Care&trade;: 0.05% (88 mL, 532 mL) [contains ethanol 11%, propylene glycol, sodium benzoate; icy clean mint flavor; equivalent to fluoride 0.02%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Act&reg; Total Care&trade;: 0.05% (88 mL, 532 mL) [ethanol free; contains menthol, propylene glycol, sodium benzoate, tartrazine; fresh mint flavor; equivalent to fluoride 0.02%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CaviRinse&trade;: 0.2% (240 mL) [mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluorinse&reg;: 0.2% (480 mL) [ethanol free; cinnamon flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluorinse&reg;: 0.2% (480 mL) [ethanol free; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OrthoWash&trade;: 0.044% (480 mL) [contains sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OrthoWash&trade;: 0.044% (480 mL) [contains sodium benzoate; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phos-Flur&reg; Rinse: 0.044% (473 mL) [ethanol free, sugar free; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phos-Flur&reg; Rinse: 0.044% (473 mL) [ethanol free, sugar free; gushing grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phos-Flur&reg; Rinse: 0.044% (500 mL) [sugar free; cool mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PreviDent&reg;: 0.2% (473 mL) [contains benzoic acid, ethanol 6%, sodium benzoate; cool mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as stannous fluoride [concentrated rinse]: 0.63% (300 mL) [equivalent to fluoride 7 mg/30 mL dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gel-Kam&reg; Rinse: 0.63% (300 mL) [mint flavor; equivalent to fluoride 7 mg/30 mL dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PerioMed&trade;: 0.63% (284 mL) [ethanol free; cinnamon flavor; equivalent to fluoride 7 mg/30 mL dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PerioMed&trade;: 0.63% (284 mL) [ethanol free; mint flavor; equivalent to fluoride 7 mg/30 mL dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PerioMed&trade;: 0.63% (284 mL) [ethanol free; tropical fruit flavor; equivalent to fluoride 7 mg/30 mL dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     StanGard&reg; Perio: 0.63% (284 mL) [mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral, as sodium: 0.55 mg [equivalent to fluoride 0.25 mg], 1.1 mg [equivalent to fluoride 0.5 mg], 2.2 mg [equivalent to fluoride 1 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epiflur&trade;: 0.55 mg [sugar free; vanilla flavor; equivalent to fluoride 0.25 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epiflur&trade;: 1.1 mg [sugar free; vanilla flavor; equivalent to fluoride 0.5 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epiflur&trade;: 2.2 mg [sugar free; vanilla flavor; equivalent to fluoride 1 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluor-A-Day&reg;: 0.55 mg [raspberry flavor; equivalent to fluoride 0.25 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluor-A-Day&reg;: 1.1 mg [raspberry flavor; equivalent to fluoride 0.5 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluor-A-Day&reg;: 2.2 mg [raspberry flavor; equivalent to fluoride 1 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluoritab: 2.2 mg [cherry flavor; equivalent to fluoride 1 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluoritab: 1.1 mg [dye free; cherry flavor; equivalent to fluoride 0.5 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F172426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes lozenge, gel drops",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dental gel: Do",
"     <b>",
"      not",
"     </b>",
"     swallow; gel drops are placed in trough of applicator; applicator is applied over upper and lower teeth at same time; bite down for 6 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dental rinse: Swish or rinse in mouth then expectorate; do not swallow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: Dissolve in mouth, chew, swallow whole, or add to drinking water or fruit juice; administer with food (but not milk) to eliminate GI upset",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1058728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium fluoride solutions decompose in glass containers; store only in tightly closed plastic containers; aqueous solutions of stannous fluoride decompose within hours of preparation; prepare solutions immediately before use",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of dental caries",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F172493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Phos-Flur&reg; may be confused with PhosLo&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fluorex [France] may be confused with Flarex brand name for fluorometholone [U.S.,  Canada, and multiple international markets] and Fluarix brand name for influenza virus vaccine (inactivated) [U.S., and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F172491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rare but important or life-threatening: Discoloration of teeth, nausea, rash, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluoride or any component; when fluoride content of drinking water exceeds 0.7 ppm; low sodium or sodium-free diets; do not use 1 mg tablets in children &lt;3 years of age or when drinking water fluoride content is &ge;0.3 ppm; do not use 1 mg/5 mL rinse (as supplement) in children &lt;6 years of age",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1058724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prolonged ingestion with excessive doses may result in dental fluorosis and osseous changes; dosage should be adjusted in proportion to the amount of fluoride in the drinking water; do",
"     <b>",
"      not",
"     </b>",
"     exceed recommended dosage",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain tartrazine which may cause allergic reactions in susceptible individuals",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F172435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1058739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not administer with milk",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F172437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13882220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies; epidemiological studies in areas with high levels of fluorinated water have not shown an increase in adverse effects. Heavy exposure",
"     <i>",
"      in utero",
"     </i>",
"     may be linked to skeletal fluorosis seen later in childhood.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1058732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Total plasma fluoride: 0.14-0.19 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Promotes remineralization of decalcified enamel; inhibits the cariogenic microbial process in dental plaque; increases tooth resistance to acid dissolution",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1058736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Via GI tract, lungs, and skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 50% of fluoride is deposited in teeth and bone after ingestion; crosses placenta; appears in breast milk; topical application works superficially on enamel and plaque",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine and feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Recommendations for Using Fluoride to Prevent and Control Dental Caries in the United States,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2001, 50(RR-14):1-42. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5014a1.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5014a1.htm",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine,&rdquo; National Academy of Sciences, Washington, DC: National Academy Press, 1997.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13312 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-31C67D9254-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_59_34742=[""].join("\n");
var outline_f33_59_34742=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172452\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172453\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058730\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442538\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058725\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172440\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172426\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058734\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058728\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058733\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172493\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172491\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058737\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058724\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058723\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299352\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172435\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058739\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172437\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13882220\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058732\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058722\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058736\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13312\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13312|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/33/4632?source=related_link\">",
"      Fluoride: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/37/6741?source=related_link\">",
"      Fluoride: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_59_34743="Epidemiology of extensively drug-resistant tuberculosis";
var content_f33_59_34743=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology of extensively drug-resistant tuberculosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/59/34743/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/59/34743/contributors\">",
"     Scott K Heysell, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/59/34743/contributors\">",
"     Gerald Friedland, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/59/34743/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/59/34743/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/59/34743/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/59/34743/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/59/34743/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 17, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycobacterium tuberculosis (M. tuberculosis) is an ancient human pathogen, which has plagued countless human societies despite the introduction of curative therapy in the last century. In recent years, international attention has turned toward the evolving burden of drug resistance. Multi-drug resistant tuberculosis (MDR TB) has emerged in epidemic proportions in the wake of widespread HIV infection in the world's poorest populations, including sub-Saharan Africa. Extensively drug-resistant TB (XDR TB) was first reported in 2006 but has now been documented on six continents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/1\">",
"     1",
"    </a>",
"    ]. These trends are critically important for global health, since drug-resistant TB mortality rates are high and second and third-line agents for the treatment of drug-resistant TB are less potent and less tolerable than first-line therapies.",
"   </p>",
"   <p>",
"    This topic will focus specifically on the epidemiology and clinical features of XDR TB. Information on MDR TB, drug-susceptible TB, and the diagnosis of tuberculosis are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39673?source=see_link\">",
"     \"Clinical manifestations and evaluation of pulmonary tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/10/1194?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/52/32586?source=see_link\">",
"     \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/53/5978?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of extensively drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;MDR TB is defined as laboratory-confirmed resistance to the two most potent first-line medications,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/2\">",
"     2",
"    </a>",
"    ]. Since 2007, XDR TB has been defined as resistance to both isoniazid and rifampin with additional resistance to at least one fluoroquinolone and one injectable agent (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/10/40102?source=see_link\">",
"     kanamycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/59/11189?source=see_link\">",
"     capreomycin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    M. tuberculosis strains resistant to all locally tested medications have been defined as &ldquo;totally drug-resistant&rdquo;, or &ldquo;TDR&rdquo; TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. However, these TDR isolates were not tested against a complete panel of second-line anti-tuberculosis drugs, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/30/43492?source=see_link\">",
"     cycloserine",
"    </a>",
"    , terizidone, clofazimine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    and the carbapenems. Regardless, reports of TDR TB raise epidemiologic concerns regarding the ability to track complex resistance patterns in resource-limited settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/7\">",
"     7",
"    </a>",
"    ]. The emergence of TDR TB also highlights the limited availability of susceptibility testing for the less commonly used anti-tuberculosis drugs, the relative inability to predict synergy or drug activity at the site of infection, and the need for optimized pharmacokinetic strategies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ESTIMATES OF XDR TB DRUG RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug resistance was first noted in the 1940s when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    was formally studied as monotherapy for the treatment of tuberculosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/8\">",
"     8",
"    </a>",
"    ]. As a result, subsequent therapeutic interventions utilized multi-drug regimens to decrease the risk of drug resistance.",
"   </p>",
"   <p>",
"    Despite this strategic approach, outbreaks of MDR TB occurred throughout the world in the mid 1990s, including the United States, Spain, Italy, Argentina, and Russia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/2,9-12\">",
"     2,9-12",
"    </a>",
"    ]. During these years, in regions where HIV infection was prevalent, the epidemiology of M. tuberculosis mirrored the epidemic of HIV infection, since severe immunosuppression greatly increases the risk of active TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/13\">",
"     13",
"    </a>",
"    ]. As a result, the number of tuberculosis cases in regions such as sub-Saharan Africa has increased substantially in the past decade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These outbreaks hinted at the potential for more extensive drug resistance in regions of the world with the greatest prevalence of TB and HIV co-infection and the least infrastructure to screen and manage such patients. Since that time, international surveillance has placed the estimated number of global cases of MDR TB and XDR TB at 500,000 and 40,000, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/15\">",
"     15",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    However, this figure is probably an underestimate given that the laboratory resources required to make accurate assessments of drug susceptibility are geographically restricted to resource-rich areas. For instance, of the estimated cases of MDR TB in 2008, only 7 percent were actually reported to the WHO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/16\">",
"     16",
"    </a>",
"    ]. Much of the world relies on sputum microscopy for detection of acid fast bacilli (AFB) as the standard means of diagnosis of TB (",
"    <a class=\"graphic graphic_picture graphicRef56964 \" href=\"mobipreview.htm?36/51/37680\">",
"     picture 1",
"    </a>",
"    ). However, this technique cannot distinguish between drug-susceptible and drug-resistant strains of M. tuberculosis. Additionally, the laboratory resources for culture and drug susceptibility testing may not exist or may be severely limited. Referral bias may also lower the estimate of drug resistance, since patients may have died before seeking medical attention or before drug-resistant TB was suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Tugela Ferry",
"    </span>",
"    &nbsp;&mdash;&nbsp;International alarm first surfaced in 2006 with the detection of a large cluster of cases of XDR TB from the rural town of Tugela Ferry in the province of KwaZulu-Natal, South Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/17\">",
"     17",
"    </a>",
"    ]. In this prospective study of enhanced surveillance, 2203 sputum specimens from 1539 individual patients with suspected TB were sent for sputum culture and drug susceptibility testing. Of 542 patients with at least one positive sample for M. tuberculosis, 221 (41 percent) had MDR TB and 53 patients of this subset were confirmed to have XDR TB. The following important observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All 44 of the 53 patients with XDR TB who were tested were HIV-seropositive. The median CD4 count at the time of sputum collection was 63",
"      <span class=\"nowrap\">",
"       cells/microL.",
"      </span>",
"      Viral loads were not available.",
"     </li>",
"     <li>",
"      Although prior treatment for TB is an important risk factor for development of drug resistance, over half of the cases had never been previously treated.",
"     </li>",
"     <li>",
"      Two-thirds of the patients with XDR TB had been admitted to the hospital within the previous two years. When genetically typed, 85 percent of tested isolates were found to be clonally related, consistent with nosocomial transmission.",
"     </li>",
"     <li>",
"      Fifty-two of 53 (98 percent) of the patients died. Approximately 70 percent of patients died within 30 days from the time of sputum collection.",
"     </li>",
"     <li>",
"      Two healthcare workers were among the XDR cases.",
"     </li>",
"     <li>",
"      Many of the patients demonstrated resistance to all of the six drugs tested at the time (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/10/40102?source=see_link\">",
"       kanamycin",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since this original collection of cases from 2005 to 2007, over 350 cases of XDR TB have been reported from Tugela Ferry; 656 from the province of KwaZulu-Natal, and 996 from South Africa as a whole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. As of 2007, there were more reported cases of XDR TB than MDR TB in Tugela Ferry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/20\">",
"     20",
"    </a>",
"    ], and nosocomial transmission has been identified as an important source of transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Worldwide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, XDR TB has now been reported in 68 countries from all geographic regions of the world (",
"    <a class=\"graphic graphic_figure graphicRef75814 \" href=\"mobipreview.htm?36/9/37016\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/1,15,17,22-24\">",
"     1,15,17,22-24",
"    </a>",
"    ]. The largest numbers of cases are found in Southeast Asia, Eastern Europe, and countries of the former Soviet Union. Rates can also vary widely within regions. For example, approximately 10 percent of MDR TB isolates from the former Soviet Union are XDR TB; however, that percentage climbs to nearly 15 percent in Latvia (",
"    <a class=\"graphic graphic_table graphicRef56811 \" href=\"mobipreview.htm?23/62/24557\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2006, a Centers for Disease Control and Prevention (CDC) task force, with assistance from the World Health Organization (WHO), surveyed 14 supranational TB reference laboratories. Among a sample of 17,490 isolates that had been previously collected from 2000 to 2004, 20 percent were found to be MDR TB and 2 percent were XDR TB isolates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. For this survey, XDR TB was defined as MDR TB plus resistance to three or more second-line medications. A subsequent conference of the WHO Stop TB Task Force officially refined the definition of XDR TB in 2007 to that referenced above; according to this later definition, an even higher prevalence of XDR TB would have been expected. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Following the reports of XDR TB in South Africa, cases have been reported in neighboring countries of Namibia, Lesotho, Mozambique and Botswana. However, data concerning the rates of drug-resistant TB from the rest of the African continent are sparse due to severe limitations in laboratory drug susceptibility testing. Only 22 of 46 (48 percent) countries in the WHO Africa region have even ever undertaken a drug-resistance survey [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/25\">",
"     25",
"    </a>",
"    ]. Consequently, many experts believe that the incidence of XDR TB may be growing throughout the continent, but subject to much underreporting. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Estimates of XDR TB drug resistance'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a descriptive analysis of US TB cases reported from 1993 to 2007, a total of 83 XDR TB cases were reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/26\">",
"     26",
"    </a>",
"    ]. The majority of cases were US born (n = 45) and 33 of the patients (40 percent) were Hispanic. The annual rates of XDR TB declined from 18 cases in 1993 (0.07 percent of 25,107 total TB cases) to 2 cases in 2007 (0.02 percent of 13,293 total TB cases).",
"   </p>",
"   <p>",
"    The decline of reported cases coincided with the introduction of potent antiretroviral therapy (ART) in the United States and improved public health control of TB and HIV infections. Of 40 cases reported from 1993 to 1997, 25 (63 percent) were known to be HIV-infected; from 1998 to 2007 only 6 (14 percent) were known to be HIV-infected. These data shed additional light on the effect of the HIV epidemic on the epidemiology of drug-resistant TB infection and emphasize the need for solid infrastructure for containment and prevention of TB.",
"   </p>",
"   <p>",
"    The following clinical observations were also made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with MDR TB cases, XDR TB cases were more likely to have disseminated TB disease and had a prolonged time to culture conversion when treated (183 days versus 93 days for MDR TB).",
"     </li>",
"     <li>",
"      Twenty-six XDR TB cases (35 percent) died during treatment, of whom 21 (81 percent) were known to be HIV-infected.",
"     </li>",
"     <li>",
"      Mortality was higher among XDR TB cases than among MDR TB cases (prevalence ratio [PR], 1.82; 95% CI 1.10-3.02) or drug-susceptible TB cases (PR, 6.10; 95% CI 3.65-10.20).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES OF DRUG RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Within any given patient infected with M. tuberculosis, there is a varied population of organisms, each with naturally occurring resistance to a given medication, which preexists prior to treatment. This observation mandates multi-drug therapy in order to decrease the risk of drug resistance.",
"   </p>",
"   <p>",
"    The mechanisms for developing drug resistance are complex and may be multi-factorial in origin even within an individual patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7497?source=see_link\">",
"     \"Epidemiology and molecular mechanisms of drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Acquired versus primary drug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important distinction is made between acquired and primary drug resistance. Patients with \"acquired\" drug resistance have had prior treatment with anti-tuberculosis medications, while patients with \"primary\" drug resistance may have contracted a drug-resistant organism from an infectious contact.",
"   </p>",
"   <p>",
"    The factors that may lead to acquired drug resistance are discussed below. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Risk factors for drug resistance'",
"    </a>",
"    below.) Primary drug resistance can result from:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial infection with drug-resistant TB",
"     </li>",
"     <li>",
"      Exogenous reinfection in a patient who had previous eradication of TB",
"     </li>",
"     <li>",
"      Exogenous superinfection with a drug-resistant isolate in a patient with a concurrent and more drug-susceptible isolate of TB",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Exogenous reinfection with TB is more common in HIV-infected patients with advanced immunosuppression than in patients with relatively intact cellular immunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/27\">",
"     27",
"    </a>",
"    ]. A study from Tugela Ferry demonstrated exogenous reinfection of either MDR or XDR TB in a cohort of 23 patients that had previously been successfully treated for drug-susceptible TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/28\">",
"     28",
"    </a>",
"    ]. Of the fifteen patients who underwent testing for HIV, all were HIV-seropositive. Reinfection was demonstrated using spoligotyping, a genetic assay that helps determine whether a patient may have a relapse of their initial infection versus acquisition of a new strain. Another report from Uzbekistan employed spoligotyping to confirm exogenous superinfection with XDR TB occurring in four patients being treated for MDR TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/53/5978?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of extensively drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prevention and management of primary versus acquired drug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree to which primary or acquired drug resistance drives MDR and XDR TB rates has significant implications for designing effective prevention and management strategies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In areas with a high proportion of primary drug resistance, strategies aimed at infection control to reduce transmission of TB in hospitals, clinics, and congregate sites are essential.",
"     </li>",
"     <li>",
"      In contrast, poor adherence or inadequate infrastructure may lead to acquired drug resistance; in this situation, strengthening and improving the performance of TB treatment programs is critically important.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2167847\">",
"    <span class=\"h3\">",
"     Geographic distribution of primary versus acquired resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The global burden of TB drug resistance is a consequence of both primary and acquired disease, but the impact of each mechanism has not been studied on a large scale. The 2008 WHO report on TB drug resistance provides MDR TB rates in newly diagnosed patients compared with those who were retreatment cases and is a broad approximation of the regional variability between primary and acquired drug resistance. Primary drug resistance is assumed to be the result of resistance transmission while acquired drug resistance is the result of unsuccessful treatment (",
"    <a class=\"graphic graphic_figure graphicRef59191 \" href=\"mobipreview.htm?36/0/36878\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Previously, the bulk of acquired drug resistance was thought to occur in Eastern Europe and states of the former Soviet Union. For instance, a study based in western Siberia found that 6 percent of 608 patients with documented MDR TB developed XDR TB while on therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/30\">",
"     30",
"    </a>",
"    ]. Previous treatment with second-line drugs is a strong and consistent risk factor for resistance to these drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/31\">",
"     31",
"    </a>",
"    ]. Risk factors for XDR TB included the presence of bilateral and cavitary lesions and poor medication adherence.",
"   </p>",
"   <p>",
"    In contrast, primary drug resistance was thought to occur in isolated outbreaks. However, prior epidemiologic distinctions are beginning to blur and primary resistance is becoming increasingly more important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In a survey from district TB hospitals in Shanghai, China from 2004 to 2007, of 175 cases of MDR TB tested for second-line resistance, 11 (6.3 percent) were XDR TB; however, more than half had never been treated for TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR DRUG RESISTANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Adherence and other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suboptimal adherence can lead to acquired drug resistance and clinical relapse.",
"   </p>",
"   <p>",
"    Poor adherence does not necessarily reflect a patient's purposeful desire to negatively affect the efficacy of the regimen. Rather, factors related to local health systems contribute to frank prescribing errors or suboptimal dosing, treatment interruptions from medication stock shortages, or poor treatment completion due to overstressed directly observed therapy &mdash; short course (DOTS) programs.",
"   </p>",
"   <p>",
"    In addition, biologic factors play a role in acquired resistance when the decreased bioavailability of anti-tuberculosis medication occurs secondary to malabsorption and drug-drug interactions that affect metabolism and excretion. This point is particularly pertinent to HIV-infected patients (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Effect of HIV on TB drug resistance'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Historical clues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain historical factors that should raise the possibility of XDR TB have been suggested in observational studies and expert opinion, but have not been formally evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/35-39\">",
"     35-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Living in or originating from an area with a known high",
"      <span class=\"nowrap\">",
"       MDR/XDR",
"      </span>",
"      TB prevalence",
"     </li>",
"     <li>",
"      Previous TB therapy without documented success despite adequate adherence",
"     </li>",
"     <li>",
"      Hospitalization within the last two years, particularly in areas of high",
"      <span class=\"nowrap\">",
"       MDR/XDR",
"      </span>",
"      prevalence",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       HIV/AIDS",
"      </span>",
"     </li>",
"     <li>",
"      Incarceration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other comorbidities that may predispose to drug resistance include a history of malabsorption or taking other medications with known pharmacokinetic interactions with TB therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30395729\">",
"    <span class=\"h2\">",
"     Healthcare workers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health care workers in endemic areas are at increased risk of tuberculosis, including MDR TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective chart review was conducted of patients who were hospitalized for initiation of treatment for MDR TB and XDR TB in KwaZulu-Natal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/42\">",
"     42",
"    </a>",
"    ]. All patients were asked whether they were healthcare workers as part of a solicited occupational history. From 2003 to 2008, 4941 patients were hospitalized and 213 healthcare workers were diagnosed with either MDR TB or XDR TB. When compared with the general population, the average incidence rate ratio for TB infection was higher for healthcare workers for both MDR and XDR TB (fivefold and sixfold higher, respectively), while HIV infection rates were comparable between groups. Healthcare workers were less likely to report prior treatment for TB compared with other patients, suggesting nosocomial acquisition in the majority of cases. Another study found a direct relationship between the amount of time a healthcare worker spent in hospital rooms with a patient with documented TB and risk of subsequent TB infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     EFFECT OF HIV ON TB DRUG RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients are more likely to have problems with malabsorption, altered drug metabolism, or drug interactions due to concomitant ART. This can lead to acquired drug resistance because of inadequate antituberculosis drug levels and increased selection for mutations.",
"   </p>",
"   <p>",
"    Patients with HIV are more susceptible to acquisition of drug-resistant strains, as illustrated by the following data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the original Tugela Ferry case series, all XDR TB patients were HIV-seropositive; subsequent epidemiologic surveys have shown that greater than 90 percent of MDR and XDR TB patients from this community are HIV-infected [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/17,19\">",
"       17,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an observational analysis of the 5200 TB patients diagnosed from Latvia, the risk of developing drug-resistant TB was more than twofold higher in patients with underlying HIV infection compared with those who were HIV-negative or without a known HIV status [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly, in a Ukrainian study of 1496 confirmed TB patients, MDR TB was identified in 24 percent of HIV-seronegative and 32 percent of HIV-seropositive patients (OR 1.3, 95% CI 1.1-1.5) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result of the association of HIV and TB drug resistance, the WHO Global Task Force has now recommended initial sputum culture and drug susceptibility testing for all HIV-seropositive patients with TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/3\">",
"     3",
"    </a>",
"    ]. Although these goals are highly desirable, the upgrade in resources necessary to implement these recommendations will be slow to develop for the countries where XDR TB is most prevalent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     COMMON GENETIC MUTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The discovery of specific genetic mutations resulting in drug resistance has allowed targets for novel PCR-based diagnostics. The best understood mutations are those associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    resistance, but while helpful for MDR TB, diagnosis of XDR TB still requires standard culture and drug susceptibility testing, which can take up to three months to complete [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34743/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7497?source=see_link\">",
"     \"Epidemiology and molecular mechanisms of drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extensively drug-resistant (XDR) tuberculosis (TB) has emerged in epidemic proportions in the wake of widespread HIV infection in the world's poorest populations, including sub-Saharan Africa. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      XDR TB is defined as resistance to both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      with additional resistance to at least one fluoroquinolone and one injectable agent. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The largest reported cluster of XDR TB cases was described from South Africa in 2006 and was associated with HIV infection and a high rate of mortality. When genetically typed, 85 percent of tested isolates were found to be clonally related, consistent with nosocomial transmission. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Estimates of XDR TB drug resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Health care workers caring for patients with MDR TB are at increased risk of MDR disease compared with the general population from the same region. (See",
"      <a class=\"local\" href=\"#H30395729\">",
"       'Healthcare workers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Overall, XDR TB has now been reported in 57 countries from all regions of the world. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Estimates of XDR TB drug resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compared with multi-drug resistant TB, XDR TB patients from the United States are more likely to have disseminated TB disease and have a higher risk of mortality. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Estimates of XDR TB drug resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with \"acquired\" drug resistance have had prior treatment with antituberculosis medications, while patients with \"primary\" drug resistance have contracted a drug-resistant organism from an infectious contact. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'General principles of drug resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-infected patients are more likely to have problems with malabsorption, altered drug metabolism, or drug interactions due to concomitant ART that may lead to acquired drug resistance because of inadequate antituberculosis drug levels and increased mutation selection. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'General principles of drug resistance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Health Organization. The WHO Global Laboratory Initiative. file://www.who.int/tb/dots/laboratory/gli/en/index.html (Accessed on March 01, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/2\">",
"      Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City--turning the tide. N Engl J Med 1995; 333:229.",
"     </a>",
"    </li>",
"    <li>",
"     Report WHO/HTM/TB/2006.375 (World Health Organization, Geneva, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/4\">",
"      Centers for Disease Control and Prevention. Revised definition of extensively drug-resistant tuberculosis. MMWR 2006; 55:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/5\">",
"      Velayati AA, Masjedi MR, Farnia P, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. Chest 2009; 136:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/6\">",
"      Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012; 54:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/7\">",
"      Shah NS, Richardson J, Moodley P, et al. Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa. Emerg Infect Dis 2011; 17:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/8\">",
"      STREPTOMYCIN treatment of pulmonary tuberculosis. Br Med J 1948; 2:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/9\">",
"      Centers for Disease Control and Prevention (CDC). Multidrug-resistant tuberculosis outbreak on an HIV ward--Madrid, Spain, 1991-1995. MMWR Morb Mortal Wkly Rep 1996; 45:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/10\">",
"      Ritacco V, Di Lonardo M, Reniero A, et al. Nosocomial spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires. J Infect Dis 1997; 176:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/11\">",
"      Moro ML, Gori A, Errante I, et al. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. Italian Multidrug-Resistant Tuberculosis Outbreak Study Group. AIDS 1998; 12:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/12\">",
"      From the Centers for Disease Control and Prevention. Tuberculosis treatment interruptions--Ivanovo Oblast, Russian Federation, 1999. JAMA 2001; 285:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/13\">",
"      Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/14\">",
"      Raviglione MC, Harries AD, Msiska R, et al. Tuberculosis and HIV: current status in Africa. AIDS 1997; 11 Suppl B:S115.",
"     </a>",
"    </li>",
"    <li>",
"     Report WHO/HTM/TB/2008.394. (World Health Organization. Antituberculosis drug resistance in the world, Report No.4, 2008).",
"    </li>",
"    <li>",
"     WHO. Global tuberculosis control: short update to 2009 report. Geneva, Switzerland: World Health Organization, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/17\">",
"      Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575.",
"     </a>",
"    </li>",
"    <li>",
"     Moll, AP, Gandhi, N. Personal communication.",
"    </li>",
"    <li>",
"     Moll, AP, Gandhi, N, Andrews, J, et al. Extensively Drug-Resistant (XDR) TB More Common than MDR TB in Tugela Ferry, South Africa with Evidence for Resistance Amplification Over Time. International Union Against Tuberculosis and Lung Disease, 38th, Cape Town, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/20\">",
"      Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010; 181:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/21\">",
"      Gandhi NR, Weissman D, Moodley P, et al. Nosocomial transmission of extensively drug-resistant tuberculosis in a rural hospital in South Africa. J Infect Dis 2013; 207:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/22\">",
"      Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/23\">",
"      Shah NS, Wright A, Bai GH, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007; 13:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/24\">",
"      Raviglione MC. Facing extensively drug-resistant tuberculosis--a hope and a challenge. N Engl J Med 2008; 359:636.",
"     </a>",
"    </li>",
"    <li>",
"     WHO. Multidrug and extensively drug-resistant tuberculosis: 2010 global report on surveillance and response. Geneva, Switzerland: World Health Organization, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/26\">",
"      Shah NS, Pratt R, Armstrong L, et al. Extensively drug-resistant tuberculosis in the United States, 1993-2007. JAMA 2008; 300:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/27\">",
"      Sonnenberg P, Murray J, Glynn JR, et al. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/28\">",
"      Andrews JR, Gandhi NR, Moodley P, et al. Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. J Infect Dis 2008; 198:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/29\">",
"      Cox HS, Sibilia K, Feuerriegel S, et al. Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis. N Engl J Med 2008; 359:2398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/30\">",
"      Shin SS, Keshavjee S, Gelmanova IY, et al. Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med 2010; 182:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/31\">",
"      Dalton T, Cegielski P, Akksilp S, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012; 380:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/32\">",
"      Dubrovina I, Miskinis K, Lyepshina S, et al. Drug-resistant tuberculosis and HIV in Ukraine: a threatening convergence of two epidemics? Int J Tuberc Lung Dis 2008; 12:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/33\">",
"      Wright A, Zignol M, Van Deun A, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009; 373:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/34\">",
"      Zhao M, Li X, Xu P, et al. Transmission of MDR and XDR tuberculosis in Shanghai, China. PLoS One 2009; 4:e4370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/35\">",
"      Raykhert I, Miskinis K, Lepshyna S, et al. HIV seroprevalence among new TB patients in the civilian and prisoner populations of Donetsk Oblast, Ukraine. Scand J Infect Dis 2008; 40:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/36\">",
"      Jeon CY, Hwang SH, Min JH, et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis 2008; 46:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/37\">",
"      Banerjee R, Allen J, Westenhouse J, et al. Extensively drug-resistant tuberculosis in california, 1993-2006. Clin Infect Dis 2008; 47:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/38\">",
"      Friedland G. Tuberculosis, drug resistance, and HIV/AIDS: a triple threat. Curr Infect Dis Rep 2007; 9:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/39\">",
"      Shenoi S, Friedland G. Extremely Drug-Resistant Tuberculosis: A New Face to an Old Pathogen. Annual Reviews 2009; 60:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/40\">",
"      Galgalo T, Dalal S, Cain KP, et al. Tuberculosis risk among staff of a large public hospital in Kenya. Int J Tuberc Lung Dis 2008; 12:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/41\">",
"      Naidoo S, Jinabhai CC. TB in health care workers in KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 2006; 10:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/42\">",
"      O'Donnell MR, Jarand J, Loveday M, et al. High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med 2010; 153:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/43\">",
"      Barnard M, Albert H, Coetzee G, et al. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008; 177:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34743/abstract/44\">",
"      Tortoli E, Marcelli F. Use of the INNO LiPA Rif.TB for detection of Mycobacterium tuberculosis DNA directly in clinical specimens and for simultaneous determination of rifampin susceptibility. Eur J Clin Microbiol Infect Dis 2007; 26:51.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8004 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-93.125.6.160-7DBF348CA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_59_34743=[""].join("\n");
var outline_f33_59_34743=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ESTIMATES OF XDR TB DRUG RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Tugela Ferry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Worldwide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GENERAL PRINCIPLES OF DRUG RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Acquired versus primary drug resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prevention and management of primary versus acquired drug resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2167847\">",
"      - Geographic distribution of primary versus acquired resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RISK FACTORS FOR DRUG RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Adherence and other factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Historical clues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30395729\">",
"      Healthcare workers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      EFFECT OF HIV ON TB DRUG RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      COMMON GENETIC MUTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8004\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8004|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/9/37016\" title=\"figure 1\">",
"      XDR TB countries 2010",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/0/36878\" title=\"figure 2\">",
"      MDR TB cases region",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8004|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/51/37680\" title=\"picture 1\">",
"      Sputum Ziehl Neelsen stain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8004|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/62/24557\" title=\"table 1\">",
"      Drug resistance data 2010",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39673?source=related_link\">",
"      Clinical manifestations and evaluation of pulmonary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/53/5978?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of extensively drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/52/32586?source=related_link\">",
"      Diagnosis, treatment, and prevention of drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7497?source=related_link\">",
"      Epidemiology and molecular mechanisms of drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/10/1194?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_59_34744="Tension-type headache in children";
var content_f33_59_34744=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tension-type headache in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/59/34744/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/59/34744/contributors\">",
"     Robert P Cruse, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/59/34744/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/59/34744/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/59/34744/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/59/34744/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/59/34744/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/59/34744/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache is a common complaint, occurring in more than 90 percent of school age children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The frequency increases with increasing age and the etiologies range from school problems to life-threatening infections and brain tumors (",
"    <a class=\"graphic graphic_table graphicRef54034 \" href=\"mobipreview.htm?35/21/36188\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/8/35977?source=see_link\">",
"     \"Approach to the child with headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tension-type headaches are characterized by a bilateral pressing tightness that occurs anywhere on the cranium or suboccipital region. The term tension-type headache (TTH) replaces the previous terms \"muscle contraction headaches\" and \"tension headaches\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tension-type headache is non-throbbing, is of mild to moderate intensity, and lasts from 30 minutes to several days. Tension headache may be associated with photophobia or phonophobia, although these occur less often than with migraine. It usually is not accompanied by nausea or vomiting nor aggravated by routine physical activity. The overlap of some of these symptoms with those of migraine can make differentiation between the two headache types difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The current classification distinguishes three subtypes of tension-type headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infrequent episodic",
"     </li>",
"     <li>",
"      Frequent episodic",
"     </li>",
"     <li>",
"      Chronic",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diagnostic criteria are discussed below (",
"    <a class=\"graphic graphic_table graphicRef79672 \" href=\"mobipreview.htm?42/32/43531\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H12875187\">",
"     'Diagnostic criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controversy exists regarding the pathophysiology of tension-type headache. Heightened sensitivity of pain pathways in the central nervous system, and perhaps in the peripheral nervous system, is thought to play a critical role in the pathogenesis of tension-type headache. Nitric oxide may be a molecular trigger for pain. The earlier concept of muscle contraction producing vasoconstriction and ischemia is no longer considered the most important factor in pathogenesis. These issues are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/43/32441?source=see_link&amp;anchor=H3#H3\">",
"     \"Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In support of the hypothesis that patients with tension-type headache may be overly sensitive to pain, one group of investigators have found decreased mechanical pain thresholds in both trigeminal and nontrigeminal peripheral nerves in children with frequent episodic tension-type headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to migraine, hereditary factors seem to play a minor role in the pathogenesis of tension-type headache. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/43/32441?source=see_link&amp;anchor=H8#H8\">",
"     \"Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis\", section on 'Genetic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12874959\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are conflicting on the prevalence of tension-type headache in children. Differences among studies likely reflect different diagnostic criteria and varying methods of data collection. One study evaluated a random sample of 10 percent of schoolchildren 5 to 15 years of age in Aberdeen, Scotland, using a screening questionnaire followed by examination of symptomatic and asymptomatic children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/7\">",
"     7",
"    </a>",
"    ]. Tension-type headache were estimated to occur in 0.9 percent of children, compared to 10.6 percent with migraine. Other reports suggest that tension-type headache is two to three times more common than migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. As examples, a study of nearly 4000 Finnish schoolchildren found that 26 percent had a history of tension-type headache, compared to 10 percent with migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/8\">",
"     8",
"    </a>",
"    ], and a review of population-based studies reported that the prevalence of tension-type headache in children was approximately 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tension-type headache typically occur in children starting at approximately five years of age, although they can occur earlier.",
"   </p>",
"   <p>",
"    The prevalence increases with age and is higher in girls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. In one survey of more than 37,000 Dutch children 12 to 18 years of age, the incidence of headache (including all types) in girls was twice that of boys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms of infrequent, frequent, and chronic tension-type headaches are similar. The headache is typically frontal, although band-like or temporal pain can occur. The pain usually is described as a continuous pressure although the intensity may vary. Light-headedness and fatigue may occur.",
"   </p>",
"   <p>",
"    Daily activities, such as school attendance, are typically not affected by tension-type headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/14\">",
"     14",
"    </a>",
"    ]. However, in one report, 15 percent of children with chronic daily headaches missed more than 10 days of school [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sensitivity to light and noise may occur but are not as common in tension headache as in migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/16\">",
"     16",
"    </a>",
"    ]. The presence of photophobia or phonophobia may lead to an erroneous diagnosis of migraine. Abdominal pain, nausea or vomiting, and changes in appetite are uncommon.",
"   </p>",
"   <p>",
"    Children with headache and their parents may be overly sensitive to pain. One study evaluated 96 children (age six years), including 58 with migraine and 38 with tension-type headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/17\">",
"     17",
"    </a>",
"    ]. Compared with matched control children, those with headache were more likely to become excited about a physical examination, cried more during blood sampling or immunization, avoided play because they were afraid of hurting themselves, and had recurrent abdominal and growing pains. More children with tension than migraine headaches had poor family environments, an unhappy family atmosphere, or a distant relationship between the parents. In one study, maternal depression was associated with headache in preschool children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of tension headache is based upon clinical criteria. The proper evaluation of a child with chronic headaches requires sufficient time to obtain a detailed medical and social history. Nevertheless, the diagnosis of tension-type headache can be limited by the inability of young children to communicate reliable information about the headaches and inciting factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In addition, there is some overlap between the features of tension-type headache and those of migraine without aura, since episodes of migraine can present as bilateral short-lasting headache resembling tension-type headache. In one study of 200 children with recurrent or chronic primary headache, current diagnostic criteria could not distinguish between migraine without aura and tension-type headache in 16 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/21\">",
"     21",
"    </a>",
"    ]. Thus, a precise diagnosis is not possible in a substantial minority of children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12875187\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the International Classification of Headache Disorders-2 (ICHD-2), tension-type headache is characterized by having at least two of the following four features (",
"    <a class=\"graphic graphic_table graphicRef79672 \" href=\"mobipreview.htm?42/32/43531\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The location of the pain is bilateral in either the head or neck",
"     </li>",
"     <li>",
"      The quality of the pain is steady (eg, pressing or tightening) and nonthrobbing",
"     </li>",
"     <li>",
"      The intensity of the pain is mild to moderate",
"     </li>",
"     <li>",
"      There is no aggravation of the headache by normal physical activity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these criteria, there must be at least 10 headache episodes fulfilling all other ICHD-2 criteria (",
"    <a class=\"graphic graphic_table graphicRef79672 \" href=\"mobipreview.htm?42/32/43531\">",
"     table 2",
"    </a>",
"    ), which include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The duration of pain is between 30 minutes to 7 days for episodic tension-type headache or may be continuous for chronic tension-type headache",
"     </li>",
"     <li>",
"      The headache is not attributable to another disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The revised ICHD-2 classification distinguishes three subtypes of tension-type headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infrequent episodic tension-type headache with headache episodes occurring less than one day a month on average",
"     </li>",
"     <li>",
"      Frequent episodic tension-type headache with headache episodes occurring one to 14 days a month",
"     </li>",
"     <li>",
"      Chronic tension-type headache with headaches 15 or more days a month (",
"      <a class=\"graphic graphic_table graphicRef68892 \" href=\"mobipreview.htm?38/22/39275\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ICHD-2 criteria were designed to distinguish between tension-type headache, migraine, and cluster headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/3\">",
"     3",
"    </a>",
"    ]. There are no auras with tension-type headache, whether visual, language, sensory, motor, or coordination. Similarly, other features typically associated with migraine headache, such as nausea, vomiting, or sensitivity to light and noise, are not features of episodic tension-type headache. However, the presence of photophobia or phonophobia (but not both) does not exclude the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/3\">",
"     3",
"    </a>",
"    ]. There is an exception for chronic tension-type that allows mild nausea as long as there is no photophobia or phonophobia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12875173\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A description of the headaches is obtained by interviewing the child and his or her parents. Observation of the interaction between the child and examiner or the child and parents may suggest stress factors in the home. Answers to essential questions about the headache provide a database that assists in the diagnosis and management (",
"    <a class=\"graphic graphic_table graphicRef56317 \" href=\"mobipreview.htm?43/8/44171\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/22\">",
"     22",
"    </a>",
"    ]. Some clinicians recommend use of a headache diary that is kept by the child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/23\">",
"     23",
"    </a>",
"    ]. As noted above, the history can be limited by the inability of young children to communicate reliable information about the headaches and inciting factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    School performance, home and family dynamics, psychosocial stressors, and coping skills should be assessed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/24\">",
"     24",
"    </a>",
"    ]. Obtaining a family history of chronic headaches or pain syndromes may be helpful. A history should be obtained of prescription or over-the-counter medications, as these can initiate a new type of headache or exacerbate a preexisting headache disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In a survey of 10,506 reports to the WHO Collaboration Centre for International Drug Monitoring,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/2/9256?source=see_link\">",
"     nifedipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/58/43943?source=see_link\">",
"     cimetidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/1/33815?source=see_link\">",
"     ranitidine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    were among the drugs most frequently associated with headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical and neurologic examination of a child with a history of tension-type headache is typically normal. Some may have tightness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tenderness of the muscle at the base of the occiput or in the paracervical region. One study found a positive correlation between referred pain trigger points in the head and shoulder regions and duration of headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/27\">",
"     27",
"    </a>",
"    ]. This finding suggests that identification of painful trigger points can be helpful in supporting the diagnosis of tension-type headache. Decreased cervical range of motion, particularly with",
"    <span class=\"nowrap\">",
"     flexion/extension",
"    </span>",
"    and lateral flexion, has also been described by the same investigators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Careful examination of the following areas should be performed to exclude pathologic causes of headache:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Measurement of height, weight, and head circumference",
"     </li>",
"     <li>",
"      Blood pressure and pulse",
"     </li>",
"     <li>",
"      Auscultation of the neck, eyes, and head for bruit (a sign of arteriovenous malformation)",
"     </li>",
"     <li>",
"      Funduscopy and otoscopy",
"     </li>",
"     <li>",
"      Examination and palpation of the head, neck, shoulders, and spine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, children should have a functional neurologic examination including getting up from a seated position without any support; walking on tiptoes and heels; cranial nerve examination; tandem gait and Romberg test; and symmetry of motor, sensory, reflex, coordination, and ataxia testing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/8/35977?source=see_link&amp;anchor=H6#H6\">",
"     \"Approach to the child with headache\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of neuroimaging remains controversial. Although most headaches in children are benign, the possibility of a brain tumor is a concern in children with chronic headache. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/8/35977?source=see_link&amp;anchor=H1170681824#H1170681824\">",
"     \"Approach to the child with headache\", section on 'Worrisome findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with suspected tension-type headache who lack signs or symptoms of neurologic dysfunction or increased intracranial pressure do not need neuroimaging. In such children, neuroimaging has a low yield of clinically significant abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/29-31\">",
"     29-31",
"    </a>",
"    ] and may detect incidental findings that require additional evaluation or follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. Other potential adverse effects of neuroimaging include radiation exposure, exposure to anesthesia if sedation is required, and false reassurance from an inadequate study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/34\">",
"     34",
"    </a>",
"    ]. However, many parents are concerned that their child's headache is caused by a brain tumor and this fear may make treatment of tension-type headache difficult. In these cases, brain imaging may be required to relieve apprehensions.",
"   </p>",
"   <p>",
"    Predictors for intracranial pathology (ie, space-occupying lesion or central nervous system infection) have been identified in small observational studies (",
"    <a class=\"graphic graphic_table graphicRef79664 \" href=\"mobipreview.htm?2/16/2317\">",
"     table 5",
"    </a>",
"    ). As an example, a retrospective study of 315 children with headache and no neurologic disorder observed that the presence of a surgical lesion on neuroimaging with CT and MRI was associated with the following clinical features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sleep-related headache",
"     </li>",
"     <li>",
"      No family history of migraine",
"     </li>",
"     <li>",
"      Presence of vomiting",
"     </li>",
"     <li>",
"      Absence of visual symptoms",
"     </li>",
"     <li>",
"      Headache of less than six months duration",
"     </li>",
"     <li>",
"      Confusion",
"     </li>",
"     <li>",
"      An abnormal neurologic examination",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many clinicians prefer MRI for imaging children who have chronic headaches, because MRI has a better resolution than CT and does not expose the child to radiation. However, CT is more readily available for emergent evaluation and is useful for identifying intracranial bleeding and a variety of other structural lesions, including associated calcification that may occur with vascular malformations, tumors, chronic subdural hematomas, and congenital viral infections. In addition, contrast-enhanced CT can demonstrate brain abscess.",
"   </p>",
"   <p>",
"    However, the available evidence is derived mainly from observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/40/23178?source=see_link&amp;anchor=H14#H14\">",
"     \"Approach to neuroimaging in children\", section on 'Magnetic resonance imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted, there is an increased risk of radiation-induced cancer associated with CT as compared with MRI. Every effort must be made to minimize the radiation dose to children from CT examinations. This concern is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/40/23178?source=see_link&amp;anchor=H9#H9\">",
"     \"Approach to neuroimaging in children\", section on 'Radiation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing rarely is helpful in the evaluation of childhood headache. A lumbar puncture is rarely indicated unless there is concern about increased intracranial pressure or infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Psychologic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A psychologic evaluation is often helpful in the diagnosis of headaches and may assist in monitoring treatment. The patient and family members should participate in the evaluation. Input from a clergyman, family counselor, psychologist, or psychiatrist may be useful. The evaluation should include an assessment of the patient's personality, depression, anxiety, parental anxiety, family history of pain, global family functioning, pain rating, and relevant social factors. Structured professional interviews may be required to obtain this information.",
"   </p>",
"   <p>",
"    Standardized tests can be used to evaluate psychologic function. The tests that are used most often are the Children's Depression Inventory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/37\">",
"     37",
"    </a>",
"    ], The Beck Depression Inventory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/38\">",
"     38",
"    </a>",
"    ], the Personality Inventory for Children (PIC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], and the Minnesota Multiphasic Personality Inventory (MMPI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5289?source=see_link\">",
"     \"Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12875674\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of tension headache includes increased intracranial pressure and infection. Brain tumors may cause chronic daily headache because of increased intracranial pressure or traction on pain sensitive structures. However, headache associated with brain tumors tends to get worse progressively, and the neurologic examination is usually abnormal.",
"   </p>",
"   <p>",
"    Chronic daily headache may also evolve from tension-type headache or chronic migraine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/8/35977?source=see_link&amp;anchor=H661158092#H661158092\">",
"     \"Approach to the child with headache\", section on 'Chronic daily headache'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anomalies such as Chiari I malformation can cause chronic headaches with painful muscles at the cranial-cervical junction.",
"   </p>",
"   <p>",
"    Some individuals may have overlapping features of both migraine and tension-type headache. Those individuals are hard to satisfactorily label with a single diagnosis, but generally should be treated as tension-type headache sufferers. The clinical features that appear to be most predictive of migraine compared with tension-type headache include nausea, photophobia, phonophobia, and exacerbation by physical activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/43\">",
"     43",
"    </a>",
"    ]. Food triggers are also more common with migraine than tension-type headache.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of tension-type headache includes emotional support and analgesic medication. It is important that the pain of tension-type headache be validated as real to the patient and parents. At the same time, they should be reassured that pathologic processes, such as brain tumor, have been excluded.",
"   </p>",
"   <p>",
"    Sources of stress for the child should be identified and minimized to the extent possible. Successful long-term management of both episodic and chronic headache depends upon decreasing or removing the source of stress. Counseling may be indicated for the patient and family.",
"   </p>",
"   <p>",
"    Treatment also may include the judicious use of non-addicting analgesic medications. A calendar can be used to document the frequency of headaches and to monitor treatment success. The parents should be instructed to count the number of pain pills used and to use the minimal effective dose. It is important to clarify how access to pain medication will be achieved and, depending upon age, whether the child will be permitted to self-medicate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Infrequent headaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute treatment of episodic tension-type headache is usually straightforward. In general, pain relief can be accomplished using simple over-the-counter analgesics such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    . Nonsteroidal antiinflammatory drugs (NSAIDs) are used commonly in adults and may be used to treat headache in children, although little information is available on long-term use in this population.",
"   </p>",
"   <p>",
"    Studies directly comparing",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    are limited for pediatric headache are limited. A 2010 systematic review found only one randomized controlled trial that included children with tension-type headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/44\">",
"     44",
"    </a>",
"    ]. The trial enrolled 154 children and adults age 12 and older (mean age 40 years) with episodic tension-type headache and found that complete relief at three hours was significantly higher for ibuprofen than for acetaminophen or placebo (75 versus 32 versus 13 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     Aspirin",
"    </a>",
"    use should be avoided in children because of its association with Reye syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/62/22506?source=see_link&amp;anchor=H28202936#H28202936\">",
"     \"Acute toxic-metabolic encephalopathy in children\", section on 'Reye syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Combination drugs containing",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/49/18196?source=see_link\">",
"     ergotamine",
"    </a>",
"    , caffeine, butalbital and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32230?source=see_link\">",
"     codeine",
"    </a>",
"    should be avoided due to the potential for drug dependency and rebound headaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Frequent or chronic headaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of frequent episodic or chronic tension-type headache is more difficult than the treatment of infrequent headaches, as the evidence supporting prophylactic medications is limited. In addition, children have a high placebo responder rate, which confounds interpretation of the available data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/46\">",
"     46",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    As with episodic headache, initial treatment with over-the-counter analgesic medication is suggested. Other drugs, particularly tricyclic antidepressants, may be helpful if simple analgesics are ineffective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/47\">",
"     47",
"    </a>",
"    ]. In this situation, low dose",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/32/7687?source=see_link\">",
"     amitriptyline",
"    </a>",
"    is commonly used first. Our suggested starting dose is 5 to 10 mg (or 0.25",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    at bedtime. Depending on the response, the dose may be increase every two to three weeks by 0.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    to a maximum dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    a day. Day time drowsiness often occurs with doses above 30 to 40 mg per day, even when the medication is given at bedtime. Other side effects include orthostatic hypotension and anticholinergic effects.",
"   </p>",
"   <p>",
"    The use of antidepressant medication in children is supported by studies in adults. In a randomized, controlled trial of 203 outpatients with chronic tension-type headaches (mean 26 headache",
"    <span class=\"nowrap\">",
"     days/month),",
"    </span>",
"    patients randomly assigned to receive a tricyclic antidepressant (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/32/7687?source=see_link\">",
"     amitriptyline",
"    </a>",
"    up to 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/26/38310?source=see_link\">",
"     nortriptyline",
"    </a>",
"    up to 75",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    experienced a significantly greater reduction in headache activity, analgesic medication use, and headache-related disability than those receiving placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/48\">",
"     48",
"    </a>",
"    ]. However, only one-third of patients who took tricyclic antidepressants had substantial (&ge;50 percent) reductions in headache activity. A meta-analysis also concluded that antidepressants (tricyclics and serotonin blockers) are effective in preventing chronic headaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/49\">",
"     49",
"    </a>",
"    ]. The efficacy of the selective serotonin reuptake inhibitors is unclear.",
"   </p>",
"   <p>",
"    There are few data regarding other drugs for pediatric tension-type headache.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/23/35191?source=see_link\">",
"     Gabapentin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/60/21448?source=see_link\">",
"     topiramate",
"    </a>",
"    are commonly used but no controlled studies are available regarding their effectiveness in children. A single uncontrolled study of nine children with episodic or chronic tension-type headache reported that treatment with magnesium pidolate for two months was associated with headache improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/50\">",
"     50",
"    </a>",
"    ]. Another study of 22 children with headache reported that melatonin at bedtime was associated with improvement in 4 of the 8 children with chronic tension-type headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biobehavioral techniques can be useful for managing chronic tension-type headaches, either alone or in combination with antidepressant medications. Psychotherapy, relaxation therapy, and biofeedback all may be helpful, but the available evidence regarding these treatments for children with tension-type headache is limited and conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. In the adult study cited above, patients randomly assigned to brief stress management therapy had similar improvements in headache-related outcomes as those taking tricyclic antidepressants, although the improvements in headache activity and analgesic medication use in the former were not evident for six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/48\">",
"     48",
"    </a>",
"    ]. The combination of tricyclic antidepressant and stress management therapy was associated with reductions in headache activity in a larger number of patients than with either intervention alone, although no significant advantage for combination therapy was observed with other outcome measures.",
"   </p>",
"   <p>",
"    Little information is available on the efficacy of biofeedback in children. In a study of five children, 8 to 14 years of age, with tension headache, thermal biofeedback resulted in clinically significant reductions in one or more headache parameters (frequency, duration, intensity) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/54\">",
"     54",
"    </a>",
"    ]. Four of the five children were free of headache six months later. In another report, a randomized trial of biofeedback-assisted relaxation was performed in 35 children with chronic daily headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/55\">",
"     55",
"    </a>",
"    ]. Patients assigned to biofeedback had greater improvement at 6 and 12 month follow-up (86 versus 50 percent) compared to control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache that begins in childhood often changes in its characteristics with time and may either transform into a different headache phenotype, or improve or remit, especially in males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/20,56,57\">",
"     20,56,57",
"    </a>",
"    ]. In one study, 100 children and adolescents with headache were seen eight years after the initial visit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/58\">",
"     58",
"    </a>",
"    ]. Between the initial presentation and follow-up visit, tension headache was more likely to remit than migraine (44 versus 28 percent). Migraine without aura persisted in the same form in 44 percent and became episodic tension headache in 26 percent. Episodic tension headache persisted in the same form in 26 percent, and changed to migraine without aura in 11 percent. Psychiatric co-morbidity at the initial visit was associated with worsening or unchanged clinical status at follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34744/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/29/27090?source=see_link\">",
"       \"Patient information: Headaches in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/15/36086?source=see_link\">",
"       \"Patient information: Headache in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87449447\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tension-type headaches are characterized by a bilateral pressing tightness that occurs anywhere on the cranium or suboccipital region. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Heightened sensitivity of pain pathways in the central nervous system, and perhaps in the peripheral nervous system, is thought to play a critical role in the pathogenesis of tension-type headache. Nitric oxide may be a molecular trigger for pain. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The signs and symptoms of infrequent, frequent, and chronic tension-type headaches are similar. The headache is typically frontal, although band-like or temporal pain can occur. The pain usually is described as a continuous pressure although the intensity may vary. Light-headedness and fatigue may occur. Daily activities, such as school attendance, are typically not affected by tension-type headache. Sensitivity to light and noise may occur but are not as common in tension headache as in migraine. The presence of photophobia or phonophobia may lead to an erroneous diagnosis of migraine. Abdominal pain, nausea or vomiting, and changes in appetite are uncommon. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of tension headache is based upon clinical criteria (",
"      <a class=\"graphic graphic_table graphicRef79672 \" href=\"mobipreview.htm?42/32/43531\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef68892 \" href=\"mobipreview.htm?38/22/39275\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12875187\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with suspected tension-type headache who lack evidence of neurologic dysfunction or increased intracranial pressure do not need neuroimaging. In such children, neuroimaging is unlikely to reveal clinically significant abnormalities and may detect incidental findings that require additional evaluation or follow-up. However, many parents are concerned that the child's headache is caused by a brain tumor. In these cases, brain imaging may be required to relieve apprehensions. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of tension headache includes increased intracranial pressure, tumor, infection, and other types of primary headache such as migraine without aura. (See",
"      <a class=\"local\" href=\"#H12875674\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of tension-type headache includes emotional support and the judicious use of non-addicting analgesic medications. Patients with frequent episodic or chronic tension-type headache may also benefit from tricyclic medications such as",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/32/7687?source=see_link\">",
"       amitriptyline",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      biobehavioral techniques including psychotherapy, relaxation therapy, and biofeedback. However, the evidence supporting the effectiveness of these methods in the treatment of pediatric tension-type headache is limited. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Headache that begins in childhood often changes in its characteristics with time and may either transform into a different headache phenotype, or improve or remit, especially in males. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/1\">",
"      Scheller JM. The history, epidemiology, and classification of headaches in childhood. Semin Pediatr Neurol 1995; 2:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/2\">",
"      Barea LM, Tannhauser M, Rotta NT. An epidemiologic study of headache among children and adolescents of southern Brazil. Cephalalgia 1996; 16:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/3\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/4\">",
"      Zebenholzer K, W&ouml;ber C, Kienbacher C, W&ouml;ber-Bing&ouml;l C. Migrainous disorder and headache of the tension-type not fulfilling the criteria: a follow-up study in children and adolescents. Cephalalgia 2000; 20:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/5\">",
"      Fern&aacute;ndez-de-Las-Pe&ntilde;as C, Fern&aacute;ndez-Mayoralas DM, Ortega-Santiago R, et al. Bilateral, wide-spread, mechanical pain sensitivity in children with frequent episodic tension-type headache suggesting impairment in central nociceptive processing. Cephalalgia 2010; 30:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/6\">",
"      Fern&aacute;ndez-Mayoralas DM, Fern&aacute;ndez-de-las-Pe&ntilde;as C, Ortega-Santiago R, et al. Generalized mechanical nerve pain hypersensitivity in children with episodic tension-type headache. Pediatrics 2010; 126:e187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/7\">",
"      Abu-Arefeh I, Russell G. Prevalence of headache and migraine in schoolchildren. BMJ 1994; 309:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/8\">",
"      Sillanp&auml;&auml; M, Piekkala P. Prevalence of migraine and other headaches in early puberty. Scand J Prim Health Care 1984; 2:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/9\">",
"      BILLE BS. Migraine in school children. A study of the incidence and short-term prognosis, and a clinical, psychological and electroencephalographic comparison between children with migraine and matched controls. Acta Paediatr Suppl 1962; 136:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/10\">",
"      Stovner Lj, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007; 27:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/11\">",
"      Linet MS, Stewart WF, Celentano DD, et al. An epidemiologic study of headache among adolescents and young adults. JAMA 1989; 261:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/12\">",
"      van der Wouden JC, van der Pas P, Baaij D, van Suijlekom-Smit LW. Headache in adolescents in Dutch general practice. Funct Neurol 2000; 15 Suppl 3:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/13\">",
"      Ozge A, Sasmaz T, Cakmak SE, et al. Epidemiological-based childhood headache natural history study: after an interval of six years. Cephalalgia 2010; 30:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/14\">",
"      Collin C, Hockaday JM, Waters WE. Headache and school absence. Arch Dis Child 1985; 60:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/15\">",
"      Rothner AD, Linder SL, Wasiewski WW, O'Neill KM. Chronic nonprogressive headaches in children and adolescents. Semin Pediatr Neurol 2001; 8:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/16\">",
"      Gallai V, Sarchielli P, Carboni F, et al. Applicability of the 1988 IHS criteria to headache patients under the age of 18 years attending 21 Italian headache clinics. Juvenile Headache Collaborative Study Group. Headache 1995; 35:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/17\">",
"      Aromaa M, Sillanp&auml;&auml; M, Rautava P, Helenius H. Pain experience of children with headache and their families: A controlled study. Pediatrics 2000; 106:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/18\">",
"      Zuckerman B, Stevenson J, Bailey V. Stomachaches and headaches in a community sample of preschool children. Pediatrics 1987; 79:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/19\">",
"      Rossi LN, Cortinovis I, Menegazzo L, et al. Classification criteria and distinction between migraine and tension-type headache in children. Dev Med Child Neurol 2001; 43:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/20\">",
"      Monteith TS, Sprenger T. Tension type headache in adolescence and childhood: where are we now? Curr Pain Headache Rep 2010; 14:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/21\">",
"      Rossi LN, Vajani S, Cortinovis I, et al. Analysis of the International Classification of Headache Disorders for diagnosis of migraine and tension-type headache in children. Dev Med Child Neurol 2008; 50:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/22\">",
"      Rothner AD. The evaluation of headaches in children and adolescents. Semin Pediatr Neurol 1995; 2:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/23\">",
"      Richardson GM, McGrath PJ, Cunningham SJ, Humphreys P. Validity of the headache diary for children. Headache 1983; 23:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/24\">",
"      Gladstein J. Headaches: the pediatrician's perspective. Semin Pediatr Neurol 1995; 2:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/25\">",
"      Askmark H, Lundberg PO, Olsson S. Drug-related headache. Headache 1989; 29:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/26\">",
"      Mathew NT, Kurman R, Perez F. Drug induced refractory headache--clinical features and management. Headache 1990; 30:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/27\">",
"      Fern&aacute;ndez-de-las-Pe&ntilde;as C, Fern&aacute;ndez-Mayoralas DM, Ortega-Santiago R, et al. Referred pain from myofascial trigger points in head and neck-shoulder muscles reproduces head pain features in children with chronic tension type headache. J Headache Pain 2011; 12:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/28\">",
"      Fern&aacute;ndez-Mayoralas DM, Fern&aacute;ndez-de-las-Pe&ntilde;as C, Palacios-Ce&ntilde;a D, et al. Restricted neck mobility in children with chronic tension type headache: a blinded, controlled study. J Headache Pain 2010; 11:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/29\">",
"      Lewis DW, Ashwal S, Dahl G, et al. Practice parameter: evaluation of children and adolescents with recurrent headaches: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2002; 59:490.",
"     </a>",
"    </li>",
"    <li>",
"     Prince JS, Gunderman R, Coley BD, et al. Expert Panel on Pediatric Imaging. ACR Appropriateness Criteria. Headache -- child. American College of Radiology, Reston, VA, 2008. file://www.acr.org/SecondaryMainMenuCategories/quality_safety/app_criteria/pdf/ExpertPanelonPediatricImaging/HeadacheChildDoc3.aspx (Accessed on March 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/31\">",
"      Sempere AP, Porta-Etessam J, Medrano V, et al. Neuroimaging in the evaluation of patients with non-acute headache. Cephalalgia 2005; 25:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/32\">",
"      Graf WD, Kayyali HR, Abdelmoity AT, et al. Incidental neuroimaging findings in nonacute headache. J Child Neurol 2010; 25:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/33\">",
"      Schwedt TJ, Guo Y, Rothner AD. \"Benign\" imaging abnormalities in children and adolescents with headache. Headache 2006; 46:387.",
"     </a>",
"    </li>",
"    <li>",
"     US Headache Consortium. Evidence-based guidelines in the primary care setting: Neuroimaging in patients with nonacute headache, 2000. www.aan.com/professionals/practice/pdfs/gl0088.pdf (Accessed on March 23, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/35\">",
"      Medina LS, Pinter JD, Zurakowski D, et al. Children with headache: clinical predictors of surgical space-occupying lesions and the role of neuroimaging. Radiology 1997; 202:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/36\">",
"      Medina LS, D'Souza B, Vasconcellos E. Adults and children with headache: evidence-based diagnostic evaluation. Neuroimaging Clin N Am 2003; 13:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/37\">",
"      Kovacs M. The Children's Depression, Inventory (CDI). Psychopharmacol Bull 1985; 21:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/38\">",
"      BECK AT, WARD CH, MENDELSON M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4:561.",
"     </a>",
"    </li>",
"    <li>",
"     Lachar D, Gruber CP.. Personality Inventory for Children, Second Edition (PIC-2), Western Psychological Services, Los Angeles 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/40\">",
"      Kline RB, Lachar D, Sprague DJ. The personality inventory for children (PIC): an unbiased predictor of cognitive and academic status. J Pediatr Psychol 1985; 10:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/41\">",
"      De Benedittis G, Lorenzetti A. Minor stressful life events (daily hassles) in chronic primary headache: relationship with MMPI personality patterns. Headache 1992; 32:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/42\">",
"      Drayton M. The Minnesota Multiphasic Personality Inventory-2 (MMPI-2). Occup Med (Lond) 2009; 59:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/43\">",
"      Smetana GW. The diagnostic value of historical features in primary headache syndromes: a comprehensive review. Arch Intern Med 2000; 160:2729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/44\">",
"      Manzano S, Doyon-Trottier E, Bailey B. Myth: Ibuprofen is superior to acetaminophen for the treatment of benign headaches in children and adults. CJEM 2010; 12:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/45\">",
"      Packman B, Packman E, Doyle G, et al. Solubilized ibuprofen: evaluation of onset, relief, and safety of a novel formulation in the treatment of episodic tension-type headache. Headache 2000; 40:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/46\">",
"      Lewis DW, Winner P, Wasiewski W. The placebo responder rate in children and adolescents. Headache 2005; 45:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/47\">",
"      Seshia SS, Abu-Arafeh I, Hershey AD. Tension-type headache in children: the Cinderella of headache disorders! Can J Neurol Sci 2009; 36:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/48\">",
"      Holroyd KA, O'Donnell FJ, Stensland M, et al. Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination: a randomized controlled trial. JAMA 2001; 285:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/49\">",
"      Tomkins GE, Jackson JL, O'Malley PG, et al. Treatment of chronic headache with antidepressants: a meta-analysis. Am J Med 2001; 111:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/50\">",
"      Grazzi L, Andrasik F, Usai S, Bussone G. Magnesium as a treatment for paediatric tension-type headache: a clinical replication series. Neurol Sci 2005; 25:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/51\">",
"      Miano S, Parisi P, Pelliccia A, et al. Melatonin to prevent migraine or tension-type headache in children. Neurol Sci 2008; 29:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/52\">",
"      Verhagen AP, Damen L, Berger MY, et al. Conservative treatments of children with episodic tension-type headache. A systematic review. J Neurol 2005; 252:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/53\">",
"      Verhagen AP, Damen L, Berger MY, et al. Behavioral treatments of chronic tension-type headache in adults: are they beneficial? CNS Neurosci Ther 2009; 15:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/54\">",
"      Arndorfer RE, Allen KD. Extending the efficacy of a thermal biofeedback treatment package to the management of tension-type headaches in children. Headache 2001; 41:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/55\">",
"      Bussone G, Grazzi L, D'Amico D, et al. Biofeedback-assisted relaxation training for young adolescents with tension-type headache: a controlled study. Cephalalgia 1998; 18:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/56\">",
"      Winner P. Classification of pediatric headache. Curr Pain Headache Rep 2008; 12:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/57\">",
"      Parisi P, Papetti L, Spalice A, et al. Tension-type headache in paediatric age. Acta Paediatr 2011; 100:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/58\">",
"      Guidetti V, Galli F. Evolution of headache in childhood and adolescence: an 8-year follow-up. Cephalalgia 1998; 18:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34744/abstract/59\">",
"      Guidetti V, Galli F, Fabrizi P, et al. Headache and psychiatric comorbidity: clinical aspects and outcome in an 8-year follow-up study. Cephalalgia 1998; 18:455.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6160 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-B2407C6BAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_59_34744=[""].join("\n");
var outline_f33_59_34744=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H87449447\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12874959\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12875187\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12875173\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Psychologic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12875674\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Infrequent headaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Frequent or chronic headaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87449447\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6160\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6160|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/21/36188\" title=\"table 1\">",
"      Etiology of headache children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/32/43531\" title=\"table 2\">",
"      Tension-type headache criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/22/39275\" title=\"table 3\">",
"      Chronic tension-type headache criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/8/44171\" title=\"table 4\">",
"      Headache database",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/16/2317\" title=\"table 5\">",
"      Worrisome headache features in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/62/22506?source=related_link\">",
"      Acute toxic-metabolic encephalopathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/40/23178?source=related_link\">",
"      Approach to neuroimaging in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/8/35977?source=related_link\">",
"      Approach to the child with headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5289?source=related_link\">",
"      Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/15/36086?source=related_link\">",
"      Patient information: Headache in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/29/27090?source=related_link\">",
"      Patient information: Headaches in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/43/32441?source=related_link\">",
"      Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_59_34745="Developmental milestones 4 through 8 yrs A";
var content_f33_59_34745=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60900%7EPEDS%2F69590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60900%7EPEDS%2F69590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 630px\">",
"   <div class=\"ttl\">",
"    Developmental milestones: 4 years, 0 months through 7 to 8 years",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 610px; height: 715px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     &copy; 2007 Chris Johnson, MD, AAP Council on Children with Disabilities. Adapted with permission and contributions from: Frances Page Glascoe, PhD and Nicholas Robertshaw, authors of PEDS:Developmental Milestones; Franklin Trimm, MD, Vice Chair of Pediatrics, USA/APA Education Committee; the Center for Disease Control \"Act Early\" Initiative; the National Institute for Literacy/Reach Out and Read; and the Inventory of Early Development by Albert Brigance published by Curriculum Associates, Inc. Permission is granted to reproduce these pages on the condition that they are only used as guide to average development and not as a substitute for standardized validated screening for developmental-behavioral problems.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 630px\">",
"   <div class=\"ttl\">",
"    Developmental milestones: 4 years, 0 months through 7 to 8 years (continued)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 610px; height: 591px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     &copy; 2007 Chris Johnson, MD, AAP Council on Children with Disabilities. Adapted with permission and contributions from: Frances Page Glascoe, PhD and Nicholas Robertshaw, authors of PEDS:Developmental Milestones; Franklin Trimm, MD, Vice Chair of Pediatrics, USA/APA Education Committee; the Center for Disease Control \"Act Early\" Initiative; the National Institute for Literacy/Reach Out and Read; and the Inventory of Early Development by Albert Brigance published by Curriculum Associates, Inc. Permission is granted to reproduce these pages on the condition that they are only used as guide to average development and not as a substitute for standardized validated screening for developmental-behavioral problems.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_59_34745=[""].join("\n");
var outline_f33_59_34745=null;
var title_f33_59_34746="Etiology and evaluation of hematuria in adults";
var content_f33_59_34746=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology and evaluation of hematuria in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/59/34746/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/59/34746/contributors\">",
"     Adam S Feldman, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/59/34746/contributors\">",
"     Chi-yuan Hsu, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/59/34746/contributors\">",
"     Michael Kurtz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/59/34746/contributors\">",
"     Kerry C Cho, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/59/34746/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/59/34746/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/59/34746/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/59/34746/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/59/34746/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/59/34746/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematuria that is not explained by an obvious underlying condition (eg, cystitis, ureteral stone) is fairly common. In many such patients, particularly young adult patients, the hematuria is transient and of no consequence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/1\">",
"     1",
"    </a>",
"    ]. On the other hand, there is an appreciable risk of malignancy in older patients (eg, over age 35 years) with hematuria, even if transient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. However, even among older patients, a urologic cause for the hematuria can often not be identified (61 percent in a series of 1930 patients referred to a Hematuria Clinic) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Transient or persistent hematuria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The etiology and evaluation of hematuria in adults will be reviewed here. The approach in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30584?source=see_link\">",
"     \"Evaluation of microscopic hematuria in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1127?source=see_link\">",
"     \"Evaluation of gross hematuria in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION OF HEMATURIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematuria may be grossly visible (macroscopic hematuria) or detectable only on urine examination (called microscopic hematuria).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Gross hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gross hematuria is suspected because of the presence of red or brown urine. The color change does not necessarily reflect the degree of blood loss, since as little as 1 mL of blood per liter of urine can induce a visible color change. In addition, the intermittent excretion of red to brown urine can be seen in a variety of clinical conditions other than bleeding into the urinary tract. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/34/22058?source=see_link&amp;anchor=H4#H4\">",
"     \"Urinalysis in the diagnosis of kidney disease\", section on 'Red to brown urine'",
"    </a>",
"    .) Gross hematuria with passage of clots almost always indicates a lower urinary tract source.",
"   </p>",
"   <p>",
"    The initial step in the evaluation of patients with red urine is centrifugation of the specimen to see if the red or brown color is in the urine sediment or the supernatant (",
"    <a class=\"graphic graphic_algorithm graphicRef55923 \" href=\"mobipreview.htm?22/63/23550\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As contamination with blood is a possibility in menstruating and post-partum women, urine for analysis is best obtained when the other cause of bleeding has ceased. If this is not possible a tampon can be inserted, and urinalysis obtained after the perineum is thoroughly cleansed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematuria is responsible if the red to brown color is seen only in the urine sediment, with the supernatant being clear. A rare exception is that lysis of red blood cells in patients with gross hematuria and very dilute urine can result in a red supernatant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If, on the other hand, it is the supernatant that is red to brown, then the supernatant should be tested for heme (hemoglobin or myoglobin) with a urine dipstick.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A red to brown supernatant that is negative for heme (hemoglobin or myoglobin) is a rare finding that can be seen in several conditions, including porphyria (",
"      <a class=\"graphic graphic_table graphicRef56337 \" href=\"mobipreview.htm?24/52/25419\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef57844 \" href=\"mobipreview.htm?14/47/15088\">",
"       picture 1",
"      </a>",
"      ), the use of the bladder analgesic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/7/41075?source=see_link\">",
"       phenazopyridine",
"      </a>",
"      , and the ingestion of beets in susceptible subjects. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28984?source=see_link&amp;anchor=H17#H17\">",
"       \"Porphyrias: An overview\", section on 'Porphobilinogen'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/34/22058?source=see_link\">",
"       \"Urinalysis in the diagnosis of kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A red to brown supernatant that is positive for heme is due to myoglobinuria or hemoglobinuria. How these disorders can be distinguished is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/34/22058?source=see_link&amp;anchor=H2011323053#H2011323053\">",
"       \"Urinalysis in the diagnosis of kidney disease\", section on 'Hemoglobinuria and myoglobinuria'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Acute renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gross hematuria occurring in patients with underlying glomerular disease has been associated with the development of transient acute renal failure. Renal biopsy shows distension of many renal tubules by intratubular red cells and tubular cell injury consistent with acute tubular necrosis. This association has been best described in patients with IgA nephropathy, but has also been noted in case reports of patients with thin basement membrane disease and lupus nephritis, who were overanticoagulated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/7/42106?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment and prognosis of IgA nephropathy\", section on 'Acute renal failure with gross hematuria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Microscopic hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microscopic hematuria may be discovered by accident when blood (either red blood cells or hemoglobin) is found on a urinalysis or dipstick done for other purposes. Although abnormal hematuria is commonly defined as the presence of three or more RBCs per high power field in a spun urine sediment, there is no \"safe\" lower limit below which significant disease can be excluded (",
"    <a class=\"graphic graphic_picture graphicRef80282 \" href=\"mobipreview.htm?43/46/44768\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/7\">",
"     7",
"    </a>",
"    ]. Lowering the cut-off value of RBCs chosen to define hematuria results in a greater number of false positive test results (eg, no underlying abnormality is found). On the other hand, if higher cut-off values are chosen, it is more likely that the test will miss the presence of significant abnormalities.",
"   </p>",
"   <p>",
"    The role of the urinalysis in distinguishing glomerular from extraglomerular bleeding is discussed below. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Glomerular versus nonglomerular bleeding'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Urine dipstick",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urine sediment (or direct counting of RBC per mL of uncentrifuged urine) is the gold standard for the detection of microscopic hematuria. Dipsticks for heme detect 1 to 2 RBCs per high power field and are therefore at least as sensitive as urine sediment examination, but result in more false positive tests due to the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Semen is present in the urine after ejaculation and may cause a positive heme reaction on the dipstick [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An alkaline urine with a pH greater than 9 or contamination with oxidizing agents used to clean the perineum",
"     </li>",
"     <li>",
"      The presence of myoglobinuria",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, a positive dipstick test must always be confirmed with microscopic examination of the urine. Rarely, a very dilute urine result in osmotic lysis of almost all the urinary RBCs, resulting in an apparently false positive result as the dipstick still detects the hemoglobin content. This does not constitute a false positive test.",
"   </p>",
"   <p>",
"    False negative tests with the urine dipstick are unusual; as a result, a negative dipstick usually excludes abnormal hematuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/9\">",
"     9",
"    </a>",
"    ]. False negative dipstick tests have been reported in patients ingesting large amounts of vitamin C; the clinical relevance of this observation is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematuria may be a symptom of an underlying disease, some of which are life threatening or treatable (",
"    <a class=\"graphic graphic_figure graphicRef63501 \" href=\"mobipreview.htm?34/49/35609\">",
"     figure 1",
"    </a>",
"    ). The causes vary with age with the most common being inflammation or infection of the prostate or bladder, stones, and, in older patients, a kidney or urinary tract malignancy or benign prostatic hyperplasia (",
"    <a class=\"graphic graphic_figure graphicRef61296 \" href=\"mobipreview.htm?13/34/13870\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/7,11-17\">",
"     7,11-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely hematuria is factitious, with blood being added to an unwitnessed urine specimen after voiding (eg, from a finger stick) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/18\">",
"     18",
"    </a>",
"    ]. Factitious hematuria can be documented by the absence of hematuria in a urine specimen obtained under direct observation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general principle, hematuria itself is not dangerous unless extraglomerular bleeding is so brisk that it causes clots that obstruct the ureter(s). Transient hematuria is common and almost always benign in young patients and a cause is often not identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Transient or persistent hematuria'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20\">",
"     'Unexplained hematuria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In contrast, even transient hematuria may be a symptom of an underlying serious condition, particularly in patients over age 40 years. (See",
"    <a class=\"local\" href=\"#H22373332\">",
"     'Risk factors for malignancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The evaluation should address the following three questions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Are there any clues from the history or physical examination that suggest a particular diagnosis?",
"     </li>",
"     <li>",
"      Does the hematuria represent glomerular or extraglomerular bleeding?",
"     </li>",
"     <li>",
"      Is the hematuria transient or persistent?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the answers to these three questions, imaging with multidetector computed tomography (CT) urography and cystoscopy may be indicated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CT urography should be performed in all patients with unexplained persistent hematuria (ie, patients without infection, glomerular hematuria, or other known source of hematuria). CT urography should also be performed in patients with transient hematuria who have risk factors for malignancy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Imaging'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H22373332\">",
"       'Risk factors for malignancy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Cystoscopy should be performed in all patients with gross hematuria unless there is an active urinary tract infection or known glomerular hematuria. However, patients who pass blood clots should have cystoscopy even if there is evidence for glomerular hematuria since glomerular lesions do",
"      <strong>",
"       not",
"      </strong>",
"      produce blood clots. Cystoscopy should also be performed in patients with persistent microscopic hematuria if the hematuria is unexplained (ie, patients without infection, glomerular hematuria, or other known source of hematuria) and if risk factors for malignancy are present. The role of cystoscopy is uncertain in patients with unexplained persistent microscopic hematuria who have no risk factors for malignancy. (See",
"      <a class=\"local\" href=\"#H91125785\">",
"       'Cystoscopy'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H22373332\">",
"       'Risk factors for malignancy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Historical clues",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are often clues from the history that point toward a specific diagnosis. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concurrent pyuria and dysuria, which are usually indicative of a urinary tract infection, but may also occur with bladder malignancy.",
"     </li>",
"     <li>",
"      A recent upper respiratory infection raises the possibility of postinfectious glomerulonephritis or IgA nephropathy or sometimes hereditary nephritis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=see_link&amp;anchor=H14578038#H14578038\">",
"       \"Differential diagnosis and evaluation of glomerular disease\", section on 'Hematuria following upper respiratory infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A positive family history of renal disease, as in hereditary nephritis, polycystic kidney disease, or sickle cell disease.",
"     </li>",
"     <li>",
"      Unilateral flank pain, which may radiate to the groin, suggests ureteral obstruction due to a calculus or blood clot, but can occasionally be seen with malignancy. Flank pain that is persistent or recurrent can also occur in the rare loin pain-hematuria syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35881?source=see_link\">",
"       \"Loin pain-hematuria syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Symptoms of prostatic obstruction in older men such as hesitancy and dribbling. The cellular proliferation in benign prostatic hyperplasia (BPH) is associated with increased vascularity, and the new vessels can be fragile. There is some controversy about whether hematuria is more common in these patients than in age-matched controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/13,20\">",
"       13,20",
"      </a>",
"      ]. However, there is general agreement that the presence of BPH should not dissuade the clinician from pursuing further evaluation of hematuria, particularly since older men are more likely to have more serious disorders such as cancer of the prostate or bladder. Among those with gross hematuria in whom no other cause can be identified,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"       finasteride",
"      </a>",
"      usually suppresses the hematuria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8698?source=see_link\">",
"       \"Medical treatment of benign prostatic hyperplasia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recent vigorous exercise or trauma in the absence of another possible cause. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27973?source=see_link\">",
"       \"Exercise-induced hematuria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      History of a bleeding disorder or bleeding from multiple sites due to excessive anticoagulant therapy. However, it should not be assumed that hematuria alone can be explained by chronic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy. In one report of 243 patients prospectively followed for two years, the incidence of hematuria was similar to that in a control group not receiving warfarin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/23\">",
"       23",
"      </a>",
"      ]. Furthermore, evaluation of patients who developed hematuria revealed a genitourinary cause in 81 percent of cases. Infection was most common, but papillary necrosis, renal cysts, and several malignancies of the bladder were also found.",
"      <br/>",
"      <br/>",
"      These observations indicate that hematuria in an anticoagulated patient should generally be evaluated in the same fashion as in other patients unless there is evidence of bleeding from multiple sites with markedly abnormal coagulation studies.",
"     </li>",
"     <li>",
"      Cyclic hematuria in women that is most prominent during and shortly after menstruation, suggesting endometriosis of the urinary tract [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/24\">",
"       24",
"      </a>",
"      ]. Contamination with menstrual blood is always a possibility, and should be ruled out by repeating the urinalysis when menstruation has ceased.",
"     </li>",
"     <li>",
"      Medications that might cause nephritis (usually with other findings, typically with renal insufficiency).",
"     </li>",
"     <li>",
"      Black patients should be screened for sickle cell trait or disease, which can lead to papillary necrosis and hematuria. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6202?source=see_link\">",
"       \"Renal manifestations of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Travel or residence in areas endemic for Schistosoma haematobium or tuberculosis.",
"     </li>",
"     <li>",
"      Sterile pyuria with hematuria, which may occur with renal tuberculosis, analgesic nephropathy and other interstitial diseases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Glomerular versus nonglomerular bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification of the glomeruli as the source of bleeding can optimize the subsequent evaluation. In particular, patients with clear evidence of glomerular hematuria may",
"    <strong>",
"     not",
"    </strong>",
"    need to be evaluated for potentially serious urologic disease unless there is some other reason to do so [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/25\">",
"     25",
"    </a>",
"    ]. Although the identification of dysmorphic red blood cells, proteinuria, cellular casts,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal insufficiency warrants a nephrologic evaluation, they do not necessarily preclude the need for a urologic workup [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21690?source=see_link&amp;anchor=H3#H3\">",
"     \"Indications for and complications of renal biopsy\", section on 'Indications and when biopsy may not be necessary'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glomerular hematuria may result from immune-mediated injury to the glomerular capillary wall or, in noninflammatory glomerulopathies such as thin basement membrane nephropathy, from localized gaps in the glomerular capillary wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/51/12088?source=see_link\">",
"     \"Thin basement membrane nephropathy (benign familial hematuria)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Signs of glomerular bleeding (best identified by a nephrologist or other experienced examiner) include red cell casts, a dysmorphic appearance of some red cells, and, in patients with gross hematuria, a brown, cola-colored urine (",
"    <a class=\"graphic graphic_table graphicRef54067 \" href=\"mobipreview.htm?11/42/11947\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef55778 graphicRef79440 graphicRef62064 \" href=\"mobipreview.htm?8/10/8359\">",
"     picture 3A-C",
"    </a>",
"    ). Glomerular bleeding is indicated by proteinuria exceeding 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    that is temporally related to the onset of hematuria, however, new onset hematuria in the setting of prior chronic proteinuria should elicit consideration of an extraglomerular or urologic source. (See",
"    <a class=\"local\" href=\"#H70188214\">",
"     'Proteinuria'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1824471548\">",
"    <span class=\"h3\">",
"     Red cell casts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of red cell casts is virtually diagnostic of glomerulonephritis or vasculitis, although such casts are infrequently seen in acute interstitial nephritis (",
"    <a class=\"graphic graphic_picture graphicRef55778 \" href=\"mobipreview.htm?34/38/35424\">",
"     picture 3A",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/28\">",
"     28",
"    </a>",
"    ]. The absence of these casts, however, does not exclude glomerular disease.",
"   </p>",
"   <p>",
"    Red cell casts tend to accumulate at the edges of the coverslip. Thus, one has to examine all of the microscopic fields, initially at low power. Prolonged centrifugation may disrupt cellular casts, diminishing the likelihood of identifying such casts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1824471562\">",
"    <span class=\"h3\">",
"     Red cell morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of red cell morphology may be helpful in identifying the cause of hematuria. The red cells are typically uniform and round (as in a peripheral blood smear) with extrarenal bleeding, but usually have a dysmorphic appearance with renal lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/29-31\">",
"     29-31",
"    </a>",
"    ], particularly but not only glomerular diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/31\">",
"     31",
"    </a>",
"    ]. This change in morphology is manifested by blebs, budding, and segmental loss of membrane, resulting in marked variability in red cell shape and a reduction in mean red cell size (",
"    <a class=\"graphic graphic_picture graphicRef79440 graphicRef62064 \" href=\"mobipreview.htm?40/13/41170\">",
"     picture 3B-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Red cell injury in this setting may be due both to mechanical trauma as the cells pass through rents in the glomerular basement membrane and to osmotic trauma as the cells flow through the nephron [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/33\">",
"     33",
"    </a>",
"    ]. The small number of red cells in normal urine are also dysmorphic, suggesting a glomerular origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential importance of red cell morphology was illustrated in a report in which isomorphic red cells were seen in all 30 patients with nonglomerular bleeding but only 1 of 87 with proven glomerulonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/30\">",
"     30",
"    </a>",
"    ]. A predominance of normal shaped red cells can occasionally be seen in patients with glomerulonephritis who undergo a forced diuresis or have advanced renal insufficiency or gross hematuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that the magnitude of dysmorphic hematuria is best expressed in absolute terms rather than as a percentage of urinary red cells. If, for example, only 25 percent of urinary red cells are dysmorphic but the patient is excreting 100,000 red cells per mL (normal less than",
"    <span class=\"nowrap\">",
"     8000/mL",
"    </span>",
"    in centrifuged urine and less than",
"    <span class=\"nowrap\">",
"     13,000/mL",
"    </span>",
"    in uncentrifuged urine) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/29,30\">",
"     29,30",
"    </a>",
"    ], then there are 25,000 dysmorphic red cells per mL, indicating the presence of glomerular disease. However, such quantitative testing is rarely performed in routine practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1824471569\">",
"    <span class=\"h4\">",
"     Acanthocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of dysmorphic red cell may be of diagnostic importance. In particular, dysmorphic red cells alone may be predictive of only renal bleeding while acanthocytes (ring-shaped red cells with vesicle shaped protrusions that are best seen on phase contrast microscopy) appear to be most predictive of glomerular disease (",
"    <a class=\"graphic graphic_picture graphicRef79440 graphicRef62064 \" href=\"mobipreview.htm?40/13/41170\">",
"     picture 3B-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. In one study, for example, the presence of acanthocytes comprising &ge;5 percent of excreted red cells had a sensitivity and specificity for glomerular disease of 52 and 98 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/35\">",
"     35",
"    </a>",
"    ]. Regardless of the absolute number or percentage, the presence of acanthocytes in the urine should lead the clinician to consider nephrology consultation rather than a lengthy urological evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1824471576\">",
"    <span class=\"h4\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major question regarding the utility of red cell morphology in determining the cause of hematuria is whether the findings in clinical studies can be replicated in clinical practice. Optimal assessment of red cell morphology requires phase contrast microscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/35\">",
"     35",
"    </a>",
"    ], which is not generally available in a physician's office and requires experience in its use to gain proficiency.",
"   </p>",
"   <p>",
"    The subjective nature of identifying \"dysmorphism\" is another potential limitation. Acanthocytes (also called G1 cells) may be easier to identify with certainty, even without phase contrast microscopy. However, most physicians do not have expertise in identifying dysmorphic red cells or distinguishing red cell casts from red cells overlying granular casts and most do not have access to phase contrast microscopy. In addition, the absence of these findings does not exclude glomerular disease. Proteinuria, if present (2+ or greater on the dipstick, which is then quantified by the urine protein-to-creatinine ratio on a random specimen) suggests the presence of glomerular disease in patients with hematuria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=see_link\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic importance of proteinuria varies with the",
"    <strong>",
"     time of onset",
"    </strong>",
"    . If, for example, the patient has previously identified proteinuria well before the onset of hematuria, then a separate disease may be responsible for the hematuria. As an example, if a patient with chronic kidney disease and proteinuria but no hematuria (eg, as in nephrosclerosis) develops new hematuria, it should not be assumed that the bleeding is due to the initial glomerular disease. Such patients should undergo a full evaluation for hematuria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/63/30714?source=see_link&amp;anchor=H95228685#H95228685\">",
"     \"Overview of diabetic nephropathy\", section on 'Hematuria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/42/6824?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1824471583\">",
"    <span class=\"h3\">",
"     Red to brown urine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A change in the urine color with gross hematuria is an additional finding that may be helpful. The urine is typically red to pink with extraglomerular bleeding. Although red urine also may be seen with glomerular bleeding (particularly in alkaline urine), the combination of prolonged transit time through the nephron and an acid urine pH may result in the formation of methemoglobin, which has a smoky brown or \"Coca cola\" color. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/34/22058?source=see_link&amp;anchor=H4#H4\">",
"     \"Urinalysis in the diagnosis of kidney disease\", section on 'Red to brown urine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1824471590\">",
"    <span class=\"h3\">",
"     Blood clots",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood clots, if present, are almost always due to",
"    <strong>",
"     extraglomerular",
"    </strong>",
"    bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/36\">",
"     36",
"    </a>",
"    ]. They are indicative of heavy focal bleeding in which whole blood is shed into the urine in amounts sufficient to support clot formation.",
"   </p>",
"   <p>",
"    The characteristic absence of blood clots with gross hematuria due to glomerular bleeding may be due to one or more of the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of urokinase and tissue-type plasminogen activators in the glomeruli and tubules [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Glomerular bleeding is typically a diffuse capillary process in which minute amounts of blood are added to relatively large volumes of glomerular filtrate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/36\">",
"       36",
"      </a>",
"      ]. Thus, clot formation is unlikely.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70188214\">",
"    <span class=\"h3\">",
"     Proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, proteinuria that is temporally related to the hematuria is suggestive of glomerular disease. Hematuria alone does",
"    <strong>",
"     not",
"    </strong>",
"    typically lead to a significant increase in protein excretion. A dipstick test for protein that is greater than 1+ is rarely observed with extraglomerular bleeding, even with gross hematuria, unless the amount of gross blood is very large. As an example, as little as 1 mL of blood in one liter of urine can produce a visible color change. This quantity of blood contains approximately 0.6 mL of plasma, which will contain only 35 mg of protein at a plasma protein concentration of 6",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (60",
"    <span class=\"nowrap\">",
"     g/L).",
"    </span>",
"    A protein concentration of 35",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    is below the sensitivity of the urine dipstick for protein and therefore will not be detected on routine urine examination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=see_link\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, a large amount of gross bleeding can cause abnormal proteinuria. Extremely bloody urine, especially with clots, should trigger an evaluation for an extraglomerular source even if abnormal proteinuria is present. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Imaging'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H91125785\">",
"     'Cystoscopy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11678456\">",
"    <span class=\"h3\">",
"     Role of renal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main indication for performing a renal biopsy in patients with glomerular hematuria (defined by the presence of dysmorphic red cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    red cell casts) is the presence of risk factors for progressive disease such as proteinuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an elevation in the serum creatinine concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. New onset hypertension or a significant elevation in blood pressure above a previous stable baseline that does not exceed",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg (eg, from",
"    <span class=\"nowrap\">",
"     100/60",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg) is also associated with a greater likelihood of progressive disease, but is primarily seen in patients who also have one or both of the other adverse predictors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/7/42106?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment and prognosis of IgA nephropathy\", section on 'Clinical predictors of progression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21690?source=see_link\">",
"     \"Indications for and complications of renal biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Renal biopsy is",
"    <strong>",
"     not",
"    </strong>",
"    usually performed for isolated glomerular hematuria (ie, no proteinuria, no elevation in serum creatinine, no elevation in blood pressure about a previous stable baseline, and no systemic manifestations), since there is no specific therapy for these conditions and the renal prognosis is excellent as long as there is",
"    <strong>",
"     no evidence",
"    </strong>",
"    of progressive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/38,40\">",
"     38,40",
"    </a>",
"    ]. In addition, management of these patients is not usually affected by the biopsy results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In one study, for example, the result of the biopsy altered management in only 1 of 36 patients with isolated hematuria compared with 9 of 28 patients with hematuria and proteinuria (3 versus 32 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When renal biopsy is performed in such patients, the most common findings are a normal biopsy or one or four disorders: IgA nephropathy, thin basement membrane disease (benign familial hematuria), mild nonspecific glomerular abnormalities, and hereditary nephritis (Alport syndrome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/40\">",
"     40",
"    </a>",
"    ]. Among the glomerular diseases, IgA nephropathy is the most common cause in Japan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Glomerular disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H142763824\">",
"    <span class=\"h4\">",
"     Monitoring if renal biopsy is not performed",
"    </span>",
"    &nbsp;&mdash;&nbsp;If renal biopsy is not performed in a patient with isolated glomerular hematuria, periodic monitoring is warranted during follow-up to detect progressive disease. The frequency with which this occurs can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study in which mass screening for asymptomatic hematuria or proteinuria was performed in over 56,000 adults, 432 had asymptomatic hematuria without proteinuria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/42\">",
"       42",
"      </a>",
"      ]. At a mean follow-up of 5.8 years, hematuria disappeared in 44 percent, persisted without proteinuria in 44 percent, and persisted with the development of proteinuria in 11 percent. None of the patients developed renal insufficiency, which was defined as a creatinine clearance less than 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a serum creatinine greater than 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (133",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      The prognosis was worse in the 134 patients with asymptomatic hematuria and proteinuria: hematuria disappeared in only 16 percent; and renal insufficiency developed in 15 percent.",
"     </li>",
"     <li>",
"      The clinical course of isolated glomerular hematuria was evaluated in a series of 85 patients who were followed for a mean of 43 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/40\">",
"       40",
"      </a>",
"      ]. Three patients developed proteinuria (two with IgA nephropathy and one without a biopsy), one developed proteinuria and renal insufficiency (membranoproliferative glomerulonephritis), and 11 developed hypertension (three with thin basement membrane disease, two with IgA nephropathy, two with a normal biopsy, one with focal segmental glomerulosclerosis, and three without a renal biopsy). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Glomerular disease'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Progressive disease is more common in patients with hematuria due to IgA nephropathy. This was illustrated in a study of 72 consecutive patients with hematuria due to IgA nephropathy and no or minimal proteinuria (400",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or less) who were followed for a median of seven years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/39\">",
"       39",
"      </a>",
"      ]. Progressive disease occurred in 32 patients (44 percent), many of whom had more than one sign of progression: 24 developed proteinuria of 1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      or more; 19 became hypertensive; and 5 developed an increase in serum creatinine. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/7/42106?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment and prognosis of IgA nephropathy\", section on 'Clinical predictors of progression'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Renal biopsy is",
"    <strong>",
"     not indicated",
"    </strong>",
"    in patients with persistent isolated",
"    <strong>",
"     nonglomerular hematuria",
"    </strong>",
"    (ie, no dysmorphic red cells or red cell casts, no proteinuria). Such patients need a thorough evaluation with imaging",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cystoscopy, particularly in patients with malignancy. These issues are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Transient or persistent hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no cause of low-level hematuria that, in the absence of other signs and symptoms, requires immediate diagnosis. As a result, it is reasonable to repeat an abnormal urinalysis in a few days to determine if hematuria is transient or persistent.",
"   </p>",
"   <p>",
"    Transient microscopic hematuria is a common problem in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/1,4,11,43\">",
"     1,4,11,43",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective cohort study including 2,421,585 members (of all ages) of a managed care organization with at least one urinalysis, 967,297 (40 percent) had asymptomatic microscopic hematuria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/43\">",
"       43",
"      </a>",
"      ]. Of these, a second urinalysis was positive for microscopic hematuria in 643,304 (66 percent). Thus, approximately one-third of individuals with an initially positive urinalysis had transient hematuria.",
"     </li>",
"     <li>",
"      Another study evaluated 1000 young men who had yearly urinalyses between the ages of 18 and 33 years; hematuria was seen in 39 percent on at least one occasion and 16 percent on two or more occasions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/1\">",
"       1",
"      </a>",
"      ]. Hematuria has also been found in up to 13 percent of men and postmenopausal women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No obvious etiology can be identified in most patients with transient hematuria. Fever, infection, trauma, and exercise are potential causes of transient hematuria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27973?source=see_link\">",
"     \"Exercise-induced hematuria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transient hematuria can also occur with urinary tract infection (eg, cystitis or prostatitis). In this setting, hematuria is typically accompanied by pyuria and bacteriuria and patients often complain of dysuria. A potential source of error is that dysuria (but not pyuria and bacteriuria) can also be seen with macroscopic hematuria from bladder cancer.",
"   </p>",
"   <p>",
"    An important exception to the typically benign nature of transient hematuria occurs in patients over age 40 years in whom even transient hematuria carries an increased risk of malignancy (assuming no evidence of glomerular bleeding as described above). (See",
"    <a class=\"local\" href=\"#H22373332\">",
"     'Risk factors for malignancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11408366\">",
"    <span class=\"h2\">",
"     Urine culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should have a urine culture to exclude infection prior to evaluation of hematuria. Patients who have a positive urine culture should be treated for infection with close follow-up. The urinalysis should be rechecked in six weeks to determine whether hematuria has resolved. Patients who have resolution of hematuria do not require further evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/41/24214?source=see_link\">",
"     \"Urine sampling and culture in the diagnosis of urinary tract infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/19/42295?source=see_link\">",
"     \"Approach to the adult with asymptomatic bacteriuria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15479?source=see_link\">",
"     \"Acute uncomplicated cystitis, pyelonephritis, and asymptomatic bacteriuria in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Urine cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;A voided urine specimen should be sent for cytology in patients at increased risk for urothelial cancers. (See",
"    <a class=\"local\" href=\"#H91125785\">",
"     'Cystoscopy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The sensitivity of urine cytology is greatest for carcinoma of the bladder (approximately 90 percent). By comparison, sensitivity for upper tract transitional cell carcinoma is limited, with the reported false negative rate overall being 65 percent (and as high as 96 percent with low grade tumors) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Urine cytology is frequently obtained immediately prior to cystoscopy, which is usually performed in patients at risk for malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20217?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical presentation, diagnosis, and staging of bladder cancer\", section on 'Urine cytology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/45/1754?source=see_link&amp;anchor=H13#H13\">",
"     \"Malignancies of the renal pelvis and ureter\", section on 'Urine cytology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients at low risk for genitourinary cancer (such as individuals under the age of 40 years without specific risk factors), some investigators recommend that either urine cytology or cystoscopy be performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/22\">",
"     22",
"    </a>",
"    ]. Cystoscopy is subsequently done if malignant",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     atypical/suspicious",
"    </span>",
"    cells are identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once glomerular bleeding has been excluded in a patient with otherwise unexplained hematuria, the diagnostic workup should include a search for lesions in the kidney, collecting system, ureters, bladder or urethra. The diagnostic yield in adults increases with age and may be higher for gross hematuria than for microscopic hematuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multidetector CT urography (CTU) is the preferred imaging study in patients with otherwise unexplained hematuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/26\">",
"     26",
"    </a>",
"    ]. Other available modalities include conventional radiography, intravenous pyelography (IVP), retrograde pyelography, ultrasonography, magnetic resonance imaging, magnetic resonance urography, and conventional CT scanning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/45\">",
"     45",
"    </a>",
"    ] .",
"   </p>",
"   <p>",
"    Patients with a history of malignancy in the bladder or kidneys are at increased risk for malignancy at the other site and should always undergo further evaluation. (See",
"    <a class=\"local\" href=\"#H38117737\">",
"     'Screening for a second lesion'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Preference for CT urography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinicians consider multidetector CTU to be the preferred initial imaging modality in most patients with unexplained hematuria. This modality may be particularly indicated in those with an increased risk of genitourinary malignancy or disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. The combination of multidetector CTU and cystoscopy, which together provide a complete evaluation of the genitourinary system, should be performed in almost all patients with unexplained hematuria. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Summary'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H91125785\">",
"     'Cystoscopy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Multidetector CT urography combines the benefits of conventional CT scanning (with and without contrast) with the ability of an IVP to accurately visualize ureteral and pelvicalyceal surfaces. Although different protocols exist to perform CT urography, images of the kidney and genitourinary system are first obtained pre-contrast; after the administration of contrast, images are then obtained in the renal parenchymal phase, followed by the excretory phase. Thus, multidetector CT urography provides global imaging of the genitourinary tract.",
"   </p>",
"   <p>",
"    Compared with other modalities, multidetector CT urography is associated with increased sensitivity and specificity for the detection of renal masses, urinary tract calculi, and pelvicalyceal and ureteric transitional cell carcinomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/45-55\">",
"     45-55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous pyelography &ndash; CTU has largely replaced IVP, which is less sensitive in detecting kidney stones and renal masses (particularly small masses) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. The magnitude of this effect was illustrated in a study of 115 patients with hematuria in which CTU imaging was significantly more sensitive (100 versus 61 percent) and specific (97 versus 91 percent) than an IVP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/47\">",
"       47",
"      </a>",
"      ]. Despite these observations, some clinicians still perform IVP because of the belief that it is best able to characterize lesions in the urothelium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/45,56\">",
"       45,56",
"      </a>",
"      ]. However, increasing evidence suggests that this is not true given that IVP is associated with only 40 to 65 percent detection rates for urothelial neoplasms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/45,57\">",
"       45,57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ultrasonography &ndash; Ultrasonography has a lower diagnostic yield and is less sensitive in detecting urothelium transitional cell carcinoma, small renal masses, and calculi [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/46,53,58\">",
"       46,53,58",
"      </a>",
"      ]. The relative insensitivity of ultrasonography in detecting small renal tumors was best shown in a study in which ultrasonography detected only 26, 60, 82, and 85 percent of CT-confirmed lesions less than 1 cm, between 1 and 2 cm, between 2 and 3 cm, and 3 cm or more in size, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/46\">",
"       46",
"      </a>",
"      ]. However, the combination of ultrasonography and CT may improve the characterization of renal masses. This is particularly true with smaller sized lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/59,60\">",
"       59,60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      MR urography &ndash; MR urography is less able to detect smaller urothelial lesions and nonobstructing stones. In addition, there is limited availability and experience with this technique. However, advances with MR urography may increase the use of this modality in this setting and kidney masses are readily observed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/50\">",
"       50",
"      </a>",
"      ]. This is an acceptable imaging alternative in patients with contraindications to iodinated contrast administration.",
"     </li>",
"     <li>",
"      Retrograde pyelography &ndash; A retrospective study evaluated the accuracy of multidetector CTU and retrograde pyelography in helping diagnose upper urinary tract urothelial tumour in 106 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/54\">",
"       54",
"      </a>",
"      ]. Both multidetector CT urography and retrograde pyelography had sensitivities and specificities of 97 and 93 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Radiation dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major concern with CTU is the relatively high radiation dose. The average effective dose with contrast-enhanced CTU (7.7 mSv) is more than double that of an IVP (excretory urography) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/61\">",
"     61",
"    </a>",
"    ]. As a result, much effort has been devoted to using lower dose protocols or synchronous acquisition of nephrogenic and excretory phase images [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the concern about radiation exposure, CTU should",
"    <strong>",
"     not",
"    </strong>",
"    be used in pregnant women. In addition, some centers avoid CTU except in patients with known risk factors for genitourinary malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22373332\">",
"     'Risk factors for malignancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although we suggest CTU in all patients with known risk factors for malignancy, some data suggest that non-enhanced imaging in young patients may provide sufficient diagnostic information. As an example, a study of 375 CTU scans performed in patients younger than 40 years for evaluation of hematuria compared the findings of contrast-enhanced and non-enhanced images (non-enhanced imaging requires less radiation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/64\">",
"     64",
"    </a>",
"    ]. The non-enhanced images identified 92 of 97 clinically significant findings (95 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of initial imaging study in patients with unexplained hematuria may vary with age, presence of comorbid conditions, and the risk of genitourinary malignancy or disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/45\">",
"     45",
"    </a>",
"    ]. As mentioned above, multidetector CT urography (CTU) is the preferred initial imaging modality in almost all patients. There are, however, some exceptions to this general recommendation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ultrasonography can be used in the evaluation of pregnant women in whom CTU should",
"      <strong>",
"       not",
"      </strong>",
"      be performed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28120?source=see_link\">",
"       \"Diagnostic imaging procedures during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some centers restrict the use of CTU to patients older than 40 years or to those younger than 40 years with known risk factors for genitourinary malignancies, due to concerns about the risk of radiation outweighing the risk of disease. With this approach, MR urography or other modalities may be considered.",
"     </li>",
"     <li>",
"      Among patients with a contraindication to iodinated contrast administration, ultrasonography, CT scan without contrast, and MR imaging are alternative modalities. Desensitization is an option in patients with a prior allergy to radiocontrast media. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38680?source=see_link\">",
"       \"Immediate hypersensitivity reactions to radiocontrast media: Prevention of recurrent reactions\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22373332\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Urological Association (AUA) best practice policy recommendations on asymptomatic microscopic hematuria included the following risk factors for malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/26,65\">",
"     26,65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &gt;35 years",
"     </li>",
"     <li>",
"      Smoking history in which the risk correlates with the extent of exposure",
"     </li>",
"     <li>",
"      Occupational exposure to chemicals or dyes (benzenes or aromatic amines), such as printers, painters, chemical plant workers",
"     </li>",
"     <li>",
"      History of gross hematuria",
"     </li>",
"     <li>",
"      History of chronic cystitis or irritative voiding symptoms",
"     </li>",
"     <li>",
"      History of pelvic irradiation",
"     </li>",
"     <li>",
"      History of exposure to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"     </li>",
"     <li>",
"      History of a chronic indwelling foreign body",
"     </li>",
"     <li>",
"      History of analgesic abuse, which is also associated with an increased incidence of carcinoma of the kidney (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1012?source=see_link\">",
"       \"Urinary tract malignancy and atherosclerotic disease in patients with chronic analgesic abuse\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk factors for bladder and renal cell carcinomas are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=see_link\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18250?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology, pathology, and pathogenesis of renal cell carcinoma\", section on 'Established risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of gross (macroscopic) hematuria and older age was illustrated in several studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective cohort study of 4414 members of a managed care organization with unexplained, asymptomatic microscopic hematuria who were referred for urologic evaluation, 111 cancers were identified (2.5 percent); 100 were bladder cancers and 11 were renal cancers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/43\">",
"       43",
"      </a>",
"      ]. However, the prevalence of malignancy was 11.2 percent among patients 50 years or older who also had a history of gross hematuria plus at least one additional risk factor (male sex, smoking, or more than 25 red blood cells per high powered field). In contrast, the prevalence of cancer was 0.2 percent among patients younger than 50 years who did not have a history of gross hematuria. This study suggests that individuals at low risk for malignancy who have asymptomatic microscopic hematuria may not require a urologic referral.",
"     </li>",
"     <li>",
"      In another study of 1930 patients (mean age 58 years, 62 percent male) who were referred to a Hematuria Clinic because of gross or microscopic hematuria, 12 percent had bladder cancer, 0.7 percent had kidney and upper tract tumors, and 61 percent had no cause identified [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/2\">",
"       2",
"      </a>",
"      ]. In addition:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At age 50 to 59 years, malignancy was identified in 20.4 versus 1.9 percent of men with macroscopic versus microscopic hematuria, respectively, and in 8.9 versus 1.9 percent of women with macroscopic versus microscopic hematuria.",
"     </li>",
"     <li>",
"      At age 60 to 69 years, malignancy was found in 28.9 versus 7.9 percent of men with macroscopic versus microscopic hematuria, and 21.1 versus 4.5 percent of women with macroscopic versus microscopic hematuria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Another report evaluated 1034 patients with microscopic hematuria who had more than five red cells per high power field on at least one of three screening urinalyses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/12\">",
"       12",
"      </a>",
"      ]. All patients were evaluated by ultrasonography, intravenous pyelography (IVP), urinary cytology, and cystoscopy. The incidence of malignancy (bladder, kidney, or prostate) was 2.4 percent. Among the remaining patients, 20 percent had kidney stones or glomerular or other intrinsic renal disease, while 78 percent had either no identifiable cause or a minor lesion such as benign prostatic hypertrophy.",
"      <br/>",
"      <br/>",
"      Neither cytology nor IVP reliably detected all of the tumors. Ultrasonography was highly accurate for renal tumors, while cystoscopy was required to reliably diagnose bladder or prostatic cancers. Tumors were more common in men and all but one occurred in patients over the age of 50 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An important exception to the typically benign nature of transient hematuria occurs in patients at high risk for malignancy, in whom even transient hematuria carries an appreciable association with malignancy (assuming no evidence of glomerular bleeding as described above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/2,4,7,11,12,66,67\">",
"     2,4,7,11,12,66,67",
"    </a>",
"    ]. As an example, screening studies limited to healthy men over the age of 50 to 60 years found that 8 to 9 percent of patients with intermittent asymptomatic hematuria, as detected by a dipstick for heme, had a urinary tract malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91125785\">",
"    <span class=\"h1\">",
"     CYSTOSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystoscopy is associated with the following benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The entire bladder can be visualized for malignancy or other abnormalities. In the presence of concomitant prostatic hypertrophy, it may be difficult to visualize the entire bladder with video-assisted flexible cystoscopy under local anesthesia. If concerns persist, rigid cystoscopy under spinal or general anesthesia may be required. Analgesic abusers also have an increased incidence of carcinoma of the kidney. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1012?source=see_link\">",
"       \"Urinary tract malignancy and atherosclerotic disease in patients with chronic analgesic abuse\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cystoscopy may identify the source of the bleeding among patients with gross hematuria. It may be possible to determine if the bleeding is originating from the bladder or from one or both ureters. Unilateral bleeding may be due to an arteriovenous malformation, fistula, venous varices, or unilateral renal or upper urinary tract tumors or stones [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cystoscopy is the only modality that permits visualization of the prostate and urethra.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38117723\">",
"    <span class=\"h2\">",
"     Gross hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients who have gross (macroscopic) hematuria and no evidence of either glomerular disease or infection should undergo cystoscopy since it permits direct visualization of bladder and can detect malignant or other sources of bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Glomerular versus nonglomerular bleeding'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients who have gross hematuria with blood clots should have cystoscopy even if they have evidence of a glomerular lesion since blood clots are virtually never associated with glomerular bleeding. Thus, the presence of blood clots in a patient glomerular bleeding suggests the presence of disease in the upper or lower collecting system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38117730\">",
"    <span class=\"h2\">",
"     Microscopic hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with microscopic hematuria who have no evidence of glomerular disease, infection, or a known cause of hematuria such as exercise and who are at increased risk for malignancy should undergo cystoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/9,12,44,66-69\">",
"     9,12,44,66-69",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22373332\">",
"     'Risk factors for malignancy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The diagnostic yield of cystoscopy is lower in patients who have microscopic hematuria, negative imaging, negative urine cytology, and are at low risk for malignancy. For such patients, the American Urological Association (AUA) guidelines do recommend cystoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/26,69,70\">",
"     26,69,70",
"    </a>",
"    ]; given its low morbidity, we discuss the risks and benefits of cystoscopy with all such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38117737\">",
"    <span class=\"h1\">",
"     SCREENING FOR A SECOND LESION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a field cancerization effect for urothelial tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Thus, among patients with hematuria who first undergo cystoscopy and are found to have a bladder tumor, the upper tracts should also be evaluated with an imaging study for possible lesions in the renal pelvis or ureter, which also have transitional epithelium. On the other hand, patients who are found to a renal pelvic or ureteral cancer with an imaging study should undergo cystoscopy. In a report of 130 consecutive patients who underwent surgery for a renal pelvic cancer, 66 (51 percent) had a bladder cancer. The bladder cancer occurred before the renal pelvic cancer in 37, after the renal pelvic cancer in 25, and synchronously in 4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20217?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical presentation, diagnosis, and staging of bladder cancer\", section on 'Urinary tract imaging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/45/1754?source=see_link&amp;anchor=H1098453941#H1098453941\">",
"     \"Malignancies of the renal pelvis and ureter\", section on 'Relationship to urothelial bladder cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     UNEXPLAINED HEMATURIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;If no diagnosis is apparent from the history, urinalysis, radiologic imaging tests, or cystoscopy, then the most likely causes of persistent isolated hematuria are a mild glomerulopathy and a predisposition to stone disease, particularly in young and middle-aged patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Glomerular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although any glomerular disease may be associated with hematuria, most patients also have other signs such as proteinuria, red cell casts, or renal insufficiency. When persistent glomerular hematuria is essentially the only manifestation of glomerular disease, one of four disorders is most likely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/3,38,40,73-76\">",
"     3,38,40,73-76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/2/17445?source=see_link\">",
"     \"Glomerular hematuria: IgA; Alport; thin basement membrane nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IgA nephropathy, in which there is often gross hematuria, and sometimes a positive family history but without any clear pattern of autosomal inheritance.",
"     </li>",
"     <li>",
"      Thin basement membrane nephropathy (also called thin basement membrane disease or benign familial hematuria), in which gross hematuria is unusual and the family history may be positive (with an autonomic dominant pattern of inheritance) for microscopic hematuria but not for renal failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mesangioproliferative glomerulonephritis without IgA deposits [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alport syndrome (hereditary nephritis), in which gross hematuria can occur in association with a positive family history of renal failure, and sometimes deafness or corneal abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In three series of 240 patients with isolated microscopic hematuria, no proteinuria, a normal serum creatinine concentration, and, in two studies, a negative radiologic and cystoscopic evaluation, IgA nephropathy was present in 20 to 30 percent, thin basement membrane disease in 4 to 43 percent, and, in one study, mesangioproliferative glomerulonephritis without IgA deposits in 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/3,38,76\">",
"     3,38,76",
"    </a>",
"    ]. In one of these reports, 86 percent of patients with hematuria persisting for four years had either IgA nephropathy or thin basement membrane disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postinfectious glomerulonephritis and exercise are other causes of isolated glomerular bleeding. The hematuria in these settings is typically transient, not persistent as in the above disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=see_link&amp;anchor=H14578038#H14578038\">",
"     \"Differential diagnosis and evaluation of glomerular disease\", section on 'Hematuria following upper respiratory infection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27973?source=see_link\">",
"     \"Exercise-induced hematuria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The distinction between glomerular and extraglomerular bleeding and the indications for renal biopsy in patients with glomerular hematuria are discussed above. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Glomerular versus nonglomerular bleeding'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11678456\">",
"     'Role of renal biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Hypercalciuria and hyperuricosuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as 30 to 35 percent of children with apparently idiopathic hematuria (no proteinuria or infection, negative radiologic evaluation) have hypercalciuria, while 5 to 20 percent of children with recurrent hematuria have hyperuricosuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]; both disorders are often associated with a positive family history (as high as 40 to 75 percent) of stone disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/77,79\">",
"     77,79",
"    </a>",
"    ]. These children are at increased risk for the future development of kidney stones. Lowering calcium excretion with a thiazide diuretic typically leads to resolution of the hematuria among those with hypercalciuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/77\">",
"     77",
"    </a>",
"    ]; a restricted purine diet or the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    commonly eliminates uricosuria and hematuria in those with hyperuricosuria.",
"   </p>",
"   <p>",
"    Similar findings may be present in adults. Some patients have hypercalciuria or hyperuricosuria (as detected by a 24-hour urine collection) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/80,81\">",
"     80,81",
"    </a>",
"    ], while others have a history suggestive of stone disease without these biochemical abnormalities (although citrate excretion was not measured in this study) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33626?source=see_link\">",
"     \"Risk factors for calcium stones in adults\"",
"    </a>",
"    .) Treatment with a thiazide diuretic for hypercalciuria or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    for hyperuricosuria usually leads to disappearance of the hematuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Rare conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare causes of hematuria include hereditary hemorrhagic telangiectasis, radiation cystitis, schistosomiasis (which is not rare in endemic areas), arteriovenous malformations and fistulas, nutcracker syndrome, and the loin pain-hematuria syndrome. Arteriovenous malformations, nutcracker syndrome, and loin pain-hematuria syndrome will be briefly reviewed here; the other conditions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23161?source=see_link\">",
"     \"Cystitis in patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/38/15977?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical features of schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Arteriovenous malformations and fistulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;An arteriovenous malformation (AVM) or fistula of the urologic tract may be either congenital or acquired. The primary presenting sign is gross hematuria, but high-output heart failure and hypertension also may be seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/68,82\">",
"     68,82",
"    </a>",
"    ]. The latter is presumably due to activation of the renin-angiotensin system resulting from ischemia distal to the AVM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis may be suspected if there is an irregular filling defect on intravenous pyelography due to compression of the pelvis or calyx. The presence of an AVM can be confirmed by arteriography (which demonstrates almost immediate visualization of the inferior vena cava) or CT scanning. There are several therapeutic options. It is often possible for an experienced radiologist to embolize the lesion at the time of arteriography by the injection of absolute ethanol, steel coils, gelatin sponges, or balloons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/84\">",
"     84",
"    </a>",
"    ]. Absolute ethanol may be safest; it denatures proteins in the vessel wall, leading to a coagulum that occludes the lumen. Surgery or nephroscopy can be performed if embolization is ineffective or the hematuria recurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/83,84\">",
"     83,84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Nutcracker syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nutcracker syndrome refers to compression of the left renal vein between the aorta and proximal superior mesenteric artery. Nutcracker syndrome can cause both microscopic and gross hematuria, primarily in children (but also adults) in Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/85-88\">",
"     85-88",
"    </a>",
"    ]. The hematuria is usually asymptomatic but may be associated with left flank pain. Nutcracker syndrome has also been associated with orthostatic proteinuria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17655?source=see_link&amp;anchor=H2#H2\">",
"     \"Orthostatic (postural) proteinuria\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30584?source=see_link&amp;anchor=H173801352#H173801352\">",
"     \"Evaluation of microscopic hematuria in children\", section on 'Etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1127?source=see_link&amp;anchor=H10#H10\">",
"     \"Evaluation of gross hematuria in children\", section on 'Asymptomatic hematuria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of nutcracker syndrome is established by Doppler ultrasonographic assessment of left renal vein diameter and peak velocity or by magnetic resonance angiography or renal venography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/85,88\">",
"     85,88",
"    </a>",
"    ]. For patients who require treatment because of recurrent or persistent symptoms, a variety of therapies have been used, including stent placement in the left renal vein, transposition of the superior mesenteric artery or left renal vein, and autotransplantation of the left kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/85,87,88\">",
"     85,87,88",
"    </a>",
"    ]. In a 2007 review of 20 patients who required intervention, stenting was performed in 15, which has the advantage of minimal invasiveness, and transposition of the superior mesenteric artery or left renal vein in five [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Loin pain-hematuria syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The loin pain-hematuria syndrome is a poorly defined disorder characterized by loin or flank pain that is often severe and unrelenting, and hematuria with dysmorphic red cell features suggesting a glomerular origin. Affected patients usually have normal kidney function. This disorder is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35881?source=see_link\">",
"     \"Loin pain-hematuria syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407243\">",
"    <span class=\"h1\">",
"     FOLLOW-UP AFTER INITIAL NEGATIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cause for hematuria is often not identified. Patients who have a negative evaluation for hematuria generally require follow-up with cytology, urinalysis, blood pressure monitoring, and in some cases with repeat imaging and cystoscopy. The necessity for repeat imaging and cystoscopy largely depends upon whether hematuria was transient or persistent, and upon the patient's risk for malignancy. (See",
"    <a class=\"local\" href=\"#H22373332\">",
"     'Risk factors for malignancy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407250\">",
"    <span class=\"h2\">",
"     Follow-up of patients with transient hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have even one episode of hematuria and are at high risk for malignancy require close follow-up following a negative evaluation. It is not clear whether obtaining surveillance urine cytology provides a benefit in detecting malignancy. The yield appears to be quite low. In a cohort of 182 patients with asymptomatic microscopic hematuria and a median age of 60 years, the first cytology resulted in detection of bladder cancer in four cases, the second identified one additional case, and the third identified no additional cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, it is reasonable to follow such patients with asymptomatic transient microhematuria and negative urologic workup but who are at risk for malignancy with annual urinalyses. After two consecutive negative urinalyses, this follow-up may be concluded. If gross hematuria occurs at any time after the initial evaluation, the full evaluation should be repeated.",
"   </p>",
"   <p>",
"    If hypertension, proteinuria, an increase in serum creatinine, or evidence of glomerular bleeding develops in a patient who has been evaluated for hematuria, the patient should be reevaluated for renal disease. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Glomerular versus nonglomerular bleeding'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11407257\">",
"    <span class=\"h2\">",
"     Follow-up of patients with persistent hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potentially the most serious disorder in the patient with unexplained persistent hematuria is the presence of an undiagnosed carcinoma of the urinary tract. The combination of a negative CT urogram, negative cytology, and negative cystoscopy is usually sufficient to exclude malignancy in the urinary tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/12\">",
"     12",
"    </a>",
"    ]. However, the cause will subsequently become evident in some patients with careful follow-up. In a series of 421 patients with unexplained, asymptomatic microscopic hematuria who were followed at six month intervals for more than one year, approximately 5 percent had an identifiable cause for hematuria within three years and approximately 1 percent had a detectable urinary tract malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=see_link\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18250?source=see_link\">",
"     \"Epidemiology, pathology, and pathogenesis of renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, monitoring with annual urinalyses is recommended for patients with asymptomatic microhematuria; if persisting for three to five years, repeating the initial urologic workup is a reasonable consideration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/69\">",
"     69",
"    </a>",
"    ]. Some physicians also recommend repeat ultrasonography and cystoscopy at one year in high-risk patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/9,25\">",
"     9,25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22373332\">",
"     'Risk factors for malignancy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SCREENING FOR HEMATURIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for hematuria in patients who have no symptoms suggestive of urinary tract disease is",
"    <strong>",
"     not",
"    </strong>",
"    &nbsp;",
"    <strong>",
"     recommended",
"    </strong>",
"    . The most plausible argument for screening would be for the early detection and treatment of cancers of the kidney, collecting system, or bladder in older adults. However, these and other diseases causing hematuria do not meet basic criteria for screening: the prevalence of undetected, asymptomatic, early disease is relatively low (&lt;2 percent); there is little evidence that hematuria is a sensitive test for localized disease; and there is little evidence in patients with renal cancer that early treatment of local disease results in a better prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/59/34746/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, expert groups such as the United States Preventive Services Task Force on the Periodic Health Examination do",
"    <strong>",
"     not",
"    </strong>",
"    recommend screening for hematuria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22039?source=see_link&amp;anchor=H5#H5\">",
"     \"Screening for bladder cancer\", section on 'Dipstick testing for hematuria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/59/23474?source=see_link\">",
"       \"Patient information: Blood in the urine (hematuria) in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/53/10066?source=see_link\">",
"       \"Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/35/37426?source=see_link\">",
"       \"Patient information: Glomerular disease overview (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11403829\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematuria is common. In many patients, particularly young adult patients, the hematuria is transient and of no consequence. However there is an appreciable risk of malignancy in patients over age 35 years with hematuria, even if transient. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hematuria may be grossly visible (macroscopic hematuria) or detectable only on urine examination (microscopic hematuria). Microscopic hematuria is defined as the presence of three or more RBCs per high power field in a spun urine sediment. Dipsticks for heme detect 1 to 2 RBCs per high power field and are therefore at least as sensitive as urine sediment examination, but result in more false positive tests. A positive dipstick test should be confirmed with microscopic examination of the urine to avoid an unnecessary initiation of a more invasive workup. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Microscopic hematuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients should have a urine culture to exclude infection prior to evaluation of hematuria. Patients who have a positive urine culture should be treated for infection with close follow-up. The urinalysis should be rechecked in six weeks to determine whether hematuria resolved. Patients who have resolution of hematuria do not require further evaluation. (See",
"      <a class=\"local\" href=\"#H11408366\">",
"       'Urine culture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A glomerular source of bleeding is suggested by the presence of proteinuria, an active sediment on urinalysis (red cell casts, dysmorphic red blood cells) and renal insufficiency. However most physicians do not have expertise in identifying dysmorphic red cells or distinguishing red cell casts from red cells overlying granular casts. In addition, the absence of the findings does not exclude glomerular disease. Thus, proteinuria, if present, is the most reliable indicator of glomerular disease in patients with hematuria. However, if the patient has previously identified proteinuria before the onset of hematuria, then a separate disease may be responsible for the hematuria. The identification of dysmorphic red blood cells, proteinuria, cellular casts,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      renal insufficiency warrants a nephrologic evaluation but does not preclude the need for a urologic workup. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Glomerular versus nonglomerular bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An imaging study of kidney and collecting system should be obtained for all patients with gross or microscopic hematuria who have no evidence of glomerular bleeding, or infection or other known cause for hematuria. Multidetector CT urography (CTU) is the preferred initial imaging modality in most patients with unexplained gross or microscopic hematuria. Multidetector CTU should",
"      <strong>",
"       not",
"      </strong>",
"      be used in pregnant woman; ultrasonography may be used in the evaluation of pregnant women. A CTU requires intravenous but not oral contrast. Among patients with a contraindication to iodinated contrast administration, ultrasonography, CT scan without contrast, and MR imaging are alternative modalities. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Preference for CT urography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cystoscopy should be performed on all patients with gross hematuria who have no evidence of glomerular bleeding or infection. Patients who have blood clots should have cystoscopy even if they have evidence of a glomerular lesion since blood clots are virtually never associated with glomerular bleeding and would suggest the presence of two separate lesions in the glomerulus and in the upper or lower collecting system. (See",
"      <a class=\"local\" href=\"#H91125785\">",
"       'Cystoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cystoscopy should be performed on all patients over 35 years with microscopic hematuria after ruling out benign causes, such as infection, menstruation, vigorous exercise, medical renal disease, viral illness, trauma, or recent urological procedures. Cystoscopy should also be performed in those patients with microscopic hematuria who are at increased risk for malignancy, regardless of age. (See",
"      <a class=\"local\" href=\"#H91125785\">",
"       'Cystoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a field cancerization effect for urothelial tumors. Thus, among patients with hematuria who first undergo cystoscopy and are found to have a bladder tumor, the upper tracts should also be evaluated with an imaging study for possible lesions in the renal pelvis or ureter, which also have transitional epithelium. Similarly, patients who are found to have a renal pelvic or ureteral cancer with an imaging study should undergo cystoscopy. (See",
"      <a class=\"local\" href=\"#H38117737\">",
"       'Screening for a second lesion'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      A cause for hematuria is often not identified. Patients who have a negative evaluation for hematuria require follow-up with annual urinalysis and blood pressure monitoring; in some cases, repeat imaging and cystoscopy may be elected. The necessity for repeat imaging and cystoscopy depends upon whether hematuria was transient or persistent, microscopic or gross, and upon the patient's risk for malignancy. We suggest the following approach (see",
"      <a class=\"local\" href=\"#H11407243\">",
"       'Follow-up after initial negative evaluation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with persistent microhematuria and risk factors for malignancy should be offered cystoscopic and imaging reevaluation in three to five years from their initial presentation. In those with irritative symptoms, tobacco, or chemical exposure, cytology may be useful. We do not recommend any urine markers for routine use.",
"     </li>",
"     <li>",
"      New gross hematuria should prompt a reevaluation without delay.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/1\">",
"      Froom P, Ribak J, Benbassat J. Significance of microhaematuria in young adults. Br Med J (Clin Res Ed) 1984; 288:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/2\">",
"      Khadra MH, Pickard RS, Charlton M, et al. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol 2000; 163:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/3\">",
"      Topham PS, Harper SJ, Furness PN, et al. Glomerular disease as a cause of isolated microscopic haematuria. Q J Med 1994; 87:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/4\">",
"      Messing EM, Young TB, Hunt VB, et al. The significance of asymptomatic microhematuria in men 50 or more years old: findings of a home screening study using urinary dipsticks. J Urol 1987; 137:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/5\">",
"      Abt AB, Carroll LE, Mohler JH. Thin basement membrane disease and acute renal failure secondary to gross hematuria and tubular necrosis. Am J Kidney Dis 2000; 35:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/6\">",
"      Kabir A, Nadasdy T, Nadasdy G, Hebert LA. An unusual cause of gross hematuria and transient ARF in an SLE patient with warfarin coagulopathy. Am J Kidney Dis 2004; 43:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/7\">",
"      Mariani AJ, Mariani MC, Macchioni C, et al. The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol 1989; 141:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/8\">",
"      Mazouz B, Almagor M. False-positive microhematuria in dipsticks urinalysis caused by the presence of semen in urine. Clin Biochem 2003; 36:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/9\">",
"      Schr&ouml;der FH. Microscopic haematuria. BMJ 1994; 309:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/10\">",
"      Brigden ML, Edgell D, McPherson M, et al. High incidence of significant urinary ascorbic acid concentrations in a west coast population--implications for routine urinalysis. Clin Chem 1992; 38:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/11\">",
"      Mohr DN, Offord KP, Owen RA, Melton LJ 3rd. Asymptomatic microhematuria and urologic disease. A population-based study. JAMA 1986; 256:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/12\">",
"      Murakami S, Igarashi T, Hara S, Shimazaki J. Strategies for asymptomatic microscopic hematuria: a prospective study of 1,034 patients. J Urol 1990; 144:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/13\">",
"      Mohr DN, Offord KP, Melton LJ 3rd. Isolated asymptomatic microhematuria: a cross-sectional analysis of test-positive and test-negative patients. J Gen Intern Med 1987; 2:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/14\">",
"      Hiatt RA, Ordo&ntilde;ez JD. Dipstick urinalysis screening, asymptomatic microhematuria, and subsequent urological cancers in a population-based sample. Cancer Epidemiol Biomarkers Prev 1994; 3:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/15\">",
"      Choi BC, Farmilo JA. Microscopic haematuria as a predictor of urological diseases among steel workers. J Soc Occup Med 1990; 40:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/16\">",
"      Argyropoulos A, Farmakis A, Doumas K, Lykourinas M. The presence of microscopic hematuria detected by urine dipstick test in the evaluation of patients with renal colic. Urol Res 2004; 32:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/17\">",
"      Grossfeld GD, Litwin MS, Wolf JS, et al. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part I: definition, detection, prevalence, and etiology. Urology 2001; 57:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/18\">",
"      Abrol RP, Heck A, Gleckel L, Rosner F. Self-induced hematuria. J Natl Med Assoc 1990; 82:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/19\">",
"      Cohen RA, Brown RS. Clinical practice. Microscopic hematuria. N Engl J Med 2003; 348:2330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/20\">",
"      Ezz el Din K, Koch WF, de Wildt MJ, et al. The predictive value of microscopic haematuria in patients with lower urinary tract symptoms and benign prostatic hyperplasia. Eur Urol 1996; 30:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/21\">",
"      Foley SJ, Soloman LZ, Wedderburn AW, et al. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol 2000; 163:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/22\">",
"      Miller MI, Puchner PJ. Effects of finasteride on hematuria associated with benign prostatic hyperplasia: long-term follow-up. Urology 1998; 51:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/23\">",
"      Culclasure TF, Bray VJ, Hasbargen JA. The significance of hematuria in the anticoagulated patient. Arch Intern Med 1994; 154:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/24\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 33-1992. A 34-year-old woman with endometriosis and bilateral hydronephrosis. N Engl J Med 1992; 327:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/25\">",
"      Schramek P, Schuster FX, Georgopoulos M, et al. Value of urinary erythrocyte morphology in assessment of symptomless microhaematuria. Lancet 1989; 2:1316.",
"     </a>",
"    </li>",
"    <li>",
"     Diagnosis, evaluation, and follow-up of asymptomatic microhematuria (AMH) in adults: American Urological Association (AUA) Guideline file://www.auanet.org/content/media/asymptomatic_microhematuria_guideline.pdf (Accessed on December 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/27\">",
"      Collar JE, Ladva S, Cairns TD, Cattell V. Red cell traverse through thin glomerular basement membranes. Kidney Int 2001; 59:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/28\">",
"      Sigala JF, Biava CG, Hulter HN. Red blood cell casts in acute interstitial nephritis. Arch Intern Med 1978; 138:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/29\">",
"      Fairley KF, Birch DF. Hematuria: a simple method for identifying glomerular bleeding. Kidney Int 1982; 21:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/30\">",
"      Birch DF, Fairley KF, Whitworth JA, et al. Urinary erythrocyte morphology in the diagnosis of glomerular hematuria. Clin Nephrol 1983; 20:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/31\">",
"      Pollock C, Liu PL, Gy&ouml;ry AZ, et al. Dysmorphism of urinary red blood cells--value in diagnosis. Kidney Int 1989; 36:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/32\">",
"      Shichiri M, Hosoda K, Nishio Y, et al. Red-cell-volume distribution curves in diagnosis of glomerular and non-glomerular haematuria. Lancet 1988; 1:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/33\">",
"      Schramek P, Moritsch A, Haschkowitz H, et al. In vitro generation of dysmorphic erythrocytes. Kidney Int 1989; 36:72.",
"     </a>",
"    </li>",
"    <li>",
"     Fogazzi GB, Ponticelli C, Ritz E. The Urinary Sediment: An Integrated View, 2nd ed, Oxford University Press, Oxford 1999. p.30.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/35\">",
"      K&ouml;hler H, Wandel E, Brunck B. Acanthocyturia--a characteristic marker for glomerular bleeding. Kidney Int 1991; 40:115.",
"     </a>",
"    </li>",
"    <li>",
"     Hebert L. Glomerular diseases: The American College of Physicians Nephrology Medical Knowledge Self Assessment Program (MKSAP), American College of Physicians-American Society of Internal Medicine, Philadelphia 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/37\">",
"      Sappino AP, Huarte J, Vassalli JD, Belin D. Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. J Clin Invest 1991; 87:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/38\">",
"      Hall CL, Bradley R, Kerr A, et al. Clinical value of renal biopsy in patients with asymptomatic microscopic hematuria with and without low-grade proteinuria. Clin Nephrol 2004; 62:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/39\">",
"      Szeto CC, Lai FM, To KF, et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med 2001; 110:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/40\">",
"      McGregor DO, Lynn KL, Bailey RR, et al. Clinical audit of the use of renal biopsy in the management of isolated microscopic hematuria. Clin Nephrol 1998; 49:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/41\">",
"      Richards NT, Darby S, Howie AJ, et al. Knowledge of renal histology alters patient management in over 40% of cases. Nephrol Dial Transplant 1994; 9:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/42\">",
"      Yamagata K, Yamagata Y, Kobayashi M, Koyama A. A long-term follow-up study of asymptomatic hematuria and/or proteinuria in adults. Clin Nephrol 1996; 45:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/43\">",
"      Loo RK, Lieberman SF, Slezak JM, et al. Stratifying risk of urinary tract malignant tumors in patients with asymptomatic microscopic hematuria. Mayo Clin Proc 2013; 88:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/44\">",
"      Sutton JM. Evaluation of hematuria in adults. JAMA 1990; 263:2475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/45\">",
"      O'Connor OJ, McSweeney SE, Maher MM. Imaging of hematuria. Radiol Clin North Am 2008; 46:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/46\">",
"      Warshauer DM, McCarthy SM, Street L, et al. Detection of renal masses: sensitivities and specificities of excretory urography/linear tomography, US, and CT. Radiology 1988; 169:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/47\">",
"      Gray Sears CL, Ward JF, Sears ST, et al. Prospective comparison of computerized tomography and excretory urography in the initial evaluation of asymptomatic microhematuria. J Urol 2002; 168:2457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/48\">",
"      Maher MM, Kalra MK, Rizzo S, et al. Multidetector CT urography in imaging of the urinary tract in patients with hematuria. Korean J Radiol 2004; 5:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/49\">",
"      Amendola MA, Bree RL, Pollack HM, et al. Small renal cell carcinomas: resolving a diagnostic dilemma. Radiology 1988; 166:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/50\">",
"      Leyendecker JR, Gianini JW. Magnetic resonance urography. Abdom Imaging 2009; 34:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/51\">",
"      Tsili AC, Efremidis SC, Kalef-Ezra J, et al. Multi-detector row CT urography on a 16-row CT scanner in the evaluation of urothelial tumors. Eur Radiol 2007; 17:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/52\">",
"      Kalra MK, Maher MM, Sahani DV, et al. Current status of multidetector computed tomography urography in imaging of the urinary tract. Curr Probl Diagn Radiol 2002; 31:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/53\">",
"      Fowler KA, Locken JA, Duchesne JH, Williamson MR. US for detecting renal calculi with nonenhanced CT as a reference standard. Radiology 2002; 222:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/54\">",
"      Cowan NC, Turney BW, Taylor NJ, et al. Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour. BJU Int 2007; 99:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/55\">",
"      Silverman SG, Leyendecker JR, Amis ES Jr. What is the current role of CT urography and MR urography in the evaluation of the urinary tract? Radiology 2009; 250:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/56\">",
"      Kawashima A, Glockner JF, King BF Jr. CT urography and MR urography. Radiol Clin North Am 2003; 41:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/57\">",
"      Caoili EM, Cohan RH, Korobkin M, et al. Urinary tract abnormalities: initial experience with multi-detector row CT urography. Radiology 2002; 222:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/58\">",
"      Browne RF, Meehan CP, Colville J, et al. Transitional cell carcinoma of the upper urinary tract: spectrum of imaging findings. Radiographics 2005; 25:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/59\">",
"      Jamis-Dow CA, Choyke PL, Jennings SB, et al. Small (&lt; or = 3-cm) renal masses: detection with CT versus US and pathologic correlation. Radiology 1996; 198:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/60\">",
"      Kluner C, Hein PA, Gralla O, et al. Does ultra-low-dose CT with a radiation dose equivalent to that of KUB suffice to detect renal and ureteral calculi? J Comput Assist Tomogr 2006; 30:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/61\">",
"      Eikefjord EN, Thorsen F, R&oslash;rvik J. Comparison of effective radiation doses in patients undergoing unenhanced MDCT and excretory urography for acute flank pain. AJR Am J Roentgenol 2007; 188:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/62\">",
"      Chow LC, Kwan SW, Olcott EW, Sommer G. Split-bolus MDCT urography with synchronous nephrographic and excretory phase enhancement. AJR Am J Roentgenol 2007; 189:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/63\">",
"      Sudakoff GS, Dunn DP, Guralnick ML, et al. Multidetector computerized tomography urography as the primary imaging modality for detecting urinary tract neoplasms in patients with asymptomatic hematuria. J Urol 2008; 179:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/64\">",
"      Lokken RP, Sadow CA, Silverman SG. Diagnostic yield of CT urography in the evaluation of young adults with hematuria. AJR Am J Roentgenol 2012; 198:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/65\">",
"      Grossfeld GD, Litwin MS, Wolf JS Jr, et al. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part II: patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrology evaluation, and follow-up. Urology 2001; 57:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/66\">",
"      Britton JP, Dowell AC, Whelan P. Dipstick haematuria and bladder cancer in men over 60: results of a community study. BMJ 1989; 299:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/67\">",
"      Messing EM, Young TB, Hunt VB, et al. Home screening for hematuria: results of a multiclinic study. J Urol 1992; 148:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/68\">",
"      Piper JM, Tonascia J, Matanoski GM. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med 1985; 313:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/69\">",
"      Grossfeld GD, Wolf JS Jr, Litwan MS, et al. Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy recommendations. Am Fam Physician 2001; 63:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/70\">",
"      Rodgers M, Nixon J, Hempel S, et al. Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation. Health Technol Assess 2006; 10:iii.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/71\">",
"      Olgac S, Mazumdar M, Dalbagni G, Reuter VE. Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases. Am J Surg Pathol 2004; 28:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/72\">",
"      Herr HW, Cookson MS, Soloway SM. Upper tract tumors in patients with primary bladder cancer followed for 15 years. J Urol 1996; 156:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/73\">",
"      van Paassen P, van Breda Vriesman PJ, van Rie H, Tervaert JW. Signs and symptoms of thin basement membrane nephropathy: a prospective regional study on primary glomerular disease-The Limburg Renal Registry. Kidney Int 2004; 66:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/74\">",
"      Iseki K, Miyasato F, Uehara H, et al. Outcome study of renal biopsy patients in Okinawa, Japan. Kidney Int 2004; 66:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/75\">",
"      Tiebosch AT, Frederik PM, van Breda Vriesman PJ, et al. Thin-basement-membrane nephropathy in adults with persistent hematuria. N Engl J Med 1989; 320:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/76\">",
"      Nieuwhof C, Doorenbos C, Grave W, et al. A prospective study of the natural history of idiopathic non-proteinuric hematuria. Kidney Int 1996; 49:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/77\">",
"      Stapleton FB, Roy S 3rd, Noe HN, Jerkins G. Hypercalciuria in children with hematuria. N Engl J Med 1984; 310:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/78\">",
"      Stapleton FB. Idiopathic hypercalciuria: association with isolated hematuria and risk for urolithiasis in children. The Southwest Pediatric Nephrology Study Group. Kidney Int 1990; 37:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/79\">",
"      Cattini Perrone H, Bruder Stapleton F, Toporovski J, Schor N. Hematuria due to hyperuricosuria in children: 36-month follow-up. Clin Nephrol 1997; 48:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/80\">",
"      Andres A, Praga M, Bello I, et al. Hematuria due to hypercalciuria and hyperuricosuria in adult patients. Kidney Int 1989; 36:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/81\">",
"      Praga M, Alegre R, Hern&aacute;ndez E, et al. Familial microscopic hematuria caused by hypercalciuria and hyperuricosuria. Am J Kidney Dis 2000; 35:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/82\">",
"      Cokkinos P, Doulaptsis C, Chrissos D, et al. Listen to my kidney! Lancet 2009; 374:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/83\">",
"      Crotty KL, Orihuela E, Warren MM. Recent advances in the diagnosis and treatment of renal arteriovenous malformations and fistulas. J Urol 1993; 150:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/84\">",
"      Kavoussi L, Clayman RV, Basler J. Flexible, actively deflectable fiberoptic ureteronephroscopy. J Urol 1989; 142:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/85\">",
"      Zhang H, Li M, Jin W, et al. The left renal entrapment syndrome: diagnosis and treatment. Ann Vasc Surg 2007; 21:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/86\">",
"      Hanna HE, Santella RN, Zawada ET Jr, Masterson TE. Nutcracker syndrome: an underdiagnosed cause for hematuria? S D J Med 1997; 50:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/87\">",
"      Russo D, Minutolo R, Iaccarino V, et al. Gross hematuria of uncommon origin: the nutcracker syndrome. Am J Kidney Dis 1998; 32:E3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/88\">",
"      Shokeir AA, el-Diasty TA, Ghoneim MA. The nutcracker syndrome: new methods of diagnosis and treatment. Br J Urol 1994; 74:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/89\">",
"      Nakamura K, Kasraeian A, Iczkowski KA, et al. Utility of serial urinary cytology in the initial evaluation of the patient with microscopic hematuria. BMC Urol 2009; 9:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/59/34746/abstract/90\">",
"      Woolhandler S, Pels RJ, Bor DH, et al. Dipstick urinalysis screening of asymptomatic adults for urinary tract disorders. I. Hematuria and proteinuria. JAMA 1989; 262:1214.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7208 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-202.43.93.2-77D3A94D3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_59_34746=[""].join("\n");
var outline_f33_59_34746=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11403829\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION OF HEMATURIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Gross hematuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Acute renal failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Microscopic hematuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Urine dipstick",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Historical clues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Glomerular versus nonglomerular bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1824471548\">",
"      - Red cell casts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1824471562\">",
"      - Red cell morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1824471569\">",
"      Acanthocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1824471576\">",
"      Limitations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1824471583\">",
"      - Red to brown urine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1824471590\">",
"      - Blood clots",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H70188214\">",
"      - Proteinuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11678456\">",
"      - Role of renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H142763824\">",
"      Monitoring if renal biopsy is not performed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Transient or persistent hematuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11408366\">",
"      Urine culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Urine cytology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Preference for CT urography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Radiation dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22373332\">",
"      RISK FACTORS FOR MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91125785\">",
"      CYSTOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38117723\">",
"      Gross hematuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38117730\">",
"      Microscopic hematuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38117737\">",
"      SCREENING FOR A SECOND LESION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      UNEXPLAINED HEMATURIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Hypercalciuria and hyperuricosuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Rare conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Arteriovenous malformations and fistulas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Nutcracker syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Loin pain-hematuria syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11407243\">",
"      FOLLOW-UP AFTER INITIAL NEGATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11407250\">",
"      Follow-up of patients with transient hematuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11407257\">",
"      Follow-up of patients with persistent hematuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SCREENING FOR HEMATURIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11403829\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7208\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7208|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?22/63/23550\" title=\"algorithm 1\">",
"      Etiology of red urine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7208|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/49/35609\" title=\"figure 1\">",
"      Causes of hematuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/34/13870\" title=\"figure 2\">",
"      Causes of hematuria by age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7208|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/47/15088\" title=\"picture 1\">",
"      Urine in AIP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/46/44768\" title=\"picture 2\">",
"      Phase contrast micrograph showing monomorphic red cells in urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/38/35424\" title=\"picture 3A\">",
"      Photomicrograph of urine sediment with a red cell cast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/0/24591\" title=\"picture 3B\">",
"      Phase contrast micrograph showing dysmorphic red cells in urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/47/14079\" title=\"picture 3C\">",
"      Scanning electron micrograph showing dysmorphic red cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7208|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/52/25419\" title=\"table 1\">",
"      Heme negative red urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/42/11947\" title=\"table 2\">",
"      Glomerular v extraglomerular",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15479?source=related_link\">",
"      Acute uncomplicated cystitis, pyelonephritis, and asymptomatic bacteriuria in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/19/42295?source=related_link\">",
"      Approach to the adult with asymptomatic bacteriuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/42/6824?source=related_link\">",
"      Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20217?source=related_link\">",
"      Clinical presentation, diagnosis, and staging of bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23161?source=related_link\">",
"      Cystitis in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=related_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/38/15977?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical features of schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18250?source=related_link\">",
"      Epidemiology, pathology, and pathogenesis of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1127?source=related_link\">",
"      Evaluation of gross hematuria in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30584?source=related_link\">",
"      Evaluation of microscopic hematuria in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27973?source=related_link\">",
"      Exercise-induced hematuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/2/17445?source=related_link\">",
"      Glomerular hematuria: IgA; Alport; thin basement membrane nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38680?source=related_link\">",
"      Immediate hypersensitivity reactions to radiocontrast media: Prevention of recurrent reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21690?source=related_link\">",
"      Indications for and complications of renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35881?source=related_link\">",
"      Loin pain-hematuria syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/45/1754?source=related_link\">",
"      Malignancies of the renal pelvis and ureter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8698?source=related_link\">",
"      Medical treatment of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17655?source=related_link\">",
"      Orthostatic (postural) proteinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/63/30714?source=related_link\">",
"      Overview of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/53/10066?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/59/23474?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/35/37426?source=related_link\">",
"      Patient information: Glomerular disease overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28984?source=related_link\">",
"      Porphyrias: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6202?source=related_link\">",
"      Renal manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22039?source=related_link\">",
"      Screening for bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/51/12088?source=related_link\">",
"      Thin basement membrane nephropathy (benign familial hematuria)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/7/42106?source=related_link\">",
"      Treatment and prognosis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1012?source=related_link\">",
"      Urinary tract malignancy and atherosclerotic disease in patients with chronic analgesic abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/41/24214?source=related_link\">",
"      Urine sampling and culture in the diagnosis of urinary tract infection in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_59_34747="Treatment for Bartonellosis";
var content_f33_59_34747=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antimicrobial therapy for Bartonellosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Phase of illness",
"      </td>",
"      <td class=\"subtitle1\">",
"       Adult therapy",
"      </td>",
"      <td class=\"subtitle1\">",
"       Pediatric therapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       Acute (Oroyo fever)",
"      </td>",
"      <td>",
"       <strong>",
"        Regimen of choice:",
"       </strong>",
"      </td>",
"      <td rowspan=\"6\">",
"       <p>",
"        Chloramphenicol: 50-75 mg/kg/day PO or IV divided in 4 doses x 14d",
"       </p>",
"       <p>",
"        <strong>",
"         PLUS",
"        </strong>",
"       </p>",
"       <p>",
"        Another antimicrobial (Beta-lactam agent preferred)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Chloramphenicol: 500 mg PO or IV qid x 14d",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <strong>",
"        PLUS",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Another antimicrobial (Beta-lactam agent preferred)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Alternative:",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Doxycycline: 100 mg PO bid x 14d",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Eruptive (Verruga peruana)",
"      </td>",
"      <td>",
"       <strong>",
"        Drug of choice:",
"       </strong>",
"      </td>",
"      <td rowspan=\"4\">",
"       Rifampin: 10 mg/kg/d PO x 14d (maximum total daily dose of 600 mg/d)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Rifampin: 10 mg/kg/d PO x 14d",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Alternative:",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Streptomycin: 15-20 mg/kg/d IM x 10d",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_59_34747=[""].join("\n");
var outline_f33_59_34747=null;
var title_f33_59_34748="Indications for ventilation";
var content_f33_59_34748=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Respiratory abnormalities suggestive of the need for mechanical ventilation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Parameter",
"       </td>",
"       <td class=\"subtitle1\">",
"        Value",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Clinical assessment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Apnea",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stridor",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Severely depressed mental status",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flail chest",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inability to clear respiratory secretions (eg, excessive secretions, loss of protective reflexes, neuromuscular failure)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trauma to mandible, larynx, trachea",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Loss of ventilatory reserve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Respiratory rate",
"       </td>",
"       <td>",
"        &gt;35 breaths/min",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tidal volume",
"       </td>",
"       <td>",
"        &lt;5 mL/kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vital capacity",
"       </td>",
"       <td>",
"        &lt;10 mL/kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Negative inspiratory force",
"       </td>",
"       <td>",
"        Weaker than -25 cm H",
"        <sub>",
"         2",
"        </sub>",
"        O (2.44 kPa)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Minute ventilation",
"       </td>",
"       <td>",
"        &lt;10 L/min",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rise in PaCO",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"       <td>",
"        &gt;10 mmHg (1.33 kPa)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Refractory hypoxemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alveolar-arterial gradient (FiO",
"        <sub>",
"         2",
"        </sub>",
"        = 1)",
"       </td>",
"       <td>",
"        &gt;450",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PaO",
"        <sub>",
"         2",
"        </sub>",
"        /PAO",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"       <td>",
"        &lt;0.15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PaO",
"        <sub>",
"         2",
"        </sub>",
"        with supplemental O",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"       <td>",
"        &lt;55 mmHg (7.32 kPa)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PaCO",
"     <sub>",
"      2",
"     </sub>",
"     : arterial tension of carbon dioxide; FiO",
"     <sub>",
"      2",
"     </sub>",
"     : fraction of inspired oxygen; PaO",
"     <sub>",
"      2",
"     </sub>",
"     : arterial tension of oxygen; PAO",
"     <sub>",
"      2",
"     </sub>",
"     : alveolar tension of oxygen.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_59_34748=[""].join("\n");
var outline_f33_59_34748=null;
var title_f33_59_34749="Amplitude alternans equation";
var content_f33_59_34749=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Equation for calculating amplitude of alternans (A) at each time sample (j) using the correlation method (ACMj)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 140px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_59_34749=[""].join("\n");
var outline_f33_59_34749=null;
var title_f33_59_34750="Eosinophilic esophagitis mucosal tear post-dilation Endosc";
var content_f33_59_34750=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eosinophilic esophagitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy performed after passing a dilator and prior to passage of the next size dilator. A deep mucosal tear is evident in the mid esophagus (arrow). There were no clinical signs of immediate perforation. Esophagography (initially with Gastrografin&reg;, a water-soluble contrast agent, and then with barium) was negative for a perforation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andres Gelrud, MD and Anthony Lembo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_59_34750=[""].join("\n");
var outline_f33_59_34750=null;
var title_f33_59_34751="Tympanosclerosis";
var content_f33_59_34751=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tympanosclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 399px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tympanosclerosis, asymptomatic whitish plaques of calcium and phosphate crystals, as depicted above, is common in children with middle ear disease and more common after&nbsp;tympanostomy tube placement.",
"    <br>",
"     <br>",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Courtesy of Glenn C Isaacson, MD.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_59_34751=[""].join("\n");
var outline_f33_59_34751=null;
